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ABSTRACT
GENETIC MAPPING AND MECHANISM OF ACTION OF RAT MAMMARY
CARCINOMA SUSCEPTIBILITY QUANTITATIVE TRAIT LOCUS MCSl B
Aaron D. denDekker
January 9,2013
Breast cancer is a complex disease that involves genetic, epigenetic, and
environmental components. High and moderate penetrant genes have been identified that
affect risk to developing breast cancer; however, these risk alleles are present in a small
percentage of breast cancer cases. Low penetrant modifier genes have risk-associated
alleles that are common in the population. Although these genes have lower penetrance,
it is expected that the majority of genetic risk to developing breast cancer is controlled by
common genetic variation. Studying mechanisms of common genetic variants on breast
cancer risk is difficult due to their small individual effects and overlapping contribution
of other risk factors; thus, animal models are commonly used.
,£arcinoma

~usceptibility

The rat mammary

quantitative trait locus (QTL) Mcsl b was identified between

mammary carcinoma-resistant Copenhagen (COP) and susceptible Wistar Furth (WF)
rats on chromosome 2. This rat QTL is an ortholog of a human breast cancer-associated
locus identified on human chromosome 5q; therefore, the rat Mcsl b model can be used to
identify mechanisms and causative factors contributing to breast cancer risk associated
with human breast cancer-associated locus 5q.

VI

The goal of the work presented in this dissertation is to identify quality candidate
breast cancer risk genetic elements associated with the rat Mcsl b locus. This project
utilized a well-defined rat mammary carcinogenesis system and congenic rat model to
fine map and characterize the rat Mcsl b locus.

My studies reduced the number of

candidate genes by narrowing the rat Mcslb locus from a 13 megabase (Mb) to a 1 Mb
containing nine annotated transcripts.

I determined that Mcsl b-conferred mammary

carcinoma resistance is being controlled by a cell type within the mammary gland. This
is an important finding because mammary carcinogenesis is dependent on both mammary
gland-extrinsic and -intrinsic factors.

I also found that the transcript Mier3 is

differentially expressed between resistant and susceptible rat mammary glands with or
without carcinogen exposure providing genetic evidence that Mier 3 is a strong mammary
carcinoma susceptibility gene.

Taken together, these results provide insight into the

mechanism by which Mier3 controls mammary carcinogenesis and implicate human
MIER3 as a potential target for breast cancer prevention.
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CHAPTER I
GENES, ENVIRONMENT, AND BREAST CANCER

General Introduction
Breast Cancer Statistics

Breast cancer is the leading cause of cancer death in the United States in women
aged 20-59 and is the second most diagnosed cancer in women in the US (Siegel et aI.,
2012). Additionally, with the exception to skin cancer, breast cancer is the most common
cancer diagnosed in women worldwide (Mathers et aI., 2008).

In the US, it was

estimated that near 230,000 new cases of invasive breast cancer were diagnosed and that
almost 40,000 women died of breast cancer in 2012 (American Cancer Society, 2011).
Breast cancer deaths in women rose 0.4% per year from 1975 to 1990. However, in
recent years, early detection, increased awareness, better treatments, and decreased use of
hormone replacement therapies have led to a decrease in breast cancer death rates with a
2.2% decrease per year from 1990 to 2007 (American Cancer Society, 2011). Still, breast
cancer remains a major health concern for many women and current risk estimates are
that lout of8 women in the US will develop breast cancer (Altekruse SF, 2010).
Breast cancer also affects men; however, male breast cancer only accounts for
approximately 1% of breast cancers diagnosed in the US (American Cancer Society,
2011). Due to its rarity, much less is known about the male form of breast cancer.
Incidence of male breast cancer has risen from I in 100,000 men being diagnosed with
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breast cancer in the late 1970's to 1.2 in 100,000 from 2000-2004 (Onami et al., 2010).
However, breast cancer death rates in men have fallen 3.3% since 2000; likely due to
increased awareness and better diagnoses (American Cancer Society, 2011; Anderson
and Devesa, 2005).

Breast Cancer Risk

Breast cancer

IS

a complex disease and the risk of developing it has

environmental, genetic, and epigenetic components. The most important factors affecting
risk to developing breast cancer are age and female gender (American Cancer Society,
2011). As noted, approximately 12% (1 in 8) of US women are predicted to be diagnosed
with breast cancer based on lifetime risk, and this probability increases as a woman gets
older (Altekruse SF, 2010; American Cancer Society, 2011). This estimate is based on
epidemiology of population incidence. However, these estimates may not be accurate for
many individual women. Risk for an individual may be higher or lower depending on
various risk factors including age, family history and reproductive history as well as other
heritable and non-heritable factors (Gail et al., 1989).
Radiation exposure is one of the most potent exogenous factors known to increase
chances for developing breast cancer (Land et al., 2003; Ronckers et al., 2005). Although
exposure to high doses of ionizing radiation is less common, many women are exposed to
low-dose radiation through mammograms and routine low-dose exposure has been
associated with an increase in breast cancer risk especially in women already with an
increased familial risk (Pijpe et al., 2012). Additionally, other non-heritable risk factors
have been identified e.g., living near nuclear power sites (chronic radiation exposure) and
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shift work cycles (prolonged exposure to light at night) but these risks aren't fully
understood (Boice et aI., 2003; Bonde et aI., 2012; Hill et aI., 2011).
Inherited genetic susceptibility to cancer is now considered an established fact
(Fletcher and Houlston, 2010). Mutations in several high-risk genes have been identified,
e.g. BRCAI and BRCA2, that increase a woman's chances of developing breast cancer by
51-75% and 33-54%, respectively (Antoniou et aI., 2003). Screening for mutations in
these genes is, under certain circumstances, more routinely conducted; however,
mutations in these genes account for approximately 3-5% of female breast cancer cases,
leaving the majority of alleles contributing to breast cancer susceptibility unknown
(Campeau et aI., 2008; Narod and Salmena, 2011).

Conversely, common genetic

modifiers have a small independent effect but can act cumulatively to exert a greater
influence on disease development (Jostins and Barrett, 2011; Pharoah et aI., 2008).
Therefore, the majority of genetic risk to breast cancer development is likely attributable
to common genetic variation (Fletcher and Houlston, 2010; Lee et aI., 2011).

Predicting Breast Cancer Risk

Accurate prediction of an individual's breast cancer risk is vital to developing
better prevention and treatment strategies. The ability to predict the development of
disease in an individual has been useful in improving strategies for breast cancer
prevention; e.g. increased frequency of mammograms for high risk breast cancer patients
(Jostins and Barrett, 2011). However, breast cancer etiology is complex, which makes
accurate individual risk assessment problematic for many women. Individual risk for
developing breast cancer is currently assessed using the Gail model. Gail and colleagues
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developed a risk-assessment model based on a set of risk factors: age at menarche, age at
first live birth, number of previous biopsies, and number of first-degree relatives with
breast cancer (Costantino et aI., 1999; Gail et aI., 1989). An interactive tool has been
developed by the National Cancer Institute (NCI) and the National Surgical Adjuvant
Breast and Bowel Project (NSABP) based on the Gail model. This tool is used by
physicians to

assess

risk

for

an individual with a limited

family history

(http://www.cancer.gov/bcrisktool/).
The Gail model provides an efficient method to project the likelihood to develop
breast cancer for most individual women; however, it has limitations. First, the Gail
model only accounts for first degree relatives with breast cancer potentially
underestimating risk in the 50% of families with cancer in the paternal lineage (Euhus et
aI., 2002; Evans and Howell, 2007). Also, the Gail model does not take into account the
age of onset of breast cancer of the affected relative, thereby, possibly overestimating risk
in women with an affected relative who developed breast cancer late in life.

Last,

although it has been modified to account for ethnic background, the Gail model focuses
primarily on non-genetic risk factors. Heritable factors are recognized to have significant
roles in complex disease risk and this is underscored by the importance of accounting for
family history in risk assessment (Bevier et aI., 2011; Costantino et aI., 1999; Gail et aI.,
1989; Lalloo and Evans, 2012).
At present, the effects of risk-predisposing genes are difficult to evaluate; thus, a
better understanding of genetics and the molecular mechanisms that influence breast
cancer susceptibility is necessary to better predict an individual's risk for developing
breast cancer. Several low- to moderate-penetrance breast cancer risk alleles have been
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identified (Easton et aI., 2007; Turnbull et aI., 2010). Relative risk conferred by alleles at
individual loci is small, but risk alleles are hypothesized to act multiplicatively. It has
been estimated that risk of developing breast cancer is approximately six times as great
among women carrying 14 risk alleles as among those carrying no risk alleles at these
loci (Pharoah et aI., 2008). Although there is little clinical use for single, low-penetrance
genes, the cumulative effects of these alleles may be useful to separate high risk
individual women from those at lower risk (Pharoah et aI., 2008).

As previously

mentioned, the genetic contribution to breast cancer development is not fully understood.
However, new technologies and approaches are available that will allow for the discovery
of common genetic risk alleles and it is believed that assessing individual breast cancer
risk based on genetic factors will be achieved in the near future (Jostins and Barrett,
2011).

Breast Cancer Risk Factors: Breast Cancer as a Complex Disease

Estrogen Exposure and Breast Cancer
As stated earlier, the most widely recognized risk factors to breast cancer
development are female gender and increasing age (American Cancer Society, 2011).
Women develop breast cancer at a rate one hundred times that of men and these rates
increase as women age. This is interpreted as a representation of accumulated exposure
to ovarian hormones in the form of estrogens and progesterone (Pike et aI., 1993). It is
thought that women exposed longer to estrogen due to early menarche, late menopause or
hormone replacement therapy exhibit an increase in breast cancer risk (Kelsey et aI.,
1993; Pike et al., 1993).

It was first discovered in 1896 that oophrectomy could
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effectively regress breast carcinomas (Beatson, 1896). Later observations indicated that
women who experienced early menarche or late menopause exhibited higher incidence of
breast cancer (Kelsey et aI., 1993). Also, women who had their first child early (before
age 18) had a lower incidence of breast cancer than women who had children later in life
(35 years of age) (Kelsey et aI., 1993; MacMahon et aI., 1970; Pike et aI., 1983). More
recently, it has been shown that oophrectomy in women before 35 years of age reduces
breast cancer risk by 75% (Kronenberg and Williams, 2008).

Taken together, this

suggests a pivotal role for endogenous estrogens in the development of breast cancer.
Estrogen exposure is now considered one of the most important factors
determining breast cancer risk. Estrogens primarily function to control the estrous cycle
but have roles in a variety of other processes. There are three forms of estrogen produced
in the body: estrone (El), estradiol (E2), and estriol (E3). These are made and secreted
primarily by the ovary but can also be made in other tissues. Of these E2 is the most
potent as El and E3 bind estrogen receptors a and P (ERa and ERP) with lower affinity
. compared to E2. However, Eland E3 can be converted to E2. Significantly, E2 is
secreted by the breast epithelium and adipose and serum E2 levels have been correlated
with an increase in breast cancer incidence (Kronenberg and Williams, 2008). During the
1940s, hormone replacement therapy (HRT) was instituted into clinical practice for the
treatment of menopausal symptoms by administration of exogenous estrogens.
Subsequent studies of groups of women receiving HRT demonstrated that the relative
risk (RR) of developing breast cancer for women receiving therapy was elevated
(RR=2.0) compared to that of the general population (RR=1.3) (Hoover et aI., 1976).
Breast cancer risk due to HRT was debated for many years citing contradictory studies;
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however, studies conducted by the Women's Health Initiative (WHI) and the Million
Women Study (MWS) indicate that continued HRT increases breast cancer risk (Beral,
2003; Rossouw et aI., 2002).

Data from the MWS showed the effect of combined

progesterone-estrogen therapy was greater (RR=2.00, [95% Confidence Interval (CI)
1.88-2.12], P<O.OOOI) compared to estrogen alone (1.30 [1.21-1.40], P<O.OOOI) when
compared to women never receiving HRT (Beral, 2003).

Women in the WHI

randomized control study receiving combined estrogen-progesterone therapy also had an
increase incidence in breast cancer compared to those receiving a placebo (Hazard Ratio
(HR)= 1.62 [95% CI 1.00-1.59], P<0.05) (Rossouw et aI., 2002).
Estrogens have been extensively studied to understand the action by which they
influence breast cancer. Estrogens promote rapid proliferation of mammary epithelial
cells, which increases the probability that mutations will become fixed and propagated,
thereby promoting tumor formation (Preston-Martin et aI., 1993).

The "canonical"

estrogen signaling pathway occurs through estrogens binding ERa and

ER~.

Estrogens

diffuse passively through cell and nuclear membranes and bind to ERa and

ER~

(Kronenberg and Williams, 2008). Once an estrogen receptor is bound to an estrogen
ligand, it undergoes a conformational change and binds to specific DNA sequences called
estrogen response elements (EREs) to drive transcription of target genes. ERE-bound
ERs interact with basal transcription factors and co-activator proteins, which stabilize
basal transcription factor binding and initiate transcription (Klinge, 2000). The products
of these genes act to promote cell growth and differentiation.
ERa and

ER~

exhibit similar binding affinities for E2, the predominate estrogen

in premenopausal women, and both ER subtypes have been shown to bind to EREs

7

similarly (Kuiper et aI., 1997; Paech et aI., 1997). Both receptors form homodimers in
response to ligand binding; however, studies have shown that they can also form
heterodimers in vitro and in vivo, and that

ER~

reduces ERa transcriptional activity (Hall

and McDonnell, 1999; Pettersson et aI., 2000; Pettersson et aI., 1997).
findings have shown that

ER~

Also, recent

can recruit a corepressor complex to the ERa gene

promoter resulting in reduced expression of ERa (Bartella et aI., 2012). This implies that
ER~

is acting as an internal regulator of ERa activity. Indeed, ERa expression is often

higher compared to

ER~

in invasive mammary tumors (Leygue et aI., 1998).

ERs are the active components controlling estrogen signaling and have, thus,
become popular targets for breast cancer treatment. There are several classes of hormone
treatment options for breast cancer therapy.

Selective estrogen-receptor modulators

(SERMs), such as tamoxifen and raloxifene, are synthetic agonist/antagonists of the ER.
In the mammary gland, both of these drugs bind ER as antagonists to prevent ERmediated transcription. Alternatively, tamoxifen is an ER agonist in uterus and bone
while raloxifene acts as an agonist in bone only (Dutertre and Smith, 2000).

Other

chemotherapeutics also act on the ER, such as fulvestrant, an ER antagonist that
abolishes estrogen-specific gene transcription by degrading the ER (Flemming et aI.,
2009). Aromatase inhibitors (AI), on the other hand, operate indirectly by inhibiting the
activity of aromatase, the enzyme responsible for converting androgens into estrogens,
thereby reducing estrogen availability for ER binding (Mokbel, 2002).
Tamoxifen is the most widely used treatment for ER-positive breast cancers in
pre- and post-menopausal women. Although tamoxifen is an effective therapeutic, it has
some disadvantages and limitations. For one, tamoxifen has been shown to increase the
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chance of endometrial cancer by acting as an agonist in the uterus and endometrium
(Fisher et aI., 1994; Gottardis et aI., 1988). Also, many breast tumors are unresponsive to
tamoxifen as they have lost the ability to express ERa (Ring and Dowsett, 2004). One of
the biggest problems clinicians face when treating with tamoxifen is that many patients
develop resistance to the drug and relapse (Cui et aI., 2012; Osborne et aI., 2005). Often,
tumors in these patients continue to express a functionally normal ER yet they grow
independently of estrogen action. Amplification and over-expression of the growth factor
receptor HER2 is thought to be a major mechanism contributing to endocrine resistance
in many cases (Osborne et aI., 2005).

Additionally, it is believed that tamoxifen

resistance in some breast cancers may is due to changes in expression of co-activators
and co-repressors (Dobrzycka et aI., 2003). For example, the co-repressor Metastatic
tumor antigen 1 (MTA1) interacts directly with ER and histone deacetylases (HDACs) to
inhibit ERE transcriptional activity and promote hormone-independent growth. Further,
MTA1 over-expression correlates with a reduced response to tamoxifen (O'Malley and
Kumar, 2009). In addition, mis-expression of many of these co-regulators is associated'
with many cancer types.

It is not clear whether this dysregulation is a cause or

consequence of the pathology; however, co-regulators of ER action appear to be
important factors in breast cancer pathogenesis.
Estrogens also function to promote breast carcinogenesis independent of the
canonical ER-signaling pathway.

Several mechanisms have been identified that are

independent of estrogen receptor activity. For example, Liehr et al. have shown that 4hydroxylated estrogen metabolites playa central role in the genotoxic activity of estrogen
via generation of free radicals, which correlates with increased cancer risk (Liehr, 1990;
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Liehr and Roy, 1990). Second, estrogen metabolites, catechol estrogen quinones, are
formed via cytochrome P450 activation. These electrophilic quinine metabolites form
depurinating adducts on DNA thereby inducing point mutations (Cavalieri et aI., 2002).
Normally, metabolism of these catechol estrogens by O-methylation, glutathionation,
glucuronidation, or sulfation renders these inactive; however, studies have shown that
when levels of catechol estrogen metabolites are increased they cannot be sufficiently
metabolically inactivated, and this associates with an increase in breast cancer incidence
(Rogan et ai., 2003).

In addition, Barrett and colleagues demonstrated that

diethylstilbestrol (DES), a synthetic estrogen previously used for the treatment of
menopause, interferes with microtubule organization at low doses (Tsutsui et ai., 1983).
Their data indicate that DES does not prevent cell division but, rather, interferes with
microtubule organization sufficiently to cause non-dysjunction at mitosis resulting in
aneuploidy (Tsutsui et ai., 1983). Therefore, endogenous estrogens may also be affecting
carcinogenesis through this pathway.
Various genetic modifiers have been identified that affect estrogen action in the
context of breast cancer susceptibility. Common variants have been identified in, ESR2,
the gene encoding ERP (Maguire et ai., 2005). Gene targeting association studies along
with in vitro studies suggest these variants may be involved in increasing risk for breast
cancer. Interestingly, an ultra-rapid metabolizing allele for CYP2C19, CYP2C19*17, has
been identified that associates with a lower risk for breast cancer (Justenhoven et ai.,
2009). Additionally, deletion alleles of CYP2C19, were identified at an increased
frequency in familial breast cancer cases from a cohort of Northern Finnish women
(Pylkas et ai., 2012). CYP2C19 is a gene encoding an enzyme involved in the catabolism
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of E2 implying that increased catabolism of E2 reduces estrogen levels and subsequently
reduces breast cancer risk. Correspondingly, haploinsufficiency of CYP2C19 may retard
estrogen catabolism and, thereby, increase risk for breast cancer. What is more, copy
number variants (CNVs) have recently been discovered in familial breast cancer cases
that affect genes in estrogen signaling pathways (Pylkas et aI., 2012). Taken together, the
effects of estrogen signaling in breast cancer development are very complex. Unraveling
these mechanisms will be useful in determining the role of estrogens in breast cancer and
may lead to better diagnoses and treatments.

Progesterone and Breast Cancer

Progesterone is another steroid hormone involved in mammary gland
development (Kronenberg and Williams, 2008). Like estrogens, progesterone passively
diffuses into the cell and binds to either of its cognate receptors, A or B (PR-A or PR-B,
respectively) and is able to activate gene transcription (Kronenberg and Williams, 2008).
It rs believed that estrogens and progesterone act in concert to promote ductal branching

and development of mammary terminal end buds (TEBs), while estrogen is responsible
for overall growth of mammary ducts emanating from the nipple (Ruan et aI., 2005;
Singletary and McNary, 1992). Although progesterone is associated with mammary duct
outgrowth, studies have also shown that PR-deficient animals develop normal mammary
glands (Kleinberg et aI., 1990; Lydon et aI., 1995). This suggests that progesterone may
be involved in ductal morphogenesis by acting through an alternative mechanism.
Although the mechanism by which progesterone is acting is not fully understood, it is

11

held that progesterone plays a role in promoting mammary gland development (Lydon et
aI., 1995; Ruan et aI., 2005).
Progesterone is also known to attenuate estrogen action via three separate
mechanisms (Kronenberg and Williams, 2008). First, progesterone can reduce synthesis
of ERa (Hsueh et aI., 1976; Tseng and Gurpide, 1975).

Second, progesterone can

activate transcription of the gene coding for 17P-hydroxysteroid dehydrogenase (17PHSD), an enzyme involved in the enzymatic inactivation of E2 to the weakly estrogenic
E1 (Casey et aI., 1994).

Third, progesterone induces transcription of estrogen

sulfotransferases; enzymes that catalyze the conjugation of sulfate groups to E2 and E1
rendering the estrogens inactive (Falany and Falany, 1996).

Therefore, although

progesterone promotes mammary gland development, it could playa role in reducing the
deleterious effects of estrogen action.
Based on these observations, one may expect progesterone to reduce the protumorigenic effects of estrogen. Not surprisingly, breast tumors that express ER and PR
are much more sensitive to endocrine chemotherapies compared to ER- and PR-negative
tumors (American Cancer Society, 2(11). However, the role of progesterone in breast
cancer risk is confounding. The WHI and the MWS Study found that women taking
estrogen plus progestin replacement therapy exhibited higher breast cancer incidence than
those taking estrogen alone (Chlebowski et aI., 2010; Chlebowski et aI., 2003; Travis et
aI., 2(10). Additionally, postmenopausal women with prior hysterectomy that received
equine conjugated estrogen alone had a lower incidence of breast cancer compared to the
placebo group (Anderson et aI., 2(12).

This implicates progesterone with a role in

promoting breast cancer development.
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The mechanism by which progesterone and PR affect mammary cell proliferation
and cancer development is not fully understood.

In vitro studies have shown that

progesterone induces cell proliferation by activating protein kinases such as MAPK,
Akt/PI3K, and c-Src (Boonyaratanakornkit et aI., 2001; Migliaccio et aI., 1998; Saitoh et

aI., 2005); however, the role this plays in human (i.e. whole animal) physiology is not
clear and further studies are needed to determine how it effects mammary carcinogenesis.
What is more, PR expression is driven by ERa but can also be expressed independently
of ERa (Horwitz et aI., 1982; Lange, 2008). Therefore, it is difficult to ascertain the
effects of progesterone alone from those of estrogen (Lange, 2008). Regardless, while
the distinct role of progesterone and PR in breast carcinogenesis is unclear, breast tumor
PR status is routinely used as a prognostic indicator for response to adjuvant
chemotherapy and PR-targeted therapies are in use to treat breast cancer (Lange, 2008).

Exogenous Environmental Effects on Breast Cancer Development

As described, breast cancer is influenced by both exogenous and endogenous
environmental chemical carcinogens. The prime example of a physical carcinogen is
irradiation.

Less common than estrogen exposure, ionizing radiation is the strongest

known exogenous environmental factor affecting breast cancer development (Ronckers et
aI., 2005). This is based on breast cancer incidence rates in atomic bomb survivors and
patients receiving prolonged radiotherapy (Land et aI., 2003; Ronckers et aI., 2005). The
effects of living near nuclear power plants and exposure to low-level ionizing radiation
sources remains a concern, but has not been extensively studied (Boice et aI., 2003).
Unrelated to radiation, there has been increasing interest in "light at night" as a risk factor
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since exposure to light at night due to night shift work correlates with both disruption in
melatonin secretion and increased breast cancer incidence (Bonde et aI., 2012; Hill et aI.,
2011).

Also, exposure to radiofrequency/microwave radiation emissions (RF) from

wireless communications has become a concern due to the increasing use of mobile
communication devices. This is thought to playa role in numerous pathologies including
breast cancer development; however, these areas are relatively new and are not fully
understood (Hardell and Sage, 2008).
Many different classes of exogenous chemical carcinogens have been identified
that associate with breast cancer risk. Some of these act though the estrogen signaling
pathway. Xenoestrogens, such as polychlorinated biphenyls (PCBs), bisphenol A (BPA)
and phthalates are structurally different from endogenous estrogens but are able to bind
ERs and activate mitotic events (Darbre and Charles, 2010; Fernandez and Russo, 2010;
Kester et aI., 2000; Tsutsui et aI., 2000). Phytoestrogens, such as genestein, are natural
plant-derived xenostrogens.

They are structurally similar to endogenous mammalian

estrogens and are able to act in a similar manner through the canonical signaling pathway
(Martin et aI., 1978). Yet, reported effects on phytoestrogens on breast cancer risk are
conflicting due to studies that have shown protective as well as detrimental effects
(Darbre and Charles, 2010; Martin et aI., 1978; Safe, 1997; Zhang and Chen, 2011).
Other chemical carcinogens are able to act to promote breast cancer development
through estrogen-independent means.

Some of the most prominent are polycyclic

aromatic hydrocarbons (P AHs) and their nitrated metabolites (nitro-P AHs), which cause
genotoxic effects (Mersch-Sundermann et aI., 1993).

For example, PAHs such as

benzo(a)pyrene (B[a]P) and 7,12-dimethylbenz(a)anthracene (DMBA) are metabolized to
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form reactive diol epoxide intermediates that directly bind DNA and induce mutations
(Todorovic et aI., 1997). B[a]P is one of the most well-studied PAHs and it is found in
many places because it is a byproduct of incomplete combustion of organic matter, e.g.,
cigarette smoke, car exhaust, and industrial smoke stack exhaust (Lawther and Waller,
1976; Phillips, 1999). DMBA is a synthetic organ-specific PAH also used as a laboratory
carcinogen (Christou et aI., 1995; Miyata et aI., 2001).

DMBA induces expression of

eYPiBi in a mammary gland-specific manner (Christou et aI., 1987). Thus, CYPIBl, is

the primary P450 enzyme metabolizing DMBA in the mammary gland. CYPIBl, along
with epoxide hydrolase, converts DMBA to its carcinogenic diol-epoxide form, which
makes it ideal to induce carcinogenesis in the mammary gland (Christou et aI., 1987;
Christou et aI., 1995; Miyata et aI., 1999). DMBA is routinely used as an experimental
mutagen for research purposes because it models PAH-induced carcinogenesis (Modi et
aI., 2012).

Lifestyle-based Factors and Breast Cancer Risk .

Many different lifestyle-based environmental factors are also contributors to
breast cancer risk. Tobacco smoke has long been accepted as modifiable lifestyle risk
factor for many different cancer types although there is limited evidence for its role in
breast cancer (American Cancer Society, 2012). Obesity and alcohol consumption are
two other factors that have been identified as risk predictors for developing breast cancer
(American Cancer Society, 2011; Cannichael, 2006; Hankinson et aI., 1995; Pelucchi et
aI., 2011).
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In post-menopausal women, obesity is positively associated with an increased
incidence of breast cancer and has also been shown to confer a poorer prognosis
(Carmichael, 2006; Hankinson et aI., 1995).

However, studies on pre-menopausal

women have had conflicting results as some data suggest an inverse relationship between
weight and breast cancer outcome. Regardless, weight gain and obesity associate with
poor outcomes in both pre- and post-menopausal women (Carmichael, 2006).
Adipocytes exhibit increased aromatase expression, the enzyme responsible for
converting androgens to estrogen (Bulun et aI., 2012; Santen et aI., 2009). Thus, it has
been postulated that increased estrogen is produced in the breast adipose tissue thereby
promoting breast cancer development (Bulun et aI., 2012).
Alcohol consumption increases endogenous estrogen levels and positively
correlates with breast density and breast cancer incidence (Boyd et aI., 1995; Hankinson
et aI., 1995).

Although alcohol consumption associates with increased incidence of

breast and other types of cancers, there are also data that suggest beneficial effects from
alcohol, especially in red wine (de Lorimier, 2000). However, the mechanisms for this
have not been extensively studied and are currently inconclusive.
Additionally, the consumption of "well-done" or charred meat has been identified
as a risk factor to a variety of cancers, including the breast (Zheng and Lee, 2009).
Heterocyclic amines (HCAs) are the most abundant mutagen found in overcooked meat.
Studies have identified associations between high-temperature cooked meat intake, HCA
exposure and breast cancer incidence (De Stefani et aI., 1997; Sinha et aI., 2000; Zheng et
aI., 1998; Zheng and Lee, 2009). Women who consistently eat overcooked meat have a
4.6-fold higher RR (95% CI=1.36-15.70) of developing breast cancer compared to
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women who consume rare or medium-done meat. (Zheng et aI., 1998). Further studies
found increased levels of 2-amino-1-methyl-6-phenylimidazo(4,5-b )pyridine (PhIP), the
most common HCA found in over-cooked meat, to correlate with an increase in breast
cancer incidence; however, there was no significant effect associated with other HCAs
(Sinha et aI., 2000).

In addition to HCAs, overcooked meat may also contain other

mutagens such as PAHs including the ubiquitous B[ a]P (Zheng and Lee, 2009). Other
studies suggest that breast cancer risk associated with HCA exposure may be modified by
common polymorphisms in genes coding for enzymes responsible for metabolizing
HCAs, thereby strengthening the role of genetics in breast cancer risk (Deitz et aI., 2000;
Zheng et aI., 1999; Zheng et aI., 2002).

Breast Cancer Genetics and Susceptibility Genes
The etiology of breast cancer is driven by multiple components that include
environmental factors, physiological host factors, and inherited genetic components.
Genes influencing complex diseases are inherited according to Mendelian principles.
However, while Mendelian disorders are monogenic, complex diseases are controlled by
multiple alleles (Badano and Katsanis, 2002). Genes associated with disease provide a
genetic predisposition to development of the disease; however, the outcome is determined
by gene-gene interactions and gene-environment interactions (Hunter, 2005; Marian,
2012). At present, the interplay between hereditary and environmental factors is not fully
understood (Hunter, 2005). Although it remains difficult to quantify the magnitude of the
effect of each of the components on breast cancer etiology, as outlined above, progress is
being made to begin to estimate the contribution of the genetic components.
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Women with a family history of breast cancer have an increased breast cancer risk
(American Cancer Society, 2011; Bevier et aI., 2011; Collaborative Group on Hormonal
Factors in Breast Cancer, 2001). RR increases with increasing numbers of first degree
relatives diagnosed with breast cancer with RR=1.80 (99% CI=1.69 - 1.91), 2.93 (2.36 3.64) and 3.90 (2.03 - 7.49) for one, two, or three affected first degree relatives,
respectively (Collaborative Group on Hormonal Factors in Breast Cancer, 2001). Having
an affected second-degree relative increases risk to a lesser degree, with RR=1.27 (95%
CI=1.09 - 1.47) and 1.26 (1.05 - 1.50) for either a maternal or paternal grandmother
affected, respectively. Further, there is a RR=1.60 (1.24 - 2.07) for two affected second
degree female relatives

(Bevier et aI., 2011).

Recent epidemiological studies have

revealed that having a brother diagnosed with breast cancer increases a woman's RR to
2.48 (95% CI=1.44 - 4.27), which is more than having an affected sister (RR=1.87, 1.801.95). This may suggest that male breast cancer has a higher genetic basis than female
breast cancer (Bevier et aI., 2011). Clearly, the inherited component affecting breast
cancer risk is significant. Moreover, estimates based on breast cancer studies in twins
suggest that the inherited genetic component in the etiology of breast cancer accounts for
at least 30% of risk (Lichtenstein et aI., 2000). However, Peto (2000) contested that this
is an underestimate and that the actual contribution is much higher.
The inherited genetic component of breast cancer in a population consists of both
highly penetrant genes at a low frequency and those genes that occur at a high frequency,
but have a low penetrance. High risk alleles have been identified in three genes; BRCA 1,
BRCA2 and TP53 (Lalloo and Evans, 2012).

Mutations in these genes are highly

penetrant, conferring a 40-85% increase in lifetime risk for developing breast cancer.
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Additionally, moderately penetrant alleles have been identified in genes such as PALB2,
BRIPl, ATM, and CHEK2 (Meijers-Heijboer et aI., 2002; Rahman et aI., 2007; Seal et aI.,

2006; Vahteristo et aI., 2002). Variants in these moderately-penetrant alleles confer a 2040% increase in breast cancer susceptibility (Lalloo and Evans, 2012).
Many mutations and variants in highly- and moderately-penetrant genes are
characteristic of specific ethnic backgrounds; therefore, frequencies of these alleles vary
across populations due to founder effects and population sizes. For example, mutations
in CHEK2 exist in

~ 1%

of Dutch, Finnish and Ashkanazi Jewish populations, while

PALB2 mutations have been identified in Finnish and French-Canadian populations

(Erkko et aI., 2007; Foulkes et aI., 2007; Nevanlinna and Bartek, 2006). In addition,
BRCAlI2 mutations have been identified in Ashkanazi Jewish women at frequencies 10-

50 times higher than those in the general population (Neuhaus en et aI., 1996; Oddoux et
aI., 1996; Roa et aI., 1996; Struewing et aI., 1995). Although variation in these highlyand moderately-penetrant alleles contribute significantly to breast cancer susceptibility,
the total population frequency is low with combined frequencies of approximately 0.4%
for BRCAlIBRCA21TP53 and <0.6% for PALB21BRIlPIATMICHEK2 (Lalloo and Evans,
2012). Furthermore, less than half of familial breast cancer patients exhibit predisposing
mutations in these genes (Ford et aI., 1995; Ford et aI., 1998; Smith et aI., 2006).
Population-based estimates indicate mutations in high-penetrance genes account
for 25% or less of the heritable component of breast cancer susceptibility (Easton, 1999).
This suggests that the majority of heritable risk of developing breast cancer is attributable
to additive, dominant, and interactive effects of low-penetrance genes. However, the
number and properties of these genes are not known. Much of the work performed to
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identify low-penetrance breast cancer genes has focused primarily on case-control studies
targeting potential candidate genes involved in cancer related pathways (de long et aI.,
2002; Nathanson and Weber, 2001). Unfortunately, results of these studies have yet to be
validated in larger population-based studies (Wooster and Weber, 2003).
Although useful, risk models that include family history, such as the Gail model,
are limited in power. It has been calculated, accounting for no genetic factors, that 62%
of breast cancer cases can be predicted to occur in 50% of the population at high risk and
15% can be predicted in the 10% of the population at highest risk. However, if all of the
low-penetrance alleles were known, the ability to predict breast cancer in 50% of the
population at high risk would increase from 62% to

~90%.

This would present the

opportunity to detect breast cancer earlier (Pharoah et aI., 2002). Therefore, identifying
and characterizing common, low-penetrance breast cancer genes will strengthen breast
cancer screening and prevention programs.

Common Human Genetic Variation and Breast Cancer
Genetic variation between individuals occurs at a myriad of sites across the
human genome. These variants fall into two broad classes based on their nucleotide
composition: single nucleotide polymorphisms (SNPs) and structural variants (Frazer et
aI., 2009). As the name implies, SNPs are variants at a single base position. To date,
more than 12 million SNPs have been catalogued (2005).

Structural variants are

insertion-deletions (indels), inversions, block substitutions, and copy number variants
(Frazer et aI., 2009). The ability to effectively detect structural variants has been lacking;
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therefore, much is still not known about the frequency of these variants and their
association with human disease.

However, current estimates point toward structural

variants accounting for 20% of all genetic variation (Frazer et aI., 2009).
Human genetic variants are defined by their minor allele frequency (MAF), which
is, simply, the lowest allele frequency that a particular variant is observed in a population.
Common variants are defined as having a MAF of 1% or higher. SNPs are observed
more often than structural variants among individuals and it is estimated that
approximately 7 million SNPs have a MAF of 5% or higher with the rest being between
1% and 5% (Barrett and Cardon, 2006; Frazer et aI., 2009). These SNPs can be used to
mark common variation that is hypothesized to underlie genetic susceptibility to
developing breast cancer (Fletcher and Houlston, 2010; Frazer et aI., 2009; Lee et aI.,
2011 ).
Identifying common genetic variants that contribute to disease requires the ability
to screen and analyze thousands of variants in a large cohort of individuals in diseased
and non.:diseased populations.

With the advent of high throughput genotyping

technologies, population-based genome-wide association studies (GW AS), which assess
thousands of SNPs in thousands of individuals, is possible. In another technological
advancement, next-generation sequencing techniques that allow for sequencing of large
regions of genomic DNA in large sample populations can be incorporated into GWASs.
By comparing the genotypes of diseased to non-diseased members of a popUlation, novel
genetic determinants may be identified that associate with disease risk. GW ASs are now
employed to identify novel common genetic variants that associate with an increased
susceptibility or resistance to developing breast cancer. Since 2008, 23 breast cancer risk
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OW AS reports have been published using libraries of common polymorphisms to assay
genetic variation in human populations (Hindorff et aI., 2009). Several common SNPs
have been identified in OWAS that associate with increased incidence of breast cancer
and these SNPs are located in regions containing novel potential breast cancer
susceptibility genes (Easton et aI., 2007; Turnbull et aI., 2010).

Particularly, a OWAS

by Easton et al. identified five independent loci that showed a strong correlation with
increased breast cancer incidence (P<10-7) (Easton et aI., 2007). Of these five loci, four
contain plausible potential causative genes, i.e. FGFR2, MAP3K1, TNRC9, and LSP 1.
Although these genes are plausible candidates, further study is necessary to confirm
genes contributing to differences in susceptibility.
Further, additional SNPs are often in linkage disequilibrium (LD) with variants
that show a positive association to risk.

Put differently, particular SNP alleles will

frequently be found together in LD and one of these SNPs can be genotyped to "tag" the
other SNPs in LD. As a consequence, SNPs used in genome-wide screens may only
mark a region carrying an allele associated with a disease phenotype while the causative
SNP may be unknown. In other words, the causal variant may not be the one tested in the
OWAS. Moreover, tagging SNPs tested in a OWAS may also be in LD with common
structural variants, the majority of which have not yet been identified. This underscores
one of the limitations of OWAS: there is no simple way of moving beyond statistical
association to understanding the functional relationship between a genetic locus and a
complex disease phenotype (Frazer et aI., 2009).
Another limitation of OW AS is the prospective lack of sufficient statistical power.
Many OWAS have been conducted using sample sizes of 2,000 to 5,000 individuals and
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have the statistical power to identify common variants an odds ratio (OR) of 1.5 or higher
(Altshuler et aI., 2008). To detect variants with an OR of 1.1, studies would require
60,000 individuals to be tested. Although, some of the common genetic variants already
identified have per allele OR of <1.30 (Ahmed et aI., 2009; Antoniou et aI., 2010; Cox et
aI., 2007; Easton et aI., 2007; Garcia-Closas et aI., 2008b; Milne et aI., 2009; Stacey et
aI., 2008; Thomas et aI., 2009; Turnbull et aI., 2010) it is likely that many low-penetrance
alleles may have been missed due to the small affect on susceptibility. Additionally,
novel or rare variants may also be missed by GWAS. Thus, although GW AS have been
useful in identifying some common genetic variants associated with breast cancer
susceptibility, new approaches are needed to effectively study common, low-penetrant
alleles and their effect on disease susceptibility.

Gene-Environment Interactions

Further complicating studies of breast cancer susceptibility is the combined action
of risk-predisposing genes and environmental factors.

Aside from studies on genetic

variants in detoxifying metabolic enzymes, relatively little is known about the majority of
genetic risk alleles and their potential interactions with the environment (Masson et aI.,
2005). Recent studies have implicated potential interactions between FGFR2 variants
and hormone replacement therapy; however, these data are inconsistent (Prentice et aI.,
2009; Travis et aI., 2010). Additionally, a study was published on potential interactions
between ten environmental risk factors (age at menarche, parity, age at first birth,
breast feeding, menopausal status, age at natural menopause, hormone replacement
therapy, body-mass index, height, alcohol consumption) and twelve breast cancer
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susceptibility-associated SNPs (Travis et aI., 2010). No strong interaction was identified
between any of the 120 possibilities. However, the majority of women in this study were
post-menopausal, and therefore, these data may miss gene-environment interactions
occurring in younger women. Also, moderate modulations may be occurring that are not
being detected.

Detecting a gene-environment interaction requires a four-fold larger

sample size than does a main effect; thus, for a RR=-1.5 thousands of cases and controls
or tens of thousands of GW AS cases would need to be assessed (Thomas, 2010). This
study examined 7610 women with breast cancer and 10,196 controls; although a large
sample size, the authors acknowledge it may be insufficient to identify moderate effects
(Travis et aI., 2010).

Furthermore, these studies are somewhat limited in that they

exclude certain environmental components; i.e. pollutants such as BP A, PHCs and PCBs.
Exposure to these environmental pollutants is becoming more common and it is relevant
to assess the effect of exogenous chemical exposure in the environment on breast cancerpredisposing alleles.

Animal Models of Breast Cancer Susceptibility

Mouse Models for Breast Cancer Research
Human studies provide the most direct way of studying breast cancer
susceptibility. However, different approaches are needed to identify the effects of lowpenetrant alleles.

Human cell lines are routinely used to study breast cancer

development, progression and metastasis (Burdall et aI., 2003). They have a number of
advantages; they are easy to handle and represent a potential unlimited self-replicating
source that can be grown in almost infinite quantities.
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In addition, they exhibit a

relatively high degree of homogeneity and are easily replaced from frozen stocks if lost
through contamination.

There are disadvantages though, as cell lines are prone to

genotypic and phenotypic drift due to continual culture. This occurs as subpopulations
may arise over time by the selection of specific, more rapidly growing clones within a
population leading to phenotypic changes (Bahia et aI., 2002; Osborne et aI., 1987). In
addition to cell growth rate, changes have been observed in hormone receptor content,
karyotype and clonogenicity, despite the cells appearing morphologically identical.
However, the most important weakness for susceptibility studies is that cell lines are
usually derived from tumors and have adapted to growth in culture. Although cell culture
tries to create a close-to-physiology milieu by adding appropriate amounts of salt,
glucose, amino acids, vitamins, and serum, the lack of tissue architecture and
heterogeneous population of cell types often abolishes cell-cell interaction, secretion, and
other functions based on tissue context (Pan et aI., 2009). As stated, cells in culture are
prone to genotypic and phenotypic drifting. Thereby cell lines can lose tissue-specific
functions and acquire a molecular phenotype quite different from cells in vivo. Thus, cell
lines are limited in scope and cannot fully replicate the disease phenotype. Although they
can be used to study specific molecular targets in transformed cells they are not an
effective model to study breast cancer susceptibility.
Use of animal models has been an effective approach for studying human
diseases.

Various model organisms have been successfully used to study aspects of

different human diseases in vivo. The most widely used animal models of breast cancer
are the mouse and the rat. Mouse models have the benefit that more genetic manipulation
techniques exist for them compared to the rat.
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Many transgenic models have been

developed taking advantage of the long terminal repeat (LTR) of the mouse mammary
tumor virus (MMTV) (Hutchinson and Muller, 2000). The MMTV-LTR is active in the
mammary gland and was shown to be able to promote expression of genes in a mammary
gland-specific manner (Cardiff and Kenney, 2007). The MMTV -Polyoma virus middle T
antigen MMTV/PyV mT mouse model is one of the most widely used experimental
animal models used to study mammary tumor development and metastasis.

In this

model, the mT antigen derived from PyV was placed under the transcriptional control of
the MMTV-LTR (Guy et aI., 1992a). The mT antigen was identified to induce multifocal
tumors in mammary glands through activation of various signaling molecules such as Src
family kinases and phosphatidylinositol 3' kinase (PI3K) in mice (Guy et aI., 1992a).
This mouse model develops polyc1onal tumors aggressively within 7-8 weeks with a high
degree of lung metastasis (Marcotte and Muller, 2008). The MMTV/PyV mT mouse
model is often used in combination with gene knockouts to examine the influence they
may have during mammary carcinogenesis or metastasis.
Another widely used transgenic mouse model is the HER21neu or ErbB2 mouse.
HER2 codes for a tyrosine kinase growth factor receptor and is the human ortholog of the

rat neu oncogene that was identified to increase neuroblastoma development (Coussens et
aI., 1985; Schechter et aI., 1985). Since it was identified in humans, HER2 has been
identified to be overexpressed in 20-30% of human breast cancers and has become a
prime therapy target for treating breast cancer (Wang et aI., 2000). The mouse ortholog
of HER21neu is ErbB2.

ErbB2 was identified to be an oncogene in studies using

transgenic mice that overexpressed activated neu under the control of an MMTV
promoter. While mammary epithelial expression of activated neu is sufficient to induce
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mammary tumorigenesis, few activating mutations in HER2 have been identified in
humans, suggesting it exerts oncogenic effects through overexpression of the wild-type
Her2 receptor (Lemoine et aI., 1990). The ErbB2 transgenic mouse model of breast

cancer was developed with a trans gene carrying the wild-type ErbB2 proto-oncogene
under the control of the MMTV promoter (Guy et aI., 1992b). Overexpression of wildtype ErbB2 results in multi focal tumors, but they occur with a longer latency compared to
the MMTV-PyV mouse model of breast cancer.

Further, MMTV-ErbB2-induced

mammary tumors are less metastatic than MMTV-PvV-induced tumors (Guy et aI.,
1992b). Regardless, the ErbB2 transgenic mouse model has been used extensively to
examine the role of the ErbB2 proto-oncogene in mammary tumor development.

In

addition, the MMTV system has been extensively used to study other proto-oncogenes,
e.g., c-myc and cyclin Dl (Stewart et aI., 1984; Wang et aI., 1994). Overall, the use of
the MMTV transgenic mouse system has led to a greater understanding of the genetic
machinery of mammary carcinogenesis.
In addition to transgenic mouse models, gene knockout mice are regularly used
and these have been combined with 'knock-in' and conditional tissue-specific gene
targeting technologies allowing for a wide range of approaches to study human disease
(Hutchinson and Muller, 2000; Maddison and Clarke, 2005).

These studies involve

deleting or inserting specific genes of interest into a targeted region using targeted
recombination.

Moreover, the development of the Cre-Lox system has allowed for

conditional and/or temporal deletion of target genes (Maddison and Clarke, 2005). With
this method, specific regions of DNA, e.g. whole genes, exons, promoters, are flanked by
specific pieces of DNA termed 10xP sites oriented in the same direction. When crossed

27

with mice carrying the Cre recombinase gene, Cre expression carries out 10xP-specific
recombination in a topoisomerase-like manner; thereby cleaving out the intervening
sequence between the two 10xP sites (Maddison and Clarke, 2005). When Cre is under
the control of a tissue- or development-specific promoter, the knockout is directed to
specific sites and/or at specific points in development. Also, inducible systems have been
developed to control expression of genes when administered a specific inducer. Gossen
and Bujard developed the tetracycline (tet)-dependent transcriptional activation system
allowing spatial and temporal control of effector gene expression through the use of a
tissue-specific transactivator (Gossen and Bujard, 1992). When an effector gene is under
the control of the tet system, expression is activated only when the mouse is administered
tetracycline in the diet.

Therefore, gene expression can be easily turned on or off.

Moreover, Cre can be placed within a tet-dependent system making it inducible (Gossen
and Bujard, 1992; Maddison and Clarke, 2005). This way, the knockout only occurs
once the mouse has been administered tetracycline. However, the Cre-Lox system has
been found to have "off target" effects where Cre acts on lox-like sites causing
inadvertent deletion (Maddison and Clarke, 2005). Regardless, the Cre-Lox and the tetinducible systems have been useful in dissecting pathways of genes involved in a host of
diseases.
A genetic "tool box" has been developed for the mouse making it a useful model
to study the genetic and molecular aspects of human disease.

The mouse has been

instrumental in identifying mechanisms of specific genes involved in mammary
carcinogenesis and this has increased our knowledge of these genes in human breast
cancer.

There are additional models and technologies not mentioned that are being
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employed to study many human diseases including breast cancer.

Furthermore, new

technologies for using the mouse continue to be developed.
Rat Models of Breast Cancer Susceptibility

Although mice are widely used to study mammary carcinogenesis, there are some
key differences between mice and humans in the pathology of mammary and breast
tumors that each species develops. First,

~50%

of breast carcinomas arising in humans

are ERa positive and thus are hormonally responsive while mouse mammary tumors are
almost exclusively ERa negative and hormone independent (Marcotte and Muller, 2008).
Also, human mammary gland tissue is primarily made up of connective tissue, while
mouse mammary gland stroma consists mainly of adipocytes (Marcotte and Muller,
2008).

Thus, mouse model studies on mammary carcinogenesis are lacking in their

ability to translate to human breast cancer.
The laboratory rat is preferable for the study of breast cancer susceptibility
because the pathology of rat mammary cancer is more similar to human breast cancer.
Although mouse models clearly have merit in understanding human disease, rats are
more similar to humans than mice in their normal physiology and pathogenesis. Both
rats and humans develop tumors that arise in epithelial cells lining the mammary gland
duct have similar histopathology, and both develop the same proportion of hormonedependent and endocrine therapy, e.g., tamoxifen, -responsive carcinomas (Gould, 1995).
This is contrary to the mouse where most mammary tumors are hormonally refractive and
many tumors are of endothelial cell origin (Gould, 1995). Additionally, while a majority
of mammary tumors that form in mice are induced by MMTV, rats and humans do not
form mammary tumors with a known viral etiology (Gould, 1995). Finally, and most
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importantly for mammary gland susceptibility studies, rats and humans both have a
natural genetic variation in mammary and breast carcinoma susceptibility (Dunning and
Curtis, 1952; Dunning et aI., 1947; Gould, 1995; Isaacs, 1986; Isaacs, 1988). These
similarities make the rat an ideal model to study natural variation in development of
.
.
mammary carcmogeneSlS.

Various rat models have been developed to study breast cancer susceptibility.
Age and gender are the most widely accepted risk factors affecting breast cancer
development and this has been attributed to ovarian hormone exposure. Dunning et al.
discovered that the ACI rat strain was susceptible to estrogen-induced mammary cancers
(Dunning and Curtis, 1952; Dunning et aI., 1947; Dunning et aI., 1953; Shull et aI.,
1997). Conversely, Copenhagen (COP) rats are almost completely resistant to developing
estrogen-induced mammary tumors. In this regard, ACI and COP rats are commonly
used together to study estrogen action in the rat. Specifically, ACI female X COP male
and COP female X ACI female intercrosses were performed to generate Fla and FIb
progeny, respectively. Fl progeny were administered E2 to induce carcinogenesis and
tested for mammary carcinoma susceptibility. Data indicated no significant difference in
tumor incidence between F 1a, FIb or homozygous ACI rats. However, latency to
appearance of the first E2-induced mammary tumor was significantly prolonged in both
Fl populations compared to ACI homozygous rats (Shull et aI., 2001). Further, siblings
from Fla and FIb progeny were mated to each other to generate F2a and F2b progeny,
respectively, and Fla and FIb males were mated back to ACI females to generate
backcrosses a (BCa) and BCb progeny, respectively.

Using these lines a locus was

mapped on chromosome 5 that conferred susceptibility to estrogen-induced mammary
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carCInoma development.

This method was further utilized to identify multiple

quantitative trait loci (QTLs) in the ACI rat responsible for estrogen-induced mammary
carcinoma susceptibility (Gould et al., 2004; Kurz et al., 2008; Shull et al., 2001).
Other rat lines have varying propensities for developing exogenous non-estrogen
carcinogen-induced mammary carcinomas.

The Wistar Furth (WF) rat strain was

identified to be susceptible to developing spontaneous, radiation-, oncogene-, and
carcinogen-induced mammary carcinomas (Gould,

1986; Moore et al.,

1983).

Conversely, the COP rat strain is susceptible to ionizing radiation and oncogene-induced
mammary carcinogenesis, but is almost completely resistant to developing chemical
carcinogen-induced mammary tumors (Isaacs, 1988). Studies using ionizing radiation on
(WF X COP) Fl rats detected random allelic imbalances throughout the genome leading
to development of mammary tumors with no preferential loss for either the WF or COP
parental alleles (Haag et al., 1996). This indicates that neither the WF nor COP allele
confer resistance to radiation-induced mammary carcinogenesis. Additionally, both WF
and COP females treated with a v-H-ras oncogene-containing retrovirus directly infused
into the mammary gland develop similar tumor incidences (Wang et al., 1991). As
previously mentioned, COP rats are resistant to estrogen-induced tumors; however,
hormonal promotion enhanced the penetrance of the ras oncogene on mammary tumor
formation in both COP and WF female rats in a similar manner (Wang et al., 1991).
Although the COP and WF rats showed similar tumor incidence from ras oncogene
induction, COP tumors were more differentiated and less invasive than WF tumors
(Wang et al., 1991). This suggests that although oncogene activation in situ was able to
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ultimately overcome the resistance phenotype, COP rats still exhibit a less malignant
phenotype compared to WF rats.
Mammary Carcinoma Susceptibility Quantitative Trait Loci
Mammary Carcinoma Susceptibility Alleles

The rat is not as easily genetically manipulated as the mouse. Until recently,
chemical or random-insertional mutagenesis screens had been employed in the rat to
identify causative genes for specific phenotypes (Aitman et aI., 2008). Now, transgenic
rat models are available and it is possible to generate knockout lines (Aitman et aI., 2008;
Geurts et aI., 2009). However, these approaches are biased towards particular genes of
interest or involve disrupting the genetic architecture by random insertion of foreign
DNA into the chromosome.

Although these methods may be used for validating or

studying the effects of specific genes, they are not suited for forward genetics studies
focused on identifying genotypes responsible for disease susceptibility phenotypes.
Instead, congenic rat lines have been developed that allow one to study mammary
carcinoma susceptibility in a "natural" context. Congenic lines take advantage of varying
susceptibility phenotypes between different rat strains. Congenic rat lines for mammary
carcinoma susceptibility studies are developed by introgressing alleles from a resistant
strain onto a susceptible strain by first identifying an allele of interest in an F 1 population
and then continuously backcrossing to a recipient strain. By genotyping and selecting for
the donor allele of interest, the donor allele is retained and introgressed onto the genotype
of the recipient background strain (FibJUre 1) (Markel et aI., 1997). Lines with different
segments of the donor allele can be tested to map a genetic locus to define the allele of
interest.
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Figure 1: Congenic Breeding Scheme. Homozygous susceptible male rats (WF) are
bred to female resistant rats (COPIWKy/BN) to create an FI heterozygous population.
FI progeny are genotyped for the allele of interest. FI males containing the allele of
interest are backcrossed to WF females to produce the N2 population.

At each

subsequent generation the litters are genotyped and males carrying the allele of interest
are backcrossed again to WF females .

At the N8 generation, speed congenics are

potentially viable to use for mapping as the background genotype is >99%. However,
backcrossing to NIO is common.

At NIO (or N8) heterozygous male and female

littermates are inbred and the offspring are genotyped to identify pups homozygous for
the target allele. These homozygotes are inbred continuously to fix the line for the allele
of interest.

0,.

and • represent resistant female, susceptible male, and susceptible

female rats, respectively.

The gray shade of a circle or square depicts the genotype

percentage of the background genome in heterozygous offspring; i.e. as the percentage of
the background genome becomes more WF, the shade becomes darker gray . • , L\I, and
~ inside a circle or square represent the target allele when it is homozygous WF,

homozygous COP, and heterozygous, respectively.
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Work by our group employs congenic strains developed with resistant alleles
COP and Wistar Kyoto (WKy) donor strains on a WF background denoted as WF.COP
and WF.WKy congenic lines, respectively. In contrast to WF rats, COP and WKy rats
have been shown to be almost completely resistant to developing mammary carcinomas
induced by the chemical carcinogens DMBA and N-Nitroso-N-methylurea (NMU) (Haag
et aI., 1992; Isaacs, 1986).
WF.WKy and WF.COP have been used to identify novel independent loci
affecting mammary carcinoma susceptibility (Cotroneo et aI., 2006; Haag et aI., 2003;
Lan et aI., 2001; Samuelson et aI., 2003). These QTLs have been denoted as mammary
farcinoma

~usceptibility

(Mes) loci. The first Mes locus, Mesl, was found in a DMBA-

induced carcinogenesis study on female progeny from a (WF X COP)Fl X WF backcross
(Hsu et aI., 1994). Since then, WF.COP and WF.WKy congenic lines have been used to
identify other Mes loci: Mes2, Mes3, and Mes4, all found in WF.COP congenics, and
Mes5, Mes6, Mes7 and Mes8, found in WF.WKy congenics (Lan et aI., 2001; Shepel et
aI., 1998).

Each strain, COP or WKy, has three QTLs that increase and one that

decreases susceptibility to developing DMBA-induced mammary tumors. Only one QTL
in each strain overlaps with a QTL at the same genetic locus in the other strain. These
are COP Mes2 and WKy Mes6.

This illustrates the genetic diversity of mammary

carcinoma genetic susceptibility as both of these strains are highly resistant to developing
DMBA-induced mammary carcinomas.

Mammary Carcinoma Susceptibility Locus lb (Mcslb)
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As stated above, (WF X COP)F1 X WF backcrosses were used to identify the
Mesi locus.

Rats were divided into groups based on susceptibility: resistant (R),

undetermined (U), and susceptible (S). Rats from Rand S groups were genotyped using
micro satellite markers and the locus conferring resistance was determined to be on the
proximal end of chromosome 2 (Hsu et al., 1994). Resistant congenic F1 rats were
backcrossed to WF rats and progeny were genotyped to identify shorter regions of the
interval to fine map the Mesilocus. Results ofphenotyping showed that the Mesilocus
contained 3 independent loci that each reduced DMBA-induced tumor incidence by
~60%

compared to homozygous WF controls (Haag et al., 2003). These were termed

Mesia, Mesib, and Mesie (Figure 2). Interestingly, one of these loci, Mesib, contains a

region orthologous to a human locus identified in a GWAS of breast cancer susceptibility
(Easton et al., 2007).
Easton et al. (2007) reported the identification and validation of five novel breast
cancer susceptibility loci in a 3-stage breast cancer GWAS (Easton et al., 2007). One of
these SNPs, rs8893J2, has MAF of 0.38 with an allelic OR of 1.13 (95% CI=1.10 - 1.16)
and associates with an increase in breast cancer incidence (P=7 x 10-2°). Additionally,
SNP rs8893J2 localizes to a region on human chromosome 5 and is in LD with 6 other
SNPs contained within a 280 kb haplotype block (Figure 3)(Barrett et al., 2005).
Importantly, this human haplotype block is orthologous to a region within the rat Mes i b
locus. There are three transcripts annotated to the human locus delineated by the 280 kb
haplotype block; MAP3Ki, MIER3, and C50RF35 (Figure 3). These transcripts are also
annotated to the rat Mesib locus. In addition there are 7 more transcripts annotated that
lie nearby, but outside the 280 kb haplotype block on the human locus, that are also
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Figure 2: Chromosome 2 genetic map of Mcsl-congenic and -recombinant rat lines. Rat

lines are designated with capital letters. . , indicates the presence of two COP alleles
for congenic lines resulting in reduced mammary tumor development (one to four
carcinomas/rat);

D indicates the presence of two COP alleles for congenic lines

incapable of conferring resistance to tumor development (six to eight carcinomas/rat).
indicates areas of unknown genotype because of recombination.

D,

Three independent

regions of chromosome 2 were capable of conferring resistance to mammary cancer
development in COP-homozygous congenic rats.

These genomic regio ns are shown

as Mcsl a, Mcsl b, and Mcsl c. The chromosome markers used to identify the congenic
rats are listed to thefar right of the figure with genetic distances in centiMorgans (cM) to
the left of the marker names. The Mcsl QTL I-LaD interval is also shown between
D2Mit29 and D2Uwm13 .
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Figure 3: 280 Kb haplotype block containing breast cancer-associated SNP rs889312.
Transcripts are shown in blue with exons designated as vertical bars. Above, the location
of the tagging SNP rs889312 is shown in red, other SNPs in LD with rs889312 are
shown in black. Below, pairwise r2 values for LD are shown; light blue represents lower
disequilibrium, white is intermediate, and red represents strong disequilibrium. An
threshold of 0.80 was used to determine SNPs in LD in this block.
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contained in the rat Mcslb locus; GPBPl, IL31RA, IL6ST, DDX4, ANKRD55, ACTBL2,
and SLC38A9. MAP3Kl has been described as the most likely candidate gene due to its
role as a protein kinase and involvement in promoting cell growth and proliferation; still,
any of these genes could be involved in affecting breast cancer susceptibility in humans.
Furthermore, any of the SNPs or combination of variants in LD with rs889312 could be
causative to affect breast cancer susceptibility. Therefore, each SNP must be studied to
identify the causative variant. The original study identifying this human locus consisted
of an initial two-stage GWAS on 4,398 breast cancer cases and 4,316 controls, followed
by a third stage testing 21,860 cases and 22,578 controls from 22 studies (Easton et aI.,
2007). Testing individual SNPs in LD with rs889312 in this population would offer a
better view of the genetic composition associated with this phenotype; however, this
provides no insight into their function. Studying the molecular mechanisms by which
these SNPs are operating in a human population is not realistic. Therefore, the WF.COP
Mcsl b congenic rat line is a good model to study this locus in the context of breast cancer

susceptibili ty.
There are over 50 transcripts annotated within the rat Mcs 1b locus.

It is

anticipated that the causative gene is conserved between humans and rats which reduces
the number of viable gene candidates to be tested. Nonetheless, all of the transcripts
annotated to the current rat Mcsl b locus must be treated as potentially causative; thus, all
genes must be tested. It is useful, then, to attempt to reduce the number of genes to be
tested by narrowing the current rat Mcs 1b locus by means of positional mapping. The rat
genome has been sequenced and many microsatellite and SNP markers are available to
effectively map Mcslb to a narrower interval. Testing genes in the rat may identify the
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causative gene involved at the human locus. Related to this, the Mcs 1b rat model can
also be used to study the cellular and physiological phenotypes affecting mammary
carcinogenesis associated with this locus. On the whole, aMes 1b rat genetic model could
help determine mechanisms controlling human breast cancer that are associated with the
locus demarcated by SNP rs889312 and expand our current understanding of breast
cancer etiology.

Dissertation Overview
Overall Goal

The work presented in this dissertation is focused on using congenic WF.COP
Mcslb rat lines to study mammary carcinoma susceptibility. I made use of the varying

propensity for developing mammary tumors between WF.COP Mcslb congenic female
rats and homozygous WF female rats.

The overall goal was to narrow the genetic

interval and to identify potential gene candidates. Mapping the Mcslb locus to a shorter
interval reduces the number of potential gene candidates and focuses on identifying the
causative gene(s). Identification of the causative gene(s) could lead to development of
novel genetic tests for better diagnosis as well as novel targets for prevention and
treatment of breast cancer. In addition, I began to identify the cellular mechanism by
which rat Mcsl b affects mammary carcinogenesis and tumor development.

By

elucidating the means by which this susceptibility locus is working, we will increase the
current understanding of breast cancer etiology.

Hypothesis and Research Aims
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I hypothesized that the rat Mcsl b locus contains genetic elements controlling
molecular and cellular phenotypes that translate into mammary carcinoma susceptibility
phenotypes. By completing aim one; I successfully delimited the rat Mcslb locus to a
region of 1.1 Mb containing three genes. In aim two, I identified that the mammary
carcinogenesis susceptibility allele is acting in a mammary gland cell-autonomous
manner.

In aim three, I show that the transcript Mier 3 is a candidate modifier gene

controlling mammary carcinogenesis based on its differential transcript expression
between susceptible and resistant rat strains. These data will help us better understand
breast cancer etiology and may lead to better diagnoses and treatments of human breast
cancer.
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CHAPTER II
RAT MCS1B IS WITHIN Al MB REGION OF RAT CHROMOSOME 2

Introduction

The rat Mesilocus was originally identified on the proximal end of chromosome
2 in (WF x COP)F1 x WF backcrosses using DMBA to induce mammary carcinomas
(Hsu et aI., 1994). Previously, the Mesilocus was physically confirmed and positionally
mapped using congenic lines containing unique segments of the Mesl predicted QTL
interval. Female rats from these lines were tested using the same DMBA carcinogenesis
protocol and revealed that the locus contained three independent susceptibility loci that
conferred resistance to developing mammary carcinomas.

These QTLs were termed

MesIa, Mesib and MesIc (Haag et aI., 2003)(Figure 2).
The Mesl b locus is of particular interest because it is orthologous to a human
locus associated with increased breast cancer incidence that was identified in a GW AS
(Easton et aI., 2007). The human breast cancer risk-associated allele was tagged with
SNP rs8893I2 which lies within a 280 kb LD block on human chromosome 5. This LD
block contains three annotated transcripts; MAP3KI, MIER3, and C50RF35 (Figure 3).
The rat ortholog to this locus is contained in the Mes I b congenic line T interval, which
was mapped to a region delimited from marker D2UwmI7 to D2Meo42 (Chr2: 32051319
- 45248161).

This locus contains over 50 annotated transcripts, including Map3kl,

Mier3, and C50rj35. Mapping rat Mesl b to a narrower region will reduce the number of
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candidate genetic elements to be functionally tested and minimize the work required for
comparative genetic studies.
Many QTLs are multigenic or affected by more than one genetic element. For
that reason, two or more elements may potentially act in concert to affect susceptibility.
Narrowing the interval may provide insight into the function of this locus. Accordingly, I
attempted to map the Mcslb locus to a tighter interval using a congenic mapping
approach previously used to segregate and identify three independent loci contained
within the original Mcsl locus (Haag et aI., 2003). This approach will reduce the genetic
elements to be functionally tested as well as potentially identify complex genetic
interactions or additional risk alleles within the line T Mcs 1b interval.
The advantages of the rat over a mouse model have been noted. However, there
are other rat-centric methods that could be employed, e.g., transgenic rat models, rather
than the congenic approach used in these studies. Many genes are annotated to the rat
Mcsl b locus, as it is currently defined, and these could be tested in a transgenic rat model

by introducing the genes as transgenes under the control of an artificial promoter.
However, this approach would be extremely labor-intensive requiring the development of
over 50 transgenic lines.

Further, gene regulatory elements cannot be cloned into

traditional transgenic cassettes. This is critical, since we do not know the transcript
profile of the hypothesized candidate gene.

In this regard, bacterial artificial

chromosome (BAC) transgenic rats may be useful. BAC transgenics allow for up to 400
kb of foreign DNA to be cloned so that all the regulatory elements may be included. For
this reason, BAC transgenes are expressed in a more spatially, temporally, and
physiologically accurate manner. The current Mcsl b locus is delineated to a
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~ 15

Mb

interval containing 50 transcripts; thus, much like traditional transgenics, the BAC
trans gene method would also require many lines to be developed to tile across the region.
Moreover, if there are multiple components involved, using a BAC transgenic may
"hide" these effects. Another shortcoming of this method is that the BAC transgene is
incorporated randomly in the genome. Although regulatory elements and surrounding
DNA are included, this technique disregards possible long range effects, e.g., distal
enhancers and long range cis regulatory elements, thereby altering the context.
Although laborious and time-consuming, the congenic rat model is the preferred
approach. It is powerful in that it is unbiased with regard to the cause of action, i.e., the
heritable element(s) controlling the susceptibility phenotype may be non-protein coding
regulatory elements that control expression or processing, causative elements may be in
cis of secondary element, or they may be multigenic and require multiple factors.

Overall, congenics allow one to study the action of the Mcsl b locus in its native
physiologically-relevant environment.

For these reasons, I continued to use the

previously-described congenic approach for these studies.
Until now, the rat Mcsl b region has been genotyped using microsatellite markers.
The genome sequence for the rat is available and groups are attempting to develop SNP
maps of the rat genome (Nijman et al., 2008; Saar et al., 2008). However, the annotated
sequence is based on the Brown Norway (BN) strain, and the COP and WF genomes
were not included in SNP and haplotype studies; therefore, there are no well-documented
polymorphisms between the COP and WF lines in the Mcslb region. Identifying new
polymorphisms between the WF and COP strains will provide better markers to more
accurately map the Mcslb locus.

Moreover, within the 280 kb haplotype block
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containing the human Mcslb ortholog, SNP rs889312 is in LD with 6 other annotated
SNPs: rs12697152, rs1910020, rs1862625, rs1862626, rs4700485, and rs961847 (Figure
3). Any of the SNPs lying in the 280 kb LD block could be causative. However, it is not
clear which of these SNPs, if any, is the causative variant responsible for conferring
breast cancer susceptibility. Rat orthologs to the 7 human SNPs lying within the LD
block are not known. Consequently, identifying novel polymorphisms between the WF
and COP rat lines could potentially lead to identifying the causative SNP controlling
mammary carcinoma susceptibility and comparative genetics could be used to accurately
identify the causative SNP in the human genome.
Overall, identifying novel polymorphisms between the WF and COP strains will
add to the current knowledge of these strains and can be used for the mapping studies
described herein. These SNPs are potentially useful in that they may shed light on the
causative element responsible for the difference in mammary carcinoma susceptibility
between these two rat lines and identify the causative variant in the human genome.
Fine-mapping this region in the rat will reduce the number of potential gene candidates
that must be functionally evaluated. As stated, this approach is powerful in that it is
unbiased with regards to the cause of action, i.e., the heritable element(s) controlling the
susceptibility phenotype may be a regulatory element(s) controlling expression or
processing of a transcript. In addition, these elements may lie within or outside of the
protein coding region of the gene. Indeed, all of the SNPs in the human breast cancerassociated haplotype block lie outside of the transcribed regions of any of the annotated
transcripts. Furthermore, this approach may uncover complex genetic interactions and/or
potential additional mammary carcinoma susceptibility loci that lie within the region.
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Design and Methods

Resequencing
WF and COP rats were euthanized and splenectomized using a protocol approved
by the University of Louisville Institutional Animal Care and Use Committee (IACUC).
Spleens were frozen until DNA was isolated. DNA was isolated using a Gentra Tissue
DNA Extraction Kit (Gentra, Minneapolis, MN) and PCR amplified using AccuPrime
Taq polymerase (Life Technologies, Grand Island, NY) at specific regions defined in an
article by Cuppen and colleagues (Nijman et aI., 2008) or compiled in the STAR
Consortium SNP database (http://www.snp-star.eu/). These PCR products were purified
using a QIAquick PCR Purification Kit (QIAGEN, Valencia, CA) and sequenced using
the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies).

Sequencing

reaction products were purified with 5 I.d Agencourt AMPure XP beads and 80% ethanol.
Beads were washed once with 80% ethanol and subsequently eluted in molecular biology
grade water.

Sequence products were submitted for analysis to the University of

Louisville Center for Genetics & Molecular Medicine DNA Core using an ABI PRISM
3130XL Sequence Detection System (Life Technologies).
Additionally, random regions across the Mcslb locus were selected to be
amplified and sequenced to identify polymorphisms. Using the UCSC genome browser,
regions exhibiting stretches of di- and tri-nucleotide repeats were selected and primers
were designed using Primer3 (Rozen and Skaletsky, 2000) oligonucleotide design
software. Primers were obtained from Integrated DNA Technologies (IDT, Coralville,
IA). Using these primers, genomic DNA (gDNA) was PCR amplified and run on highresolution agarose gels to identify potential micro satellite polymorphisms between WF
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and COP sequence. Additionally, long spans were selected randomly across the Meslb
locus and PCR amplified and sequenced to identify potential SNPs between WF and COP
sequence. Sequence reads were analyzed using DNAStar Sequence Analysis software
(DNA Star, Madison, WI).

Congenic Strain Breeding

The congenic breeding method was detailed above (Figure I). The rat WF.COP
Mes 1b congenic lines T and B were used to generate new recombinant lines and

potentially isolate the SNP(s) and/or gene(s) involved in the breast cancer susceptibility
phenotype. These lines, containing varying pieces of the rat Mesl b locus, will be tested
using the DMBA mammary carcinoma susceptibility assay. The line T Meslb locus was
delineated to

~13

Mb interval at D2UwmI7:g2UL2-30 (Chr2:32051320-44932309) and

confers a reduction in mammary tumor development (Figure 2) (Haag et at, 2003). Line
B was delineated a Chr2 region from marker D2Mit29 to marker D2Rat201 Figure 2. In
addition to Meslb, the Line B COP interval contains Mesla and MesIc; however, the
recombinant lines at the distal end may be used to narrow the Mesl b locus.
Inbred WF male and female rats were obtained from Harlan Sprague Dawley, Inc.
(Indianapolis, IN). All housing and breeding was performed in the Research Resources
Center Animal Facility at the University of Louisville under protocols approved by the
University of Louisville Animal Care and Use Committee. Line T male and female rats
at the NIO generation or beyond were bred with inbred homozygous WF female or male
rats, respectively, at 12 weeks of age. Progeny were genotyped for unique recombinant
intervals of the Meslb locus. Novel recombinant rats were backcrossed with inbred
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homozygous WF rats to obtain heterozygous progeny. Heterozygous male and female
progeny were inbred to obtain progeny homozygous for the unique recombinant allele.
WF.BN-RN02 animals were generated in a similar manner by initially breeding

BN female rats (Harlan Sprague Dawley, Indianapolis, IN) to a WF male rat to obtain an
FI generation. An FI generation male was backcrossed to inbred (homozygous) WF
female rats and progeny were screened for the Mcslb locus using the markers mentioned.
WF.BN animals were bred out to the N6 generation. Mammary carcinoma susceptibility
phenotype studies were performed as described.

Genotype Analysis

Progeny from crosses between congemc and homozygous WF rats were
genotyped using an approved protocol. A tail clipping of each pup was taken at 1-2
weeks of age. DNA was extracted from tail clip samples using a Gentra Tissue DNA
Extraction Kit, diluted and PCR amplified using primers for informative micro satellite
markers. Multiple markers were tested spanning the length of the original line T locus
from D2Rat194 to D2Rat201 (Table 1). Microsatellite markers were analyzed by PCR
amplification using the GeneAmp Fast PCR system (Life Technologies) and separation
on 3% high-resolution agarose gels in TBE buffer. SNP markers were analyzed by either
PCR amplification followed by sequence analysis by the University of Louisville Center
for Genetics & Molecular Medicine DNA Core.
Phenotype Analysis

At 50-55 days of age nUlliparous female homozygous WF and female congenic
rats were administered DMBA (Acros, Pittsburgh, PA) at 65 mg/kg body weight by
gavage. DMBA was suspended in sesame oil at a concentration of 20 mg/ml, heated in
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Tabi" 1:

Informative microsattelite markers used to narrow Mcslh locus to 1.8 Mh interval

VI

0

Samuelson I.ah TD
D2Rat194
D2Uwm17
D2Mco43
D2GotIl
D2Rat195
D2Rat12
D2Mgh2
D2Rat199
D2Rat142
D2Ratl6
g2ULl-5
g2liL2-27
g2liL2-29
D2Mc042
g2UL2-30
D2Rat200
D2Rat201
D2Rat202

Public TD
D2Rat194
D2Uwml7
D2Mco43
D2Gotli
D2Ratl95
D2Rat12
D2Mgh2
D2Ratl99
D2Rat142
D2Rat16
12324219t
I 2324060t
NA
D2Mc042
I 2324220t
D2Rat200
D2Rat201
D2Rat202

Position*
29237360-29237535
32051319 73205163
32836549-32836763
33838802-33839075
33957192-33957523
39101957-39102109
39829003-39829053
41032096-4103220 I
42318356-42318464
43376467-43376635
43485572-43485628
44195286-44195382
44325512-44325564
45247893-45248161
44932096-44932309
48762858-48762979
49691463-49691646
51821000-51821161

Forward Primer Se9uence
TAATIGCAACAGGTCAGGGC
A AC,cTACAATGCCTAGCAAC
AACCACTlTI'AGAAI'GTfAATCAG
CCTGGTCTCTGTCTCTGTCTCA
TIGCTGTITCTi\GT,\TGTGCAGG
CC AGTCCCTC AGAAGGAACA
GAAATGGGGAGTCAGAGAAGG
TCAGGTATCTCCTATGGGGG
CACAAATGCATGTGTGCCTI
CTGCATGTGTIAAATCATTAGTCA
AGACAi\TCCCCCACAGACA!'
TAAATGTGGTITCCTITGCT
CATAACAGCAA.GAAGCATCA
GAGGAGTATATI'AGTlTGGGCTG
ATTCAATTCCAACAATCCTC
AGGGTGGTITGAAGCCAUIT
GCAACCACAAAAGGAGAAGG
TGGCTIAGCATAATCTCAGCA

Abbreviations: WF, Wistar Furth; COP, Copenhagen
Genotypes detem1ined using 3°'0 high-resolution agarose gel

*Position based 011 Rattus norvegicus
tMarkcr IDs in NCill database

Chromosome 2, genome bulid version 3.4

Reverse Primer Se9ucnce
GAGTGGATITGAGAGCAGCTG
CCAACAGGACTITAGTCATTG
CGATCCn'CATGGGGCTAACACI'
TCCTITAGCCTICCTITTGG
CCCATGCACACAAGTATGAA
GCAACCACATTITCAGAATIGA
TTrCTfGTTTACCTCTGTCTGGG
GAG CGC TCA 'ITG erc TeT CT
CAAAGCCTITGATIGTGCAA
ACTICACGATCCAGTCTGGG
GAGAAGGl'GCA'l'GTTCCAAA
TCAACGTAGCTGAAATIGTG
OOAAAAGAACAACrGTITGG
ATGGGCTGGCTAGTGAGAAAGTl'
CATITTCAAGCCTTACAGGT
CAGGA'ITGAACAGCAAGCAG
GCTAAC'l'AGAATGC ATlTCAAAATr
CGCCCAGCTCACATTAATTT

boiling water to dissolve and cooled to room temperature. For each congenic line, 15-25
female rats were used for phenotype analysis. At 15 weeks post DMBA administration,
rats were euthanized and the total number of mammary carcinomas measuring2:3x3 mm
in diameter were counted per rat. Spleens were removed to confirm genotype. Statview
(SAS Institute, Cary, NC) statistical analysis software was utilized for analysis. Data are
presented as means ± SD.

Nonparametric Mann-Whitney tests were performed for

analysis within congenic groups.

Haplotype Block Analysis
Human haplotype blocks and SNPs in LD are based on the GRCh371hg19 human
genome assembly and were identified using the LD and Tagger functions in Haploview
v.4.2

(www.broad.mit.edu/mpglhaploview/),

respectively (Barrett

et

aI.,

2005).

Sequences for human haplotype blocks were identified using the UCSC Genome Browser
(genome.ucsc.edu/). Syntenic analysis was performed using the Convert function of the
browser to determine the rat ortholog for the human haplotype block associated with each
SNP (Kent et aI., 2002).

Results

Line T Backcrosses Result in Novel WF.COP Mcslb Congenic Rat Strains/Lines
Mapping the Mcsl b QTL to a shorter syntenic interval reduces future comparative
genetics work and abbreviates the list of potential candidate genes to be tested. To fine
map the locus five congenic lines were generated by backcrossing Mcs 1b line T and line
B (Figure 2) to homozygous WF rats. These were termed F3, U2, W2, N3, and 14
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(Figure 4). Each of these lines contain a unique COP rat Chr2 segment of the Mcslb
candidate region from D2Uwm17:D2Rat201 (Chr2: 32051319 - 49691646) on a
susceptible WF genetic background (Table 2, Figure 4). Lines W2 and U2 contained a
COP allele spanning from marker D2Uwm17 to marker D2Rat142. Line N3 contained a
COP allele spanning from marker D2Uwm17 to marker g2ULl-5. Line 14 contained a
COP allele spanning from marker g2 Uwm65-18 to marker bUwm15-3.
When a unique recombinant animal was identified from a backcross, it was bred
to a homozygous WF animal to generate additional heterozygous rats. Progeny were
genotyped and pups lacking the recombinant allele were not used. Once enough male
and female rats carrying the allele of interest had been generated they were inbred to
produce homozygous rats. These homozygous rats were inbred from here forth to expand
and maintain the line.

Mammary Carcinoma Susceptibility Phenotypes of Congenic Lines F3, U2, W2, 14 and
N3 Shorten Mcslb to a 2 Mb Interval

Mcs phenotypes were determined using tumor multiplicity at 15 weeks following
DMBA induction of mammary carcinogenesis.

As anticipated, the lines exhibited

varying propensities to developing DMBA-induced mammary carcmomas.

Rats

homozygous for the F3, U2, and W2 COP allele developed 9.6 ± 4.1 (N=32), 5.7 ±
3.9(N=6) and 6.0 ± 1.8 (N=18) tumors per rat, respectively, while littermate homozygous
WF control rats developed 8.8 ± 3.5 (N=32), 6.3 ± 2.2 (N=12) and 5.9 ± 3.2 (N=9),
respectively (Table 2). These numbers suggest that there is no difference between rats
carrying the U2 and W2 COP alleles and rats having the WF allele in this interval.
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Figure 4: Rat Chr 2 map ofWF.COP lines delimiting Mcslb to 1.8 Mb. Markers used
to genotype WF.COP congenics are listed in relative positions on the y-axis. Lines are
labeled with letter-number combinations and designated with filled dark-gray bars to
indicate Mcsl b-resistant alleles. Lines that are drawn with unfilled bars represent COP
intervals incapable of conferring decreased susceptibility or resistance to mammary
carcinoma development. The filled light-gray bars at ends of each congenic segment are
intervals of unknown genotype. Lines T and K are shown again for reference.
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Table 2:
Mammary carcinoma multiplicity phenotypes (mean mammary carcinomas per rat ± SD) by genotype for WF.COP Chr 2
congenic lines used to map Mcs1b to 0.75 Mb

WF.COP Chr2 region

Line

coP/coP

N

WF/WF

N

P value *

21
18
32
25
15
18
6
19
12

8.3±3.3

19

8.8 ± 3.5
7.8±3.1

32
25

5.9 ± 3.2
6.3 ± 3.3
7.9 ± 3.7
6.4 ± 1.9

9
12
13
8

0.001
NS
0.8433
0.0001
0.0413
0.8498
0.8866
0.247
0.4179

(COP/WF)

D2Uwm171g2UL2-30
Vl
Vl

D2Uwm171D2Ulb4
D2Mgh21g2ULl-5
D2Ulb41ENSRlVOSNP 274
D2Ratl161ENSRNOSNP27
g2UL2-271D2Rat201
D2Rat16/g2UL2-30

Tt
Tt
F3
N3
N3
W2
U2
14
1b-ll

3.5 ± 2.2
(7.6 ± 3.4)
9.6 ± 4.1
3.4 ± 2.0
(5.5 ± 3.6)
6.0 ± 1.8
5.7 ± 3.9
9.3 ± 3.0
5.9 ± 2.2

Abbreviations: WF, Wistar Furth; COP, Copenhagen; Chr, chromosome
*P values from Mann Whitney tests

tLine T phenotype published previously by Haag et al. Cancer Research, 63:5808-5812, 2003

Similarly, female rats homozygous for the 14 COP allele developed 9.3 ± 3.0 (N=19)
tumors per rat compared to 7.9 ± 3.7 (N=13) for homozygous WF littermate controls
again suggesting that the congenic 14 rats have the same mammary carcinoma
susceptibility phenotype as homozygous WF rats. Conversely, female rats from line N3
that were homozygous for the N3 COP allele developed 3.4 ± 2.0 tumors (N=25) per rat
while rats homozygous for the WF allele developed 7.9 ± 3.7 (N=13) tumors per rat.
This is a ~56% reduction in tumor multiplicity for animals bearing the N3 COP allele and
is similar to the

~58%

reduction exhibited by rats carrying the line T COP allele.

Additionally, line N3 heterozygotes, only carrying one N3 COP allele, developed 5.5 ±
3.6 (N= 15) tumors per animal suggesting that the N3 COP resistance allele exhibits no
dominance over the WF susceptible allele.
1 was unable to define a precise distal end to the Mcsl b interval. Comparison of

microsatellite DNA and published rat SNPs located in the 0.66 Mb of genomic sequence
between the distal and proximal ends of lines N3 and 14 yielded no genetic variation
between resistant COP and susceptible WF alleles (Tables 3 and 4). It is possible that
polymorphisms between WF and COP exist in this 0.66 Mb region and have yet to be
found; therefore, there remains a potential area of recombination from marker g2ULl-5
to marker g2Uwm65-18. Taken together these data delineate the Mcslb locus to a 1.7
Mb region spanning from marker D2Rat142 at position chr2:42318464 to marker

g2UL2-29 at chr2: 44325564.

Targeted Resequencing of the WF and COP Mcslb Locus Reveals New Polymorphic
Markers and Tightens the Mcslb Interval
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Table 3:
Primer Sequences for MkTosatel\ites in 0,66 NIb region of ~lcs1b locus

VI
-....J

Samuelson Lab ID
AU046380
g2llL2-22
g2l'L2-13
g2t'L2-23
g2UL2-1
D2RAT267
D2Rat254
g2UL2-14
g21 :1,2-2
g21:1,2-15
g21'L2-16
g21:L2-3
g2{ 'L2-24
g21'L2-4
g2l'L2-25
g2UL2-5
g2t:L2-6
g2U1.2-7
g2t:L2-26
g2UL2-9
g2liL2-10
g2UL2-18
g2VL2-11
g2UL2-19
D2Rat298
g2CL2-12
g2UL2-27
D2Oot27
B!\, Brown

!\orway~

Public ID
AU046380
12324055
12324048
12324056
12324044
D2RAT267
D2Rat254
12324049
12324054
12324050
12324051
12324061
12324057
12324062
12324058
12324063
12324064
12324065
12324059
12324066
12324045
12324052
12324046
12324053
12324043
12324047
12324060
D2Got27
COP,

EnsembllD
AU046380

Copenhagen~

Forward Primer Seguence
GCCACCATTGTTATCTGACACA

Reverse Primer Seguence
CTCAGTGTGAGACCATGGTTCA

CAAC~AACTGACruGAGATAC

AGAGC~AATCAATTTGAA.GA

GTGTATGTrTAGGGGGTGM
GGACACATGAGCCAGTATTT
TACACrrGAGCAAGGACACA
CGCAGGAGAAACOCCrrATA
AGCATGACCAAGACATTCCA
CGCICfCTCTCTCATACACAC
(j(3AGGrrCATTAT<flTGT<iG
rrGGACCTAAC ACCTAGC'AT
GCCAGATGTAGTGGCATATT
GCACKiCAAAACATCTATACAC
CTTCCATACCTGACACACCT
GTAGGGGCTACAAAGGAAGT
GCrroAcTCiGTOACAAAGATr
TCTGGTTC AAAGAA.GACCTG
AATCCCCTTCTCA TTCTlTC
TCTGTrcAGTGAGAGATCCA
AGCAGCTGGTATAGAAAACKiT
OGGAAGGAAAGACTGACITC
CGGATCTTTTGAGTlTGAAG
TCGAGCTGTCTTCTGACTG
CGCTAAACCTGTCAACCTAC
TTCCCACn'CTrCATrCCTA
TCK.' AACTATCTATGCCAGTI'Cj(J
GACruAGTC ATCGAC'f(j(J'rJ'A
TAMTGTGGTITCCTrJ'OCT
ACCGTATGCACTTGATTTACAGAT

CCCAAAGA'fA:JUGTGAAGM
CTTGGAGACGACTGAAACTC
ACMGCCTGTTG'lTGTAGGT
CCTCAmTITCATCA(iCCTG
CGCCATGGAGAGAGATGCTA
CCTAAGACACTGGCTGAGAC
CTITC TC1TC TCrCC CCATr
ATAGGTCGAGATCj(JAAA4..CA
GTTTGACTTTTGGGACAAAT
ACTATGGGTAGAAACGCAAA
:\AC ATG ACACK.'TITGGA,'\AT
CCCAGGCTACACCAITAITA
GTCAGCTlTrGAAOGAACAC
AGGAGTTTTGGAGTGTCCTT
C,{,'A TCTTAAGGTCTGGAGTG
AGTCAGGACAAAGATACACAAG
OCACACn'GAGAGTGAGTGA
AGTCK.'TI'Gl'CJATGTCCTCrC
GTCruAATGGGGAAACTATTA
TTCTCCCTTCATCATGTCTC
AATAAAACCCACCACACAAC
GTCTGAACCCTACCATGAA.A
CAGGACAGGCAGAJ\GATGCT
CCTrGCTCTCT1-rCAAATTC
TCA4..CG'!·AGCTGAAATrGTG

WF, Wistar Furth

*Position is Rattus nonregiCllS genome build version 3.4
+Microsatellite D!\A genotypes were determined using 3°'0 high resolution agarose

CCATr.~\GTTGTCCTCTGCCC

Position·
43313765-43313989
43531384-43531546
43536766-43536909
43541442-43541637
43598558-43598706
43605867-43605989
43624817-43625068
43659242-43659460
43697612-43697849
43704760-43704927
43753048-43753283
43751704-43751942
43840761-43841043
43845450-43845697
43911826-43912026
43934522-43934761
43935644-43935818
43951932-43951951
43969019-43969339
44024519-44024723
44033098-44033281
44089085-44089302
44118131-44118361
44128126-44128291
44149293-44149181
44164273-44164510
44195286-44195382
44205860-44205910

Variant
WF"COPt
WFCOPt
WF-COPt
WF=CoPt
WF-COPt
WF=COPt
WF-COPt
WF-COPt
WFCOP+
WF-COPt
WF-COP+
WF-COPt
WFCOP+
WF COP+
WF-COP+
WF=COPt
WFCOPt
WF~COP+
WF~COPt

WF-COPt
WF;COP+
WFCOPt
WF=COPt
WF~COPt
WF~COPt

WF;COPt
WF,>COPt
WF<COPt

T .....:
S1\P markers tested on WI' and COP rats based on Ilublished datAofSNPs in the l>kslb inlerval
Samudson lab ID

PubliCID

bnsemble ID

R~02U1?:\12t

R N02n ,-,\ 1211
Rl'IJ2UI ,-A J1\'+

VI
00

",63769957

E:-;SR~OSNP274{)1l54

I:lN

COP

WI'

C
C

T

('

A

A

C

42421698

A
,\

0
G

0

12514359

C

A

A

(J

,.\

\

Forward Primer S«I,",n."

Reverse Primor Sequence

Position"

-\AA.'\TGCAGACCCATGTG{'
ClCAAACi(lTrTCATCT(nnTC

TGATGCCCTTTCATTGTCC
(iCT \(' <\A{;C A(iC An nOAA

42142131
42J10174

GAOCI'G'I,('AO'IUr(j(JCAAA

'I'GGAOC,\,\A'IU(lCI"I'CAO,\

4236415;

AGTCCCTCACAAATGGTAGAA

OGCCAOOAATAATGAGCAA
,\. \TG. HCTC,\TCGGCCTGT
CAGC ,\ATIACCG:\G:\TnC:\C

(reference)
C

'\

RN02l'L-AI2\\

",64618233

RN02t'In\12x

rs6441857K

ENSR~OSNP2785536

,\,\TOA TIGGCCCCAGTGT

RN021'T?AI2y

ENSRNOSNPI1R2721

Rr...021'L-AI27

rs 105808796
",(,616254'1

ENSRNOSNt>27855J8

C,('CTIGGTGTTTACATOAC.c
j"I('AlTGCrACClAlli(',\(iTlli

A(iCTATCCC ACTGA'\'nCI'CC

426U911
4267'}()O6

R.'1021'L-A 12aa

rs 105703830

ENSR.'IIOSNP1382993

CTGTACC ArnCTGCCATGC

CATCAnn,\ATJ-rroAOAAOCA

42782209

A

T

T

R,,02l'I?AI2bb

rs 105836290

ENSRNOSNPJ383048

CCGAGCTI'(ICTTGlTTGTT

TG(J,\OACCC ACGCTC'ITr

~2822772

T

C

C

RN02l'L·AI2cc

N639~8035

F.NSRXOS'llP2i~ ~ ~41

(i('CT ATGATOnATGCCC AOT

CACATGTGTG,\TCOC;\T,\(JC

T

C

C

J{l\U21'I~AI2dd

rs \1)70420115

ENSRNOSNl'2785542

GOn.'ATCJTO(iACAGlliAO

A

U

U

RN02l '1.."\ 12cc

I'sl06693272

ENSRNOSNP2785543

TITC'IG<iGAIT(iA(J(iACCA

Tl'OOATUGUU<.'AAAUACIA
C,\:\OCCG,\'!'Cn::AOCAU1T

4286%64
,UU52!!9
·U2525115

C

T

T

RN02I.L-A 121f

",64339116

ENSRNOSNP1383915

CT(ICCAGA,AGC XrCTAAA'\ACT

AAGTGG(JTGCTCTUTCITC A

43523570

T

C

C

RMJ2t:l.. ,\12gg

",107369228

ENSR.'<OSNP2785545

CTAArnOTfTCTGCTK

,\,\TCCTATCC,\AACTCrr

43544727

C

C

('

R'X021 'I-A 12hh

",66091~Rl

E:\'SRNOS:\'PI384088

T

C

C

ENSJ{NOSNt>271 X470

CC AlGA TL\CTCCTTTI
CI(iAACTI',\lrl"I"rll."l'Hi

43660982

rs(,5K2484lJ

TOe <\A "'CTOTrAC "'AM;
rrAOACCAOAAACCI'I"l'

H1>9'1296

A

(i

(j

CCAGOAAATIAACACTI
,\C, \AAGTCTT(.'TC, \;\GC

GCTCCATGATACATCC

43836007

C

T

T

OTCCCATG'rfTC!',\GTrA

C

T

T
;\

RNII21

l~,"\lZii

RN02l'l ,-A 12ii

1>8143555

R}'021'L-,\12kk

rs8171129

ENSR.\iOSNP2785549

G

RN02t'lrA1211

rslO7117602

ENSRNosNP2785550

CTACGATGAGTJ'(iTCTn

G

A

RMJ2UL-AI2mm

",65844~85

ENSRNOSNI'1384598

CTI'AOCAAC <\ TACC1TCT
CA'rCAITAGTCA('TG("1T

43838288
43')1807')

CCAACAGITrIAGTnCr

43987419

G

A

A

Rl'021IJ ~A 12nn

rs66189322

ENSRNOSNP2731297

OATOCA'r(IGTA,!'ATAGTGr

GA1'O'IT\AA,\CCA1T,\(jO

44180666

C

C

C

R;\02t'l?,,\12oo+

1'8107066908

ENSRNOSNP2785553

GCATTG,\CACTIGTJ'T,\

:\(ICTA TOTOTA TTGGTIC

44210175

C

C

G

Rl"02tJL-, \1 2pp

rs6402 1638

ENSR.'IIOSNPJ38496 7

CGTOO'lTOT:\'ITCTAACT

C :\OT AGTC:\CTCCACA TT

44242105

C

T

T

Table 4

VI

l;orward Pnm..:r Sequence

PubliCJU

Ensemble 1U

A48·ENSRNOSC'lP·1383684

... 105214022

EC'lSRC'lOSNP1383684

AGCCTGCACTGCC AACGTA

".48·ENSRNOS'<P·13836%

... J(J6710684

F'<SR'IOSl\'P 13836%

CTCTCC(,,oC,\GTCACAGGTT

Samuel""n lah JU

1.0

~ontinuted

Position-

RN
(rd,m:nc<)

TGGT(,'(}A.A TGC ACCGCTAC

43294777

C

T

T

TOGAO ".CT(;(,'{'AA TOCAAA TO

43308266

T

C

C

Reverse rrimcr Sequence

COP

WI'

,\4!l·ENSRNOS'II'· IJ~JN'JG

rs64N39!73

I.'1SR'IOSl\PI3113l196

I'CAGOGCG,\AC'I,(;A<.iAAAlK,

(j{,'UII..·Al'Ala.:AAACAIC nce

435U7047

0

,\

A

A48 .. ENSRNOS:-IP.. 138435 1

...64812820

E'ISR'IOS1\PI384351

GAACCCCTTCCTCGCTTGA'j'

TGTGOCTOTGGGTCACCA

43843704

A

(j

G

:\48 .. ENSRNOS'IP .. 1384874

n;65209285

,\Crt::CI':\OGTGOC,\,j'OTO.\TOA

44159855

T

C.UGTCGTGCTTCCTGTCCTT

TCAGGA.\GTCATGGAUGTGAGAC'

44164060

C
A

T

rs66201784

E:-ISR:-IOSNP 1384874
E'ISR'IOSl\'P 13848S0

CTGTG<.'C.\GCi\GGCT.\AGGT

".48·ENSRNOS'IP.. 13848S0

fi

(;

A48..ENSRNOS:-IP.. 2645369

... 107488981

DJSR'IOSNP2645369

42712802

T

C

C

... 64619323

,\OCCTGGTCCAGTGTCTC, \1\ TC
('('TOe A ,\'\T,,\TCT<K K:ATGT Acrrc

4366962~

\

G

G

",6~ltiH2ti

DJSR:-IOSNP2654615
E'ISR'IOSl\'1'2657179

nCAAUTGGCOOAGTOCn
,\-\T,\CAGGC(KiTGGATAATGi\o\(l,\
TfC(i(l'f(HCT .\('GTCKi'lT '\{K~'\

TCTOOOAG'rTCAOTGCTOTCTG

,\48 .. ENSRNOS'IP·2654615
,\4R .. ENSIINOS'II'·2657'7'J

4,181544,

'\

(;

(1

A4li .. ENSRNOS'II'.. 2685221

",66162549

F'ISR'IOS1\P2685221

C AITOCI 'ACCTA'llK.' AGn'OOA

OACOTG,\(K:GCATACAAAfC

42679006

<>

A

A

,'\48 .. ENSRNOS'IP .. 2686459

...63770151

DISR"IOSNP2686459

C AOTGTCTCC ,,\CCGACTGACC

43529896

C

T

T

'\48.. ENSllNOS"II'·2705085

",6546,1491'

F '1SR 'lOS l\' 1'27050S5

A(iTCl<l<iCOCTACCTrCA,\C,\

C-rITGCCCCGATACATCCAC
G<lCCATTG!\(;TC(l(iT(l(,rL\

4,1418586

T

T

,\4S .. ENSRNOS,'i1'·27060U5

rs66268295

L'ISR:-.IOS1\P2706005

(JOAG(;'L\AOCOUIOTGAOOA

AOCCI'rCAAOOA1OUUOAAU

43517914

C
G

A

A

A48 .. ENSRNOS"IP·2706295

rs66174360

E'ISR'IOSl\'P2706295

.\A TGCeC AAC ATCCCTTCCT

C ATGCC AC \CCCA,," \C A TTG

43377935

,\

A

,\

e

A48·ENSRNOS"Ip.. 2708093

... 65540697

E"ISR"IOSNP2708093
E'ISR'iOS!\P274411O

ACiOGACTCCTGGAAC,oG ATG
CAM 1.,\(;0 nlTH ;(irRTITC\

43418057
43006{)I.'

C

rs64996390

TAGOC ACCGAG AAGCC AC ,\T
,\(jCAllicnn UACTCTGAAT

lj

A48·ENSRN(]S;o.!P·27441 JO

C

T

T

A48 .. ENSRNOS:-II'·2769457

1'863803615

E:-.ISR'IOS~1'27694~7

,\AGAG'I'CC,\OOT,\GOO'lUUAU

O(,'ACTAAGCUATACCCXJ'GA

43376687

C

C

C

:\48 .. ENSRNOS"lP·2753~29
-\4R .. ENSRNOS'<1'.. 2778924

... 64232116
",106914580

E'ISR:-IOS1\P2753529

TCTTOOOTAC\CTUCCCACA

43753769
43191996

T

T

".CTC,ciCTTGCiCTGTTGGTGT

,\CGU,\(J(JO'nTI'GCCTGI1T
TGnTG(,OCT AAAA(l(;(;,-\C;(,T

,\

F"JSR'IOSl\'P2778924

T

C

C

AbbreviatIons: 111\, Brown Norwav (reference) COl'. l'oponhascn; WI'. W,.tar Furth
·Position IS based on RaUIH norveglclis ('hrt)mosomc 2. genome build

versi(~n

3.4

tlnionnative markers llsed in nam)\\IOO!vlcslb loem.

Sources' R1\02l'L mark"r.<, '1ijman eTal. mdC'Genomics 2008; A48 mark""" STAR COI1S1ortmm databa."

Up to this point, all mapping had been perfonned using microsatellite markers.
SNPs between WF and COP have not been tested and new markers were needed in the
region to effectively fine-map the Mcs1 b locus. I resequenced targeted regions in the
newly delineated Mcslb interval from D2Ratl42 to g2Uwm65-18.

Cuppen and

colleagues published a panel of SNP markers for the rat genome consisting of 820
different SNP assays tested in 34 different rat strains (Nijman et aI., 2008). SNPs assayed
in the study were chosen based on being polymorphic between BN, Wistar and Dahl/Salt
Sensitive (SS) rats. Of the 820 SNPs tested, 22 lie within the Mcs1 b locus, making this a
good tool to identify polymorphisms between WF and COP alleles (Table 4). Although
the Cuppen panel was tested on 34 different rat lines, the COP strain was not included.
Further, WF rats were tested but they were not the Harlan (WF IHsd) strain used in my
study. It was therefore, necessary to resequence WF and COP gDNA at these 22 sites to
detennine if they were polymorphic.
Additionally, a rat SNP map has been developed by the Specific Targeted
Research Project (STAR) Consortium (Saar et aI., 2008). The consortium sequenced
>100,000 SNPs in 60 different rat strains, including COP/Hsd; however, WF/Hsd was not
included.

To identify potential polymorphisms between WF and COP sequences I

identified 20 non-redundant SNPs from the STAR Consortium database lying within the
rat Mcs1b locus (Table 4). These were tested in WF and COP gDNA samples by Sanger
sequencmg.
Of the 22 Cuppen SNPs tested, 4 were identified to be polymorphic between WF
and COP alleles. These were tenned A12t, A12u, A12v, and A1200. Markers A12t, A12u,
and A12v lie relatively close to each other at positions chr2:42142131, chr2:42170174
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and ehr2:42364155 (Figure 5). Marker A12oo, however, lies much further downstream
near the proximal end of line 14 at position ehr2:44210175 (Figure 5). Sequence results
of SNPs from the STAR Consortium database revealed no polymorphisms between WF
and COP at any of these markers. All newly-identified markers will be useful in future
mapping studies to narrow down the Ales 1b locus.
I also attempted to identify new micro satellite markers by amplifying regions of
sequence containing di- and tri-nucleotide repeats, which are typical of microsatellite
polymorphisms. Results of these studies uncovered no polymorphisms between WF and
COP sequences. In addition, large regions of gDNA were resequenced in these areas
across the Mes 1b interval to identify potential SNPs. The results of this study showed no
polymorphisms between the two rat strains (Table 5).
The new SNP markers were tested on rats from congenic lines U2, W2, N3 and
14. Lines U2 and W2 tested homozygous for the COP allele at A12v and homozygous for
the WF allele at the more distal SNPs. Line 14 tested homozygous for the COP allele at
A1200 and homozygous for the WI' allele at the proximal SNPs.

Line N3 tested

homozygous for the WF allele at a12oo. Taken together, these markers slightly shorten
the Meslb interval to a region from A12v to A1200 (Chr2: 42364155 - 44210175).

Backcrossing Line T Generates a Novel WF.COP Congenic Line: Jb-ll

There are 10 annotated transcripts that lie in the newly-defined Mesl b locus
(Figure 5). Also, there is a region of potential recombination between markers g2 ULl-5
and A12oo. Further mapping could eliminate some of these transcripts and reduce the
number of potential gene candidates that need to be tested. To do this, 1 attempted to
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Figure 5: Genetic landscape of fine-mapped rat Mcsl b locus.

and

0 represent

regions with a COP genotype with resistant and susceptible Mcs phenotypes,
respectively.

0

represents regions with the COP genotype where the Mcs phenotype is

not known.

•

denotes regions of potential recombination where no markers are

currently known. Red and blue lines demarcate the location of informative SNP and STS
markers used to genotype the locus. The blue bar depicts the rat interval orthologous to
the human breast cancer-associated locus; SNP rs889312 and SNPs in LD are shown.
Annotated transcripts obtained from UCSC Genome database shown in black.
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Table 5:

Regions sequenced between Rat Chr2:43125940 and Chr2:43632545 to identify potential
polymorphisms between WF and COP in the Mcs 1b locus

Total conserved regions attempted to sequence
Regions Successfully Sequenced
Regions successfully sequenced with results that match reference gDNA files
% Regions sequenced resulting in both WF and COP sequences matching
reference
% Regions sequenced resulting in either WF or COP sequences matching
reference

Total potential polymorphic regions identified
Potential Microsatellites
Potential Insertion/Deletions
Potential SNPs
Potential Polymorphisms validated

194
142
103

24%
54%

86
4
27
55
0
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generate a new congenic line containing a COP allele from the end of line N3 at
micro satellite marker g2ULl-5 and spanning marker A1200 and beyond. I backcrossed
line T heterozygous rats to homozygous WF rats to generate novel unique recombinants
containing this region. 268 progeny were tested from these crosses and generated 3 new
recombinants.

These recombinant animals contained COP alleles spanning markers

g2ULl-5 to g2UL2-30 and were termed lines 1b-11, 1b-13, and 1b-14 (Figure 5). These
recombinants were backcrossed to expand the population and progeny were genotyped.
Pups containing the recombinant COP allele were inbred to establish a homozygous fixed
congenic line. Due to complications with attaining recombinant pups and insufficient
litter sizes, only 1b-11 was established as a new congenic line.

This line was

subsequently phenotyped as described.

Mammary Carcinoma Susceptibility Phenotype of WF.COP Congenic Line lb-ll Is
Not Different Than Homozygous WF Controls
Female rats homozygous for the 1b-11 COP allele and homozygous WF controls
were administered DMBA at 50-55 days of age and euthanized at 15 weeks post-DMBA
administration. Female 1b-11 rats developed 5.9 ± 2.5 (N=12) tumors per rat compared
to 6.4 ± 1.9 (N=8) tumors for WF controls (Table 2, Figure 6). The difference in tumor
multiplicity between the two lines is not statistically significant (P=0.4179). These data
suggest that there is no difference in the mammary carcinoma susceptibility phenotype
between I b-11 congenic rats and WF rats.

WF.BN Congenic Rat Strain/Line Is Resistant To Developing Mammary Tumors
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BN rats are almost completely resistant to chemical, radiation and oncogeneinduced mammary carcinogenesis. The Mcs 1b locus was identified between WF and
COP rat strains and it is not known whether this locus is functioning in the BN rat to
reduce mammary carcinoma susceptibility. If it is, the BN rat may be another useful
strain to study the Mcsl b QTL.
To address this, I used a WF.BN congenic line.

WF.BN congenic rats were

developed by introgressing a BN allele at the Mcsl b locus onto a WF background using
the method described previously.

Female WF.BN N4FI homozygous rats were

phenotyped along with homozygous WF controls.

WF.BN N4FI homozygous rats

developed 2.3 ± 1.5 (N=l1) tumors per rat while WF controls developed 5.4 ± 2.6
(N=28) tumors per rat (Figure 7A). The difference between these means is significant
(P=0.0012) and it suggests that the mammary carcinoma resistance exhibited by the BN
rat strain may be partly conferred by heritable elements lying within the Mcs 1b locus. To
be certain there was no difference between WF.BN N4FI rats carrying a WF allele at
Mcsl b and inbred homozygous WF rats, these groups were also compared (Figure 7B).

There is no statistical difference (P=0.2039) between congenic WF.BN N4FI rats
homozygous for the WF allele at Mcs 1b and inbred WF rats; therefore, these could be
pooled as susceptible controls.
With the knowledge that there are two other Mcs loci on rat chromosome 2, it was
necessary to define the full interval of the BN allele. To determine the length of the Mcsl
locus within the WF.BN locus, the N4FI rats were genotyped at markers along the
original Mcsl locus (Figure 2, line B; Table I). WF.BN N4FI rats had a BN allele
spanning markers D2Uwm17 to D2Rat210 (chr2:32051319-82193231) delineating a-50
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Figure 7: Tumor multiplicity in WF.BN congemc lines. A; Average mammary

carcinomas formed in congenic WF.BN N4F l and homozygous WF control female rats
after being administered DMBA.

Error bars denote standard deviation.

analyzed using Mann Whitney test.

Data was

B; Average mammary carcinomas formed in

congenic WF.BN female rats compared to inbred WF female rats. C; Map of WF.BN
congenic lines at N4 and N6 generations . • denotes a BN genotype with a resistant Mcs
phenotype. •

denotes regions of potential recombination. Black bars designate Mcs

loci 1a, I b, and 1c previously identified by Haag et al.
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Mb region (Figure 7C). There is a region of potential recombination at the proximal end
of the interval that overlaps with the Mcsic locus; therefore, the Mcsic locus may be
contributing to mammary carcinoma resistance in this line. Thus, 1 again attempted to
reduce the interval by backcrossing the WF.BN congenic rats to WF rats up to the N6
generation and these animals were again genotyped to identify the ends of BN allele. The
N6 generation contained the BN allele spanning markers D2Rat116 to D2Rat2iO
(chr2:33845498-82193231) shortening the interval to

with the Mcsic locus.

~48

Mb and eliminating overlap

1 attempted to further breed these animals out to the NIO

generation to eliminate the long stretches of BN genomic sequence flanking the Mcsi b
locus; however, due to complications, the WF.BN congenic line was lost. It was decided
that it was not feasible to pursue reestablishing the WF.BN congenic line.

Discussion

The Mcsib locus was previously delineated to a

~15

Mb interval bounded by

markers D2Uwmi7 and g2UL2-30 on rat chromosome 2 (Haag et aI., 2003)(Figure).
More than 50 transcripts lie in this region. To shorten this list and reduce subsequent
comparative genetics work 1 sought to fine-map this locus using a combination of
WF.COP and WF.BN congenic rats.
Five congenic lines were developed using a similar approach to what was used
previously to identify the Mcsi and its subloci: Mcsia, band c. Lines F3, U2, W2, 14
and N3 all contain COP alleles spanning various portions of the original line T
background genome (Figure 4).

Testing these lines for mammary carCInoma

susceptibility enabled me to narrow the Mcsi b locus. The tumor multiplicity data
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obtained from lines U2, W2, 14 and N3 delineate the Mesl b locus to a ~ 1.8 Mb interval
on chromosome 2 between markers Al2v and Al2oo. This markedly reduces the number
of transcripts to be functionally tested to thirteen.
As anticipated, the rat ortho10g to the human breast cancer-associated 280 kb
haplotype block lies within this 1.8 Mb region. It is likely that a heritable e1ement(s)
lying in this region is controlling rat mammary carcinoma susceptibility in a manner
potentially analogous to the human ortho10gous locus. Therefore, the rat may be used to
identify the mechanism of action and translate this to human disease susceptibility. The
human block contains 2 known transcripts, MJER3 and MAP3Kl, as well as a predicted
gene transcript, C50RF35 (Figure 3). Nearby, but lying outside of the human haplotype
block associated with rs8893l2, are approximately 7 other annotated transcripts (Figure
8). The rat contains ortho10gs to these transcripts within the Mes 1b locus although the
orientation of the rat Mesl b locus is reverse of the human locus (Figure 5). I anticipate
that one or a combination of the three transcripts lying inside the human haplotype
ortho10g is causative for the mammary carcinoma susceptibility phenotype. However, all
of the transcripts within the IIIesl b locus, including those lying outside the human
haplotype block ortho10gous interval, must be tested as they cannot be ruled out as
causa1.
The Meslb locus was mapped with the use of polymorphic microsatellite markers
published in the ROD public database (Dwinell et a1., 2009). However, many of these
were not informative between WF and COP genotypes.

Targeted resequencing of

regions in the narrowed Mesl b locus uncovered 4 SNPs polymorphic between the WF
and COP strains. Using these new SNP markers, the Mcslb locus was mapped to a
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shorter interval between markers A12v and A1200. Also, short genomic regions rich in
di- and tri-nucelotide repeats within the Mcsl b interval were sequenced; however, no
polymorphisms were identified between WF and COP alleles. Taken together these data
suggest that WF and COP share similar haplotypes.

However, since these newly

identified SNPs are positioned at the ends of the Mcsl b interval, it is unlikely that they
are causative; therefore, more polymorphisms likely exist in this region.
Breeding of line T led to the development of another congenic line, I b-ll. Line
lb-ll has a COP genotype from marker D2Rat16 to marker g2UL2-30. This interval
crosses the 0.66 Mb region from g2ULl-5 to A 1200 making it useful in identifying if this
area of potential recombination is contributing to the resistance phenotype (Figure 5).
Tumor multiplicity between homozygous I b-ll female rats and homozygous WF
littermates was not statistically different (Table 2). These data imply that this 0.66 region
from D2Ratl6 to Al200 does not contain the element responsible for the Mcslb
phenotype. It stands to reason, then, that the element conferring resistance to mammary
carcinoma development resides in the interval from Al2v to D2RatJ-6, thereby narrowing
the Mcslb locus to ~1.01 Mb.
These data signify that a more complex mechanism may be at work. Tumor
multiplicity data for line 14 and WF littermate control rats was 9.3 ± 3.0 and 7.9 ± 3.7,
respectively. Although the difference is not significant, it suggests a trend that may
indicate that the mechanism controlling susceptibility in the Mcsl b locus is much more
complex than originally thought. A resistant phenotype could be compensated for by the
action of another risk allele lying outside of the Mcsl b locus on the distal side. Indeed,
the OWAS by Easton et at. reported two additional alleles identified upstream of SNP
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rs889312 and an additional breast cancer-associated allele was identified on human
chromosome 5 in a subsequent breast cancer-GWAS (Easton et aI., 2007; Turnbull et aI.,
2010). SNPs rs981782 and rs30099 reported by Easton et al. are positioned on human
chromosome 5 at bases 45321475 and 52454339, respectively.

SNP rs981782 has a

minor allele frequency of 0.47 in the SEARCH population studied and associates with a
reduction in breast cancer incidence with an OR of 0.92 (95% CI=0.87-0.97) when
homozygous for the minor allele (Easton et aI., 2007). SNP rs30099 has a minor allele
frequency of 0.08 in the SEARCH population and associates with an increase in breast
cancer incidence with an OR of 1.09 (95% CI=0.96-1.24) when homozygous for the
minor allele (Easton et aI., 20(7). The magnitude of the affect associated with these loci
is much smaller than what is seen for SNP rs889 312. Regardless, the results from the 1b11 phenotype suggest that an additional risk allele may be present in the 1b-l1 locus. To
address this, I used a bioinformatics approach to identify rat orthologs of human SNPs

rs981782 and rs30099. I determined that LD blocks associated with these SNPs have
orthologs on rat chromosome 2 (Figure 9A). SNP rs981782 lies in a 56kb haplotype
block on human chromosome 5 and is in LD with one other SNP, rs4866929 (Figure 9B).
This haplotype block has a rat ortholog that spans from base pairs (bp) 49907723 to
49954324 on chromosome 2 (Figure 9A). SNP rs30099 is also in LD with only one other
SNP, rs30727 and lies in a 3kb haplotype block on human chromosome 2 (Figure 9C).
The haplotype block has a rat ortholog that lies on chromosome 2 from bases 46916997
to 46918680 (Figure 9A). SNP rs9790879 reported by Turnbull et al. lies within a 488
kb haplotype block on the p arm of human chromosome 5 and is in LD with
approximately 100 other SNPs (Figure 9D).
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Figure 9: Additional breast cancer-associated loci identified in GWAS with rat
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delimited by bp 49961197 and 50564367 (Figure 9A). When mapped to the rat genome,
none of these rat orthologs lie within the 1b-ll congenic region (Figure 9A).

This

negates the notion that there is a second allele that is offsetting the affect of the Mcs 1b
locus. However, this is based on the assumption that there must be a human ortholog. It
is possible that a second risk allele is present in this region but is specific to the rat or that
an ortholog to a human risk allele lies within the 1b-ll locus yet unidentified in human
studies.

Testing this idea would require the development of new congenic lines

containing varying portions of the distal end of line 1b-ll to define the specific region for
this phenotype.

However, this would be meaningless to human breast cancer

susceptibility if the effect is rat-specific.
Another potential explanation for the susceptible phenotype seen in the 1b-l1 line
is that Mcs 1b is a compound locus, i.e., resulting from the action of two or more variants
working in concert to give rise to the phenotype. Line N3 shows a

~56%

reduction in

tumor multiplicity compared to WF controls (Table 1). This indicates that the N3 allele
contains the necessary variants required to give rise to the resistant phenotype. The 1b11 interval overlaps the distal end of the N3 interval. Therefore, the 1b-ll allele could

harbor a variant that is insufficient alone and requires an additional variant lying
upstream. This variant would be present in N3 but lost in 1b-ll, thereby eliminating the
resistance phenotype in 1b-l1 congenic rats. Work here is not conclusive, but other
complex QTLs were identified that operate this way (Samuelson et al., 2007). To further
study this potential mechanism would require modifying the current approach by
incorporating cross-breeding of different congenic lines to determine whether the
resistant phenotype can be restored, i.e., breeding of U2 or W2 rats to 1b-l1 rats and
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phenotyping offspring containing both U2/W2 and 1b-11 alleles. If Mcslb is a complex
locus, these offspring should exhibit a resistant phenotype.
Gould and colleagues show that line T heterozygous female rats average 7.6 ± 0.8
(N=18) mammary carcinomas per rat (Haag et aI., 2003). This result was not statistically
different from WF-homozygous littermates (8.3 ± 0.8, N=18) but was significantly
increased (P<O.OOOl) compared to COP-homozygous line T rats (3.5 ± 0.5, N=21).
These data suggest that the WF allele at the line T locus exerts a dominant phenotype in a
Mendelian sense.

On the other hand, Line N3 heterozygous and COP-homozygous

littermates develop 5.4 ± 3.6 (N=15) and 3.4 ± 2.0 (N=25) carcinomas per rat,
respectively (Table 1). Both of these values are statistically reduced compared to WFhomozygous line N3 littermate female rats (7.8 ± 3.1, N=25). Tumor multiplicity in line
N3 heterozygous rats is approximately half compared to COP-homozygous littermates
signifying neither the WF nor the COP allele is acting dominantly. Taken together, these
figures show that there is a decided difference between the line T and N3 alleles. This
substantiates the notion that there is a more complex mechanism occurring at this locus.
The simplest explanation is that there is an epistatic allele placed in either the proximal or
distal regions flanking the N3 allele; however, other mechanisms may be at play. A
compound locus could exist as described above. Moreover, it may be that there is a cisinteraction requiring a second element that is present in the line T interval but is absent in
line N3. My data are insufficient to favor one scenario over another but suggest that the
mechanism of action at this locus is much more complex than originally anticipated.
In addition to the COP rat, the BN rat strain is also almost completely resistant to
developing

spontaneous,

chemically-induced,
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and

oncogene-induced

mammary

carcmomas. As previously mentioned, the BN sequence has been completely sequenced.
It is currently not known whether the resistant phenotype exhibited by the BN rat is

associated with the Mcsl b locus. The BN rat was tested to determine if the mammary
carcinoma resistant phenotype is controlled in part by the Mcsl b locus. If it is, the BN
could be an additional tool to help discover SNPs that may be involved in the COP
Mcslb phenotype. A WF.BN }.,{cslb congenic line had been initiated and I attempted to

establish this line in order to determine if the BN Mcsl b region confers resistance to
developing mammary carcinomas in similar manner to the COP strain.
Results of WF.BN phenotype studies were to be applied to further characterize
the Mcslb locus in the COP line as well as determine whether the Mcslb locus is
involved in controlling mammary carcinoma susceptibility in the BN line. By examining
the phenotype of the BN allele a 3-way haplotype analysis would rule in/out specific
polymorphisms in the Mcs 1b locus for their contribution to the mammary carcinoma
resistance phenotype. The BN haplotype carries a set of SNPs that is shared with the
COP allele (BN=COP at A'12v and A12oo) and can, therefore, be used to develop the
Mcsl b locus with a BN haplotype. Markers between WF and COP are infrequent in the
Mcslb interval; however, the BN strain has been sequenced and many more markers have

been identified. Therefore, these may be used to identify markers that may be used to
narrow the Mcslb locus.
Unfortunately, however, the line was lost before the NIO generation and the
Mcslb region narrowed. Regardless, data from initial studies with the WF.BN congenic

line at the N4FI generation imply that the mammary carcinoma resistance exhibited by
BN rats is, at least in part, controlled by the Mcsl b locus. This cannot be stated with
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complete confidence as the proximal end of the WF .BN rats contains a region of potential
recombination that overlaps with the Mesic locus. Therefore, the Mesic locus could be
involved. Additionally, these WF.BN congenics have large intervals ofBN sequence that
flank the distal side of the Mcs I b locus. These rats potentially harbor other risk alleles
that are controlling mammary carcinoma susceptibility, i.e. the rat orthologs of the human
haplotype blocks associated with SNPs rs981782, rs30099 or rs9790879. With the loss
of the WF.BN congenic line further investigation of the BN phenotype is not practical at
this time.
Overall, the data delineate the Mcsi b locus to a 1.01 Mb region flanked by SNP
markers A12v and D2Ratl6.

The variant(s) contributing to the Mcslb-conferred

resistance phenotype likely lies inside this interval unless the mechanism is much more
complex, as discussed. To determine the specific variant(s) contributing to mammary
carcinoma susceptibility deep sequencing of this region is needed to identify new variants
and test them accordingly. If no variant is identified lying inside the region delineated by
A12v and D2ratI6, this strongly implicates that Mcsi b requires additional cooperative

loci or that the 1b-11 line contains an epistatic allele downstream.
One of the goals for this project was to shorten the interval containing the Mcslb
locus to minimize the list of potential gene candidates that would need to be functionally
tested. This was achieved by mapping the Mcslb locus to 1.01 Mb. Within the 1.01 Mb
Mcslb locus there are five potential gene candidates: Actbl2, GpbpI, Mier3, C50rj35 and
Map3kI.

Mier3, C50rj35 and Map3kI all lie inside the region orthologous to the

rs889312 LD block. Although these three transcripts are the most likely candidates, any

one or combination of the genes contained within Mcs I b may be involved in controlling
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mammary carcinoma susceptibility and they must be tested further to determine their
role.
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CHAPTER III
RAT MCS1B ACTS IN A MAMMARY GLAND CELL-AUTONOMOUS
MANNER TO CONTROL MAMMARY CARCINOMA SUSCEPTIBILITY

Introduction

The etiology of mammary carcinogenesis is complex, involving events that occur
within the mammary parenchyma as well as events that are external to the mammary
gland. In both humans and rats, mammary tumors arise primarily in the cells that line the
mammary duct, the ductal epithelial cells.

One would expect, then, that genetic

differences that give rise to sustained proliferation and carcinogenesis would originate in
these cells.

Likewise, it would be likely that anti-oncogenic properties, such as the

phenotype conferred by the Mcsl b COP allele, also lie within these cells. Indeed, there
are both oncogenes and tumor suppressor genes expressed in the ductal epithelia that
affect tumor development; however, as mentioned previously, different groups have
shown that other cell types external to the mammary gland can affect pathogenesis
(Pollard, 2004; Sica et aI., 2006; Smits et aI., 2011b; Trimboli et aI., 2009).
Consonant with data illustrating mammary tumors originating in the mammary
epithelial cell (MEC) population, it has been shown previously that the effects of the
Mcsl COP locus are generally intrinsic to the mammary gland (Zhang et aI., 1990).

However, in these studies a slight mammary gland-external effect was observed, likely
due to mixed effects of multiple QTLs: Mcsla, band c. It is necessary, then, to test the
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Mcs 1b allele independently of the other COP Mcs alleles. This is critical to functionally

analyze potential candidate genes.

For instance, results of these mammary gland

autonomy studies will guide us as to what tissues or cell types to examine when assessing
transcript levels or protein expression. Moreover, knowing the site of function of the
Mcsl b allele may lend some insight into a viable gene candidate or a plausible role that a

gene may be performing to control mammary carcinoma susceptibility. There are five
potential gene candidates lying in the narrowed Mcslb locus; Actbl2, Gpbpl, Mier3,
C50rj35 and Map3kl. Of these, only Map3kl has been fully characterized. Therefore,

identifying the tissue or cell type that the Mcs 1b locus is conferring resistance to
mammary carcinoma development may provide leads as to potential functions of these
transcripts in the context of mammary carcinogenesis. Further, these mammary gland
cell-autonomy studies are critical in that they provide the basis for all functional studies
of the Mcs 1b locus and will potentially provide needed insight into the etiology of
mammary carcinogenesis.

Design and Methods
Whole Mammary Gland Tramplant Assays
Donor nulliparous female homozygous WF and line N3 WF.COP congenic rats
(N=~25

animals per group) were euthanized at 30-35 days of age and their abdominal

and inguinal mammary glands excised. The glands were scissor-minced and, using an
IACUC-approved protocol, transplanted into the interscapular white fat pad of agematched nulliparous female rats in a reciprocal manner; i.e. WF into WF.COP and
WF.COP into WF. Also, WF into WF and WF.COP into WF.COP transplants were
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perfonned as controls.

At 50-55 days of age, recipient animals were administered

DMBA dissolved in sesame oil (20 mg/ml) by oral gavage (65 mglkg body mass) to
induce mammary carcinogenesis. At 15 weeks post-DMBA administration, recipient rats
were necropsied and interscapular fat pads were examined for tumor development
(Figure 10). Fat pads were whole mounted onto glass slides and stored in 70% ethanol
for two weeks to allow for clearing of lipids from the pad. After two weeks, the whole
mounts were fixed with 1 part glacial acetic acid and 3 parts 100% ethanol for 1 hour,
hydrated by serially-decreasing ethanol washes (70%, 50%, 40%, distilled water) for 15
minutes each, and stained in aluminum cannine for four days. Aluminum cannine was
prepared by dissolving 2.5 g alum potassium sulfate (Spectrum Chemical, New
Brunswick, NJ) and 1 g Cannine stain (TCI America, Portland, OR) in 500 ml distilled
water, boiling for 20 minutes and filtering out precipitate. Once stained, whole mounts
were dehydrated again with serially-increasing ethanol washes (50%, 70%, 100%) and
finally a xylene wash. Whole mounts were stored long tenn in mineral oil. To verify
properly mammary gland development in the transplant site whole mounts were
examined for proper mammary gland duct elongation and TEB fonnation.

Whole

mounted fat pads were examined microscopically for frank carcinoma, ductal carcinoma
in situ (DCIS) and hyperplasia development. Tumor outcome was analyzed using

logarithmic regression analysis. DCIS and hyperplasia multiplicity data were analyzed
by Mann-Whitney rank test.

Mammary Gland Cell Preparation and Injection into Interscapular Fatpad
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Figure 10: Flow diagram of mammary gland grafting assay.
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Donor nulliparous female homozygous WF and line N3 WF.COP congenic rats
(N=~25

animals per group) were euthanized at 30-35 days of age and their abdominal

and inguinal mammary glands excised. The glands were scissor minced and epithelial
cells were enriched by enzymatic digestion in collagenase III (Worthington, Lakewood,
NJ) for 3-4 hours at 37° C.

Details of this method have been previously published

(Gould and Clifton, 1985). The mammary epithelial cell-enriched suspensions (hereafter
referred to as MEC preparations) were injected into the interscapular white fat pads of
30-35 day old nulliparious WF female recipients (N=16 animals per group) at 1 x 106
cells per animal in 100 III ofDMEM/F12 (Life Technologies,) media (1 x 107 cells/ml).
Whole mammary gland transplants from WF donors were performed as positive controls.
Tumor development in the ectopic mammary glands was examined 15 weeks
following DMBA administration to determine the mammary carcinoma susceptibility of
the ectopic mammary gland. Transplants that did not develop tumors were examined by
whole mounting the fat pad and staining with aluminum carmine to confirm that the
transplanted gland developed properly in the fat pad, as previously described. Fat pads
that failed to develop mammary glands greater than 3 x 3 mm2 were excluded from
further analysis. Previous studies utilizing this method have reported that a very small
percentage of recipient rats develop multiple tumors in the transplant site. Therefore,
tumor outcome was assessed as a binary response and analyzed by logistic regression.

Mammary Gland Cell Injections supplemented with Adherent Cell Fraction
Mammary gland cell preparations were made from WF donors usmg the
mammary gland cell preparation protocol described above. Adherent cells left in the
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flask were removed with Trypsin +EDTA (Life Technologies) for 5 minutes and placed
into 15 ml centrifuge tubes. Approximately 250 Jll FBS was gently added to the bottom
of each tube to form a distinct layer for the cells to be centrifuged into. The cell solution
was centrifuged briefly to collect cells and the supernatant discarded. The cell pellet was
resuspended in media and counted and herein referred to as adherent cell fraction (ACF)
preparations. ACF preparations were added to MEC preparations at 1: 10 ratio resulting
in a final MEC concentration of 1 x 107 cells/ml plus a final ACF concentration of 1 x 106
cells/ml.

MEC/ACF preparations were injected into the interscapular fat pads of

nulliparious WF female rats.

MEC preps alone were injected into the fat pads of

nulliparous WF female rats as a control. At 12 weeks of age all recipient rats were
administered DMBA.

Recipient rats were necropsied 15 weeks post-DMBA and

examined for tumor development in the ectopic site.
processed and stained with aluminum carmine.

Fat pads were mounted and

Stained fat pads were evaluated for

proper mammary gland development and hyperplasia and DCIS development was
assessed. Tumor, hyperplasia and DC IS data were analyzed using a Mann-Whitney rank
test.

Results

Whole Mammary Gland Transplants Suggest Rat Mcslb Is Mammary Cell
Autonomous
To determine if the Mcsl b COP allele reduces mammary carcinoma susceptibility
in a manner that is intrinsic to the mammary gland, rats were transplanted with whole
mammary gland tissue into their interscapular fat pads and exposed to DMBA (Figure
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10). All of the donor and recipient female rats used had a WF background and only

differed at the Mcs 1b locus having either a resistant COP or susceptible WF allele. We
expected that there would be no rejection of the graft as both genotypes have the same
major histocompatibility complex (MHC) type and, thus, have compatible immune
systems. To verify this, we determined that recipients did not reject mammary tissue
grafts from donors of different genotypes by microscopic assessment of whole mounted
fat pads.

There was no statistically significant association (P=0.1869) between the

outcome of ectopic mammary gland development and donor or recipient genotype (Table
6).

Data from ectopic mammary gland-positive fat pad whole mounts were analyzed
for associations of donor and recipient genotypes with ectopic carcinoma development.
Ectopic mammary glands formed from mammary gland tissue from Mcsl b resistant
donors, when grafted into either resistant or susceptible recipients, resulted in fewer
ectopic tumors forming compared to ectopic mammary glands from susceptible donors
when grafted into animals of either genotype (Figure 11). The genotype of the-donor was
significantly associated (P=O.OO 19) with ectopic mammary carcinoma outcome while
there was no effect seen from the recipient genotype (Table 7). These data signify that
the resistant phenotype conferred by the Mcs 1b COP allele is acting in a mammary glandautonomous manner. Based on this, future studies to functionally characterize the Mcsl b
locus should be focused on the mammary gland.

Enzymatically-Isolated Mammary Gland Cells Injected into the Interscapular Fat Pad
Reconstitute a Normal Mammary Gland in the Ectopic Site
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Table 6:

Graft site MG development outcome (dependent) and Mcslb donor and recipient
genotypes (independent)
Coefficient

P value

Donor Effect

0.99

0.1869

Recipient Effect

-1.31

0.116

2.7

0.0004

Intercept

89

Odds Ratio
(95% CI)

2.69
(0.62 - 11.68)
0.27
(0.05 - 1.38)
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Figure 11: Rat Mcs 1b is mammary gland autonomous, Percentage of mammary gland-

graft-positive recipients that developed ectopic mammary gland carcinomas are shown
for each susceptible (S) and Mcs 1b-resistant (R) donor:recipient group, Groups with S
donors are shown as filled bars, and groups with R donors are shown as unfilled bars.
The total number of mammary gland-graft-positive recipients that were evaluated for
tumor outcome in each group were, respectively, 27, 22, 23, and 18 for S:S, R:R, S:R,
and R:S,
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Table 7:
MG graft site tumor outcome (dependent) and Mcsl b donor and recipient genotypes
(independent)

Coefficient

P value

Donor Effect

1.48

0.0019*

Recipient Effect

-0.04

0.9381

Intercept

-1.22

0.0045
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Odds Ratio
(95% CI)
4.4
(1.73 - 11.18)
0.96
(0.39 - 2.36)

The Mcsl b COP resistance effect is intrinsic to a mammary gland cell type. As
mentioned, the majority of rat mammary tumors arise in the epithelial cells lining the
duct.

In addition to these ductal epithelial cells there are myoepithelial cells that

surround the duct and TEB and multi potent cap cells that can differentiate into
myoepithelial cells or move inward and differentiate into luminal cells (Williams and
Daniel, 1983). Based on the fact that mammary tumors originate in the cells lining the
mammary gland duct we hypothesized that one or more of these epithelial cell types are
responsible for Mcsl b COP-conferred resistance. However, there is evidence that other
cell types in the mammary mesenchyme affect tumor development (Pollard, 2004; Sica et
aI., 2006; Smits et aI., 2011b). To test which cell type the Mcslb COP allele is acting on
to control mammary carcinoma development I used a MEC-enriched c1onogen transplant
approach that had been previously developed (Gould and Clifton, 1985). This method is
used to enrich for MECs and non-adherent leukocytes and lymphocytes by removing
mammary gland adipocytes, fibroblasts, and other strongly adherent cells by negative
selection. These cells are injected into the interscapular fat pad of recipients to induce
development of an ectopic mammary gland similar to the whole mammary gland
transplantation experiments.
Enzymatic preparation of mammary glands to enrich for MECs is the standard
protocol. However, this method is time-consuming and I wished to decrease the time
required to dissociate mammary glands.

To do this, I compared cells dissociated

mechanically using a Medicon tissue dissociator to cells from enzymatic preparations to
determine whether they recapitulated a morphologically normal mammary gland in the
transplant site.

Rats receiving mechanically-dissociated MECs did not develop
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mammary glands in the ectopic site while 75% of the rats injected with enzymaticallyisolated MECs developed ectopic mammary glands when a 1: 1 donor:recipient ratio was
used (Table 8).

Mammary glands grown in the ectopic site looked morphologically

normal (Figure 12).

Based on these results, subsequent MEC preparations were

performed using the enzymatic method.
To estimate the number of rats to use for these studies we used standard
deviations (SD) data from previous mammary cell autonomy experiments resulting in SD
of approximately 0.6 ectopic mammary tumors. For a 95% confidence interval and using
a tolerable error of ± 0.15 of the mean ectopic mammary tumors with a SD of 0.6,
approximately 60 animals must be tested. Given we achieved 75% transplant efficiency
in the pilot study, to be successful 80 animals per group are required.

Mammary Gland Cell Preparations Are Not Sufficient to Allow for Efficient Mammary
Carcinoma Development at Ectopic Graft Sites
Since injection of MECs into the interscapular fat pad resulted in mammary
glands formed in the ectopic transplant site, I intended to use this method to determine if
the Mcslb locus was controlling mammary carcinoma susceptibility in MECs. MECs
isolated from susceptible WF (N=16) or resistant WF.COP (N=14) rats and injected into
the fat pads of age-matched susceptible WF female rats to determine the effect of the
genotype on tumor outcome in the transplant site. Upon inspection of stained whole
mounts, all recipients (100%) exhibited mammary gland development in the ectopic site.
However, tumor development was not significantly different (P=0.9221), as each group
developed only one tumor each (Figure 13A).
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Tumor outcome in MEC-derived

Table 8:
Mammary gland outcome in enzymatically-dissociated versus mechanically-dissociated
mammary gland cell preparations.

MEC isolation
method

# Rats

# Ectopic Mammary Glands

Administered

formed

%
Positive

Medicon
Collagenase Digestion

3
4

o

o

3

75

94

Figure 12: Representative whole mounted interscapular fat pad from MEC pilot study.
lOX magnified image of aluminum carmine stained mammary gland formed in the fat
pad following injection ofMECs isolated via collagenase digestion.
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mammary glands was determined to be significantly reduced when analyzed against
whole mammary gland transplant controls (P=O.0007, Figure 13A).
Since tumor development was considerably reduced in animals receIvmg
mammary gland cell preparations compared to whole mammary gland transplants, I
examined the fat pads microscopically to determine if there were any gross
morphological changes compared to ectopic mammary glands developed from whole
mammary gland transplants. There did not appear to be gross morphological differences
in ductal branching or TEB formation at the microscopic level ; however, hyperplasia and
DCIS formation was detected in the majority of whole mounts (Figure 12B). When
quantified, hyperplasia were not significantly different (P=0.4884, Kruskal-Wallis test)
between ectopic mammary glands from recipients of WF, WF.COP, or whole mammary
gland transplants (Figure 12C).

DCIS development was not significantly different

(P=O.3545, Mann-Whitney test) between ectopic mammary glands formed from MECs
from either genotype (Figure l3C). However, DCIS formation in whole mammary gland
transplants was significantly greater (P=O.0003 , Mann-Whitney test) than for ectopic
mammary glands formed from MECs of both genotypes.

Injection of Mammary Gland Cell Preparations Along With Adherent Cell Fractions
Does Not Allow for Mammary Carcinoma Development at Ectopic Graft Sites
Since there was no distinction in tumor outcome between ectopic mammary
glands from susceptible and resistant MEC preparations and the ability to form frank
carcinomas was nearly ablated, I sought to determine what was missing in cell
preparations that was necessary for tumorigenesis.
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The MEC isolation method I
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Figure 13:

Tumor outcome in ectopic mammary glands derived from MECs.

A",

Proportion of interscapular fat pads with ectopic mammary glands exhibiting tumor
development. P values based on logistic regression analysis. B; Microscopic images of
aluminum carmine-stained normal TEB, hyperplastic TEB, and precancerous lesion
stained from interscapular fat pad whole mounts. C; Quantification of hyperplasia and
DCIS formed per mm 2 in ectopic mammary glands.
Mann-Whitney test.
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P values based on non parametric

originally employed enriches MECs by negative selection removing most adherent cells,
i.e., fibroblasts, macrophages, mast cells, as well as, adipocytes, which remain on the top
layer when centrifuged.

These cell types play roles in mammary gland function ;

therefore, we hypothesized that the absence of one or more of these cell types resulted in
retarding tumor development. To test this I adapted the original MEC isolation method
to include the ACF that was discarded in the original protocol.

These ACFs were

retained and injected along with MECs. MEC-only injections and whole mammary gland
transplants were performed as controls. I was attempting to restore the DMBA-induced
mammary tumorigenesis susceptibility phenotype seen previously with WF whole
mammary gland transplants; therefore, resistant cells were not considered and only WF
donor cells were used.
I anticipated that co-injecting the adherent cells lost during dissociation along
with MECs would restore mammary tumor development in the transplant site.
Surprisingly, there was no difference (P=O.6664) in ectopic tumor outcome in WF rats
receiving WF MECs (N=9) and WF MECs co-injected with the AHC (N=9) but,
combined, these were significantly different from those receiving whole mammary gland
transplants demonstrating that inclusion of the ACF was not sufficient to restore
tumorigenesis (Figure 14A). Additionally, I quantified hyperplasia and DCIS formation
microscopically by counting hyperplastic TEBs or DCIS foci . I noted no significant
difference (P=O.8345, Kruskal-Wallis test) in hyperplasia formation between ectopic
glands formed from MECs, MEC plus ACF cells or whole mammary gland transplants.
DCIS development did not statistically differ between rats receiving WF MECs and those
getting WF MECs plus the adherent cell fraction.
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However, DCIS formation was

A
~

Q)

l~

P<O.0001

.8

Iho

to a.
6
0
.
0
OUJ
Il:

C:c:

~ ~ .4
00
o.E
o :::J
~ ~ .2

P=O.6664

I

o

8
Hyperplasia

DCIS

.14
]

.12

.02

Figure 14: Tumor outcome in ectopic mammary glands derived from MECs or MECs
supplemented with adherent cells. A; Proportion of interscapular fat pads with ectopic
mammary glands exhibiting tumor development. P values based on logistic regression
analysis.

B; Quantification of hyperplasia and DCIS formed per mm 2 in ectopic

mammary glands. P values based on nonparametric Mann-Whitney test.
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significantly increased (P<O.OOOl) in whole mammary gland transplants compared to
either cell injection (Figure 14B).

DMBA Susceptibility Is Delayed In Ectopic Mammary Glands Formed from Injection
of Mammary Gland Cell Preparations
Injection of cellular components of mammary glands into the interscapular white
fat pad failed to form tumors in the resulting ectopically-formed mammary gland. Coinjecting the AHC along with MECs again showed no difference in formation of frank
carcinomas, DCIS or hyperplasia suggesting that there was a more complex process
taking place.

Within the process of dissociation of the mammary gland for MEC

enrichment adipocytes are removed.

Adipocytes are critical in mammary gland

development and could be the missing link in efficient tumor formation that is lost in the
mammary cell preparation transplants. However, there is an adequate concentration of
host adipocytes within the interscapular fat pad cellular milieu making this less likely.
Additionally, extracellular matrix (ECM) proteins are removed during MEC enrichment
by collagenase digestion. The ECM provides an essential substrate required for normal
mammary gland development; therefore, ECM may be required for tumor growth in these
ectopic mammary glands. However, reintegrating MEC preparations with the adherent
cells would restore fibroblasts which are responsible for ECM deposition, making this
scenario less likely as well. DMBA-induced mammary carcinogenesis in the rat has been
established to be dependent on a distinct mammary gland developmental window of 5055 days of age; however, this window is based on fully developed mammary glands
(Russo and Russo, 1994). We hypothesized that a different time span is required for
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dissociated mammary gland cells to reconstitute a functional mammary gland than for
whole gland transplants, i.e., the DMBA-susceptibility window is shifted.
To test this idea I used the original MEC isolation protocol, including susceptible
and resistant MEC preparations only and administered DMBA at 40-45, 50-55, 60-65,
and 70-75 days of age days. By including susceptible and resistant donor MECs, I would
be able to identify whether the Mcs 1b COP resistant phenotype is acting in the MEC
population.
Interestingly, only 32% (8 of 25) of female rats receiving DMBA at the 40-45 day
susceptibility window developed a mammary gland in the interscapular fat pad while
those receiving DMBA at 50-55, 60-65, or 70-75 days of age developed 81 %, 74%, and
68%, respectively (Figure 15A). This may suggest that administering DMBA too early
after MEC injection may affect the efficiency of the graft to develop into a proper
mammary gland.
Tumor outcome in the ectopic site was higher at the 40-45, 60-65, and 70-75 day
susceptibility windows compared to the 50-55 day window (Figure 15B). These results
are without regard to genotype of the MEC transplant as no genotype effect was detected
(Figure 15B, bottom).

Results for the 40-45 and 60-65 day windows were not

statistically different from that of the original 50-55 day window (P=0.2352 and 0.0659,
respectively). However, fat pad whole mounts from rats that received DMBA at 70-75
days exhibited a significantly higher tumor outcome when compared to the original 50-55
day DMBA window (P=0.0041). Furthermore, tumor outcome for the 70-75 day window
was not significantly different than what was observed in whole mammary gland
transplants (P=0.2025). These results suggest a shift in the susceptibility window of
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Figure 15: Results of DMBA susceptibility window studies with MEC injections. A;
Mammary gland development outcome in the interscapular fat pad. Bars represent the
proportion of rats injected that developed a mammary gland in the injection site. B;
Tumor outcome in the ectopic mammary gland at varying windows of DMBAadministration. P values are based on logistic regression analysis.
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ectopic mammary glands derived from MECs compared to those from whole mammary
glands. Also, since no genotype effect was observed it is likely that the action of the
Mcs 1b locus to control mammary carcinogenesis is not intrinsic to a mammary epithelial

cell type.

Discussion

Carcinogenesis in the mammary gland is complex involving multiple cell types
and signaling mechanisms. On these lines, we set out to determine if the resistance to
mammary carcinoma development conferred by the Mcslb locus was acting in a
mammary gland-intrinsic or extrinsic manner. The majority of mammary carcinomas
arising in the rat originate in the ductal epithelium; thus, we hypothesized that the Mcsl b
locus was acting within a mammary gland cell type to confer resistance.
Transplanting immature mammary glands into the interscapular fat pad results in
the development of a properly branched and formed mammary gland (Gould and Clifton,
1985). We used this approach and induced mammary carcinogenesis with a single dose
of DMBA. The results of these experiments supported our hypothesis that the Mcslbconferred phenotype is mammary gland intrinsic.
Transcripts within the Mcsl b locus remain to be functionally tested and these
results indicate that the mammary gland should be the focus of these assays, e.g., gene
expression profiles and splice variant analysis. Moreover, these data focus on a cell type
of interest.

Cells from the immune system can have an effect on mammary

carcinogenesis in the tumor microenvironment (Pollard, 2004; Sica et aI., 2006; Smits et
aI., 2011b; Trimboli et aI., 2009). Herein, we have shown that this is not likely the case
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and focused on the mammary gland cellular milieu. The mammary gland is composed of
a variety of cell types all of which have roles in normal gland development as well as
progression to a neoplastic and malignant state (Lanigan et aI., 2007).

Therefore,

identifying a candidate cell type will afford a greater understanding of the etiology of
mammary cancer.
Given that rat mammary tumors arise predominantly in the epithelial cells lining
the ducts, I hypothesized that MECs were responsible for the Mcsl b-conferred
phenotype. To test this I modified the original transplant protocol by injecting MECenriched cell preparations and tracking the phenotype. I anticipated that approximately
twice as many WF MEC-derived ectopic mammary glands would exhibit tumor
development than glands developed from WF.COP MEC donors, similar to what was
seen in whole mammary gland transplant assays. However, the ability to form tumors in
the transplant site was lost, suggesting that there is a component missing necessary for
tumor development.
I estimated that 80 animals of each genotype would have to be tested to estimate a
mean tumor outcome to within ± 0.15; however, I only tested 16 homozygous WF and 14
resistant congenic WF.COP rats in these studies.

Although this is below the target

number, the ability to form tumors in the fat pad was nearly completely ablated in all
animals. Moreover, the lack of tumor development was not an artifact of poor transplant
efficiency since the majority of recipients (97%) developed mammary glands in the
interscapular fat pad. These ectopic glands appeared to have developed normally and,
upon microscopic inspection, exhibited hyperplasia and DCIS development suggesting
that DMBA was sufficiently initiating carcinogenesis within the ectopic site. Hyperplasia
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and DCIS were quantified to determine if there was a difference between the MEC and
the whole mammary gland transplants.

No significant difference in hyperplasia was

identified between ectopic mammary glands formed by MECs from the two genotypes,
nor were these different than hyperplasia in whole mammary gland transplants.
Similarly, DCIS formation was not statistically different in ectopic glands formed from
congenic WF.COP MECs compared to ectopic glands from homozygous WF MECs.
However, DCIS formation in ectopic mammary glands from either genotype was much
lower than what was observed in whole mammary gland transplants suggesting
carcinogenesis was being initiated in the MEC-derived glands but something involved in
the MEC-isolation process removed a component required for progression to a frank
carcmoma.
My hypothesis was that a cellular component was removed during MEC-isolation
that was required for complete tumor-induction by DMBA. To address this hypothesis, I
first attempted to restore the ability to form tumors by reclaiming the cells removed
during MEC enrichment and re-introducing them along with MECs into the fat pad and
following the phenotype. However, including these adherent cells with MECs had no
effect on tumor outcome compared to MECs alone, suggesting that the mechanism is
more complex.

The loss of tumorigenisis could be explained by the absence of

adipocytes since these were discarded during MEC-enrichment. However, this seemed
unlikely since the recipient fat pad contains adequate adipocyte content and allowed for
mammary gland development in the majority of recipients. Therefore, it appeared that
this effect could not be explained simply by a single missing cellular component.
Whole WF mammary gland transplants were performed as controls in these
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experiments and these exhibited a nonnal ectopic tumor outcome. Also, hyperplasia and
DCIS development was quantified in ectopic glands from MEC-, MEC plus adherent
cell-, and whole mammary gland-induced grafts.

All grafts exhibited hyperplasia

development, but there was no statistical effect associated with MECs, MECs plus
adherent cells, or whole mammary gland transplants. Moreover, DCIS fonnation was not
statistically different between ectopic mammary glands fonned from MEC or MEC plus
adherent cell grafts; however, again the level of DC IS fonnation in either cell-derived
ectopic gland was significantly reduced compared to whole mammary gland grafts.
Taken together, these data suggest that DMBA is driving neoplastic events to
fonn hyperplasia and precancerous DC IS lesions but is insufficient for progression to
development of frank carcinomas. We hypothesized that there was a developmental gap
in these ectopic mammary glands affecting their susceptibility to DMBA-induced
carcinogenesis. I sought to detennine if there was a difference in susceptibility to DMBA
in WF MEC-grafted ectopic mammary glands at different developmental windows.
DMBA was administered in previous experiments at 50-55 days of·age of the recipient
rat; approximately 20 days after cell injections were perfonned. Rather than adjust the
age at which cell injections were perfonned, we chose to keep this constant at 30-35 days
and, instead, administer DMBA at 4 different time points: 40-45 days, 50-55 days, 60-65
days, and 70-75 days. If there was an effect from the developmental stage of the ectopic
mammary gland, it was anticipated that one ofthese windows would return the mammary
carcinogenesis phenotype towards a level similar to that seen in the whole mammary
gland transplant studies. One may predict that an earlier DMBA window would likely
result in an increase in tumor fonnation as these cells would be expected to be more
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mitotic and, therefore, more vulnerable to DNA damaging agents. However, outcomes of
the susceptibility window tests showed that female rats receiving DMBA at the 70-75 day
window developed significantly more tumors than rats receiving DMBA at the 40-45, 5055, and 60-65 day windows. Tumor outcome in the 70-75 day group was not statistically
different than that observed in whole mammary gland transplants, suggesting a
developmental dependency for mammary carcinogenesis induction by DMBA. This may
hold true for other PHCs as well.
In addition, efficiency of proper mammary gland development in the interscapular
fat pad was retarded at the 40-45 day DMBA window. This implies that DMBA may
have an effect on mammary gland development.

At this time point, DMBA was

administered only ten days following cell injections.

DMBA causes acute

immunotoxicity immediately after it is given (Gao et aI., 2005). It may be that immune
cells necessary for appropriate ductal branching and elongation are not present, resulting
in atrophy of the mammary gland in the ectopic site. However, the high dose of DMBA
administered to rats is not physiologically relevant; therefore, this effect is not applicable
to human health but has implications on future rat studies. More studies will need to
assess the mechanism by which DMBA affects mammary gland growth in these studies,
e.g. measure immunological cells in the plasma and in the ectopic mammary gland.
The shift in the DMBA-susceptibility window suggests that at earlier stages of
mammary gland development, DNA-damaging agents, such as PHCs, have less effect on
mammary carcinogenesis. It is not clear what the implications of this are. These data
may suggest a reduced role for mammary "stem" cells in progression to full carcinoma
development. Cancer stem cells have been proposed to be principal mediators in primary
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tumor development and relapse following therapy. My data suggest, however, at earlier
stages the stem cell niche may not be capable of driving full carcinogenesis and, rather, a
more differentiated cell type is requisite for tumor development. Still, it could be argued
that these undifferentiated cells may require more than a single dose of DMBA to
develop frank carcinomas. Indeed, DMBA-induced carcinogenesis relies on steroidal
hormone activation, such as estrogens, as a "second hit" to drive carcinogenesis and
potentially these stem niche cells lack ample ER expression.

We currently have no

information regarding the cell populations present or how they act within the 60-65 or 7075 day window. Therefore, there is no evidence for or against a role for a particular
mammary gland cell type in DMBA-induced mammary carcinogenesis.
Previous studies have demonstrated that the clonogen transplantation method is
sufficient to induce mammary gland formation in an ectopic site; yet, to date, no one has
shown a capacity to stimulate mammary cancer development in these ectopic glands.
These experiments are important because they provide insight into mammary
carcinogenesis

III

the context of environmental exposures.

Herein, I show that the

mammary carcinogenic effects of DMBA are dependent on a specific stage of mammary
gland development. Although the data imply that the Mcslb-conferred phenotype is not
intrinsic to a mammary epithelial cell population, work to identify a specific cell type
responsible for Mcs 1b-induced resistance, regrettably, remains inconclusive. Regardless,
the initial goal of this aim was to identify a tissue type involved in Mcsl b-conferred
resistance to mammary carcinoma development. My data show that the action of the
Mcsl b COP allele is specific to the mammary gland. Future efforts to functionally test
gene candidates within the Mcsl b locus will, consequently, be focused on the mammary
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gland as a target tissue. Although these studies do not provide definitive answers as to
what the specific factors are affecting tumor development, they afford a means by which
to study these effects further. On the whole, my data identify that the Mcsl b COP allele
is acting in mammary gland-autonomous manner and indicate that the effectiveness of
DMBA to induce mammary carcinogenesis is dependent on the developmental stage of
the mammary gland.
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CHAPTER IV
MIER3 IS A CANDIDATE BREAST CANCER-ASSOCIATED GENE

Introduction

There are thirteen transcripts annotated within the 1.8 Mb Mcslb locus delineated
by lines N3, W2, U2, and 14 and six of these transcripts reside in the 1 Mb region
delineated by addition of line 1b-ll (Figure 5). All of these genes are also annotated to
the human breast cancer-associated locus marked by SNP rs889312, and any combination
of these transcripts could be the responsible gene(s) involved in Mcsl b COP-conferred
mammary carcinoma resistance (Figure 8). The most plausible breast cancer candidate
gene within this region is Map3kl. However, no direct evidence is available to support
Map~kl

as the causal gene. It is relevant, then, to test the transcripts annotated to this

region. We hypothesize that a genotypic variant between WF and COP in the McsJb
locus lies within the coding region of one or more of these transcripts and results in an
amino acid change that gives rise to a differential mammary carcinoma susceptibility
phenotype.

This approach is important in that SNP haplotype maps in the rat are

incomplete; thus, identifying variants will increase current knowledge of rat genetics and
potentially identify causative SNPs. Many cancers are caused by detrimental mutations
or variants that alter protein function and this may be the basis the Mcsl b phenotype.
All of the human SNPs tagged along with rs889312 lie outside of annotated
transcribed genes (Figure 3). Consequently, it is possible that the inherited element(s)

110

controlling the risk phenotype are non-coding regulatory elements. Indeed, many low
penetrance alleles associated with disease phenotypes are now being found to involve
non-coding variations.

There may be additional SNPs not yet identified that lie in

transcribed regions that may be causative; thus, it is important to first test for changes in
the coding region.
To not bias the approach towards any specific transcript(s), I first set out to
resequence the open reading frames (ORFs) of each transcript lying in the 1.8 Mb Mcslb
locus as it was delineated from marker A12v (ch2:42364155) to marker a1200
(ch2:44210175). The mechanism by which the Mcslb locus is controlling mammary
carcinogenesis susceptibility is not clear; therefore, including all of the transcripts in this
interval reduces the probability of missing the causative factor.
In the past decade there has been increasing interest in regulatory microRNAs
(miRNAs) in cancer research. These miRNAs are short pieces of untranslated RNA
transcribed by the cell that can recognize and bind specific target sequence sites on
translated mRNAs and mark them for degradation.

They regulate rrormal processes

within the cell and have been shown to be dysregulated in some cancers. Differential
effects can result either through sequence variation in the miRNA target sequence or
through alterations in the sequence or the expression of the miRNA itself. These miRNA
target sequences are principally located in the 3' untranslated regions (UTRs) of the
mRNA to be regulated.

Therefore, in addition to resequencing the ORFs, I also

resequenced the 3' UTRs of these transcripts.
Sequence differences between WF and COP sequence in any of the transcripts
will be analyzed in silico to determine if the variation(s) disrupts the normal structure of
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the protein, e.g., results in an amino acid change or introduces a premature stop codon. It
may be that variation between the two rat lines results in differences in stability of a
transcript. Efforts will be focused on determining transcript expression levels between
susceptible WF and resistant WF.COP line T and N3 rats. Conversely, if no variation is
identified in the coding region of any of these transcripts, it will be tacit that the
mechanism of the Mcs 1b-conferred phenotype is regulatory in nature. In this case, gene
expression of all the transcripts will be tested. In each case, gene expression levels will
be first assessed in mammary gland tissue as we found Mcsl b COP-conferred mammary
carcinoma resistance to be autonomous to the mammary gland. Other tissues will be
tested to establish whether the effect is mammary gland-specific.

Design and Methods

Resequencing Mcslb Transcripts
Spleen or thymus tissue from WF/Hsd and WF.COP lines N3 and T rats was
excised and total RNA was extracted using TriReagent (Molecular Research Center) and
standard chloroform/isopropanol precipitation. RNA samples were treated with TURBO
DNase (Life Technologies) to reduce DNA contamination and cDNA was made using
Superscript III reverse transcriptase (Life Technologies). Sequences were not attainable
from cDNA in some instances; therefore, genomic DNA, extracted from frozen spleen or
liver tissues using standard phenol-chloroform/isopropanol precipitation, was used.
Samples were PCR amplified using Accuprime HiFi Taq polymerase (Life Technologies)
and, subsequently, cleaned with the QIAquick PCR Purification Kit (Qiagen) to remove
unincorporated nucleotides.

Amplified samples were sequenced using the BigDye
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Terminator v.3.1 Cycle Sequencing Kit (Life Technologies and purified with Agencourt
CleanSeq magnetic beads (Beckman Coulter). These were submitted for analysis to the
University of Louisville Center for Genetics & Molecular Medicine DNA Core using an
ABI PRISM 3130XL Sequence Detection System (Life Technologies). Primer sequences
for amplifying and sequencing McsJh ORFs and 3'-UTRs are in Table 9. Nucleic acid
sequences were submitted to NCBVGenBank and assigned accession numbers JQ013728
through JQ013739.

Gene Expression Assays
Tissues were excised from WF/Hsd and WF.COP lines N3 and T rats that had
been treated with DMBA or not and flash-frozen in liquid nitrogen. Total RNA was
extracted with TRI-Reagent (Molecular Research Center) followed by standard
chloroform/ethanol precipitation. To reduce possible solvent and DNA contamination
RNA samples were further processed by a 1110 v/v 3M sodium acetate and 2.5x v/v
100% ethanol wash on ice for 10 minutes followed by 80% ethanol wash followed by
Turbo DNase (Life Technologies) treatment.

Total RNA quantity and quality were

measured with a Nanodrop 1000 (Fisher Scientific) and a Bioanalyzer with RNA 6000
NanoChips (Agilent). cDNA was made by reverse transcription reactions using (20 III
f.v.) 11lg total RNA 0.5x RNAsecure, 51lM random hexamers, 25ng/IlL 0Iigo(dTI8), and
0.5 mM dNTPs were incubated 5 minutes at 65° C prior to adding 1x first strand buffer,
100mM DTT, and 11lL Superscript III (Life Technologies). Reactions were incubated 5
mat 25° C, 1 hat 50° C, and 15 m at 70° C. TaqMan QPCR primers and MGB probes
(Applied Biosystems) were designed by using Primer Express v 2.0 (Applied
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Biosystems). Primer and probe sequences are provided in Table 10.

One I.d of the

dilution (;:::;12.5 ng of RNA-equivalent cDNA) was used in a 16-fll TaqMan QPCR. The
reaction components were 1x TaqMan Buffer A (Applied Biosystems); 5.5 mM MgCh;
dATP, dCTP, dGTP, and dTTP at 400 flM each; experimental primers at 300 nM each;
200 nM TaqMan experimental probe (Applied Biosystems); Rplp2 primers at 100 nM
each, 200 nM rodent Rplp2 probe; and 0.4 units of Taq Gold DNA Pol (Applied
Biosystems).

Real-time QPCR was run on an ABI PRISM 7900HT real-time PCR

machine. Real-time QPCR cycling conditions were 50°C for 2 min and 95°C for 10 min,
followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. FAM (Mcs 1b region target
gene probe) and VIC (Rodent Rplp2 probe; Applied Biosystems) fluorescence values
were measured by using Applied Biosystems SDS v 2.3 software; quantities of transcripts
were measured by comparison of cycle threshold values with a standard curve calculated
from serial dilutions. Sample measurements are an average of four replicates per sample
and were standardized by dividing the quantity of rodent Rplp2. Data were analyzed by
Mann-Whitney tests.

Comparative Genomics

Human and mouse sequences for genes annotated to the Mcsl b locus were
obtained using the UCSC Genome Browser using the Homo sapiens verSIOn
GRCh37/hg19, Rattus norvegicus version 3.4/m4, and Mus musculus verSIOn
NCBI37/mm9 genome assemblies. Sequences were aligned using the DNAStar SeqMan

sequence analysis program (DNAStar) to identify orthologous regions.
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Primers were

Table 10:
Rat \1cs I b Target and Rplp2 Primers and Probe

Assay Name

......
-...J
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S~yuences

Used for (JPCR

Forwam Prim .. r Sequefl('e (5' to 3')
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ID

designed against the rat orthologous sequence using Primer3 (Rozen and Skaletsky,
2000) and used to test for alternate start sites for Mcsl b transcripts in rat cDNA samples.

Genomics and Statistical Analysis

Mammary carcinoma multiplicity phenotypes were compared by nonparametric
Mann-Whitney tests. Results from mammary gland grafting experiments were analyzed
using logistic regression. Donor and recipient genotypes were incorporated as dependent
variables. In independent models, graft site tumor outcome and grafting ability were
used as independent variables.

Quantitative PCR (QPCR) data were analyzed using

ANOVAs with log2 (Target quantity/Rp/p2 quantity) as the dependent variable.
Independent variables for comparing mammary gland transcript levels were Mcslb
genotype and DMBA exposure. Mcsl b genotype and tissue source were independent
variables for mammary carcinoma and non-diseased mammary tissue QPCRs. Fisher's
PLSD tests were used to compare groups following a significant F-test (a:S 0.05).
Statview software (SAS Institute) was used.

Cloning of Mier3 Splice Variants

Splice variants for rat Mier3 were amplified from susceptible and Mcsl b resistant
rat mammary gland cDNAs by standard PCR and cloned into a pCR® 2.1-TOPO® vector
(Life Technologies) according to manufacturer specifications. Clones were transformed
into chemically-competent DH5a E. coli cells, plated on Miller's LB Agar (Amresco)
plates containing 50 Ilg/ml Kanamycin and coated with 40 III of 40 mg/ml X-gal, and
incubated at 37° C overnight. White colonies were picked from each plate and inoculated
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into individual wells of a 96 well plate containing 40 III Miller's LB broth (Amresco) and
incubated for 2 hours while shaking. 0.2 III of inoculated media was amplified by PCR
using M13 reverse and T7 promoter primers specific for flanking regions of the multiple
cloning site within the pCR® 2.1-TOPO vector. PCR products were resolved on 1%
agarose TBE gels and stained with SYBR Gold. Large and small bands corresponding to
full-length and spliced Mier3, respectively, were counted for each sample. Analysis was
performed on the proportion of full-length bands in the total number counted.
Proportions were arcsine-transformed and analyzed by a student's t-test.

Results

Mcslh Potential Candidate Open Reading Frame Sequences Yields Are Not Different
Between WF and COP

As shown in Figure 5, rat McsJ b was found to contain thirteen potential candidate
gene transcripts as well as sequence orthologous to human 5qll.2, a GWAS-identified
breast cancer risk associated allele marked by SNP rs889312 (Easton et aI., 2007). To
prioritize potential candidates, I resequenced conserved protein coding ORFs that were
within the 1.8 Mb interval that delimited Mcslb, and based on RT-PCR gel
electrophoresis, were expressed in mammary glands of susceptible WF and Mcsl b
resistant females (lines N3 and T). Transcripts from Gpbpl, Map3kl, Mier3, Ankrd55,
116st, Il31ra, Ddx4, SIc38a9, and Ppap2a genes were detected in mammary gland total

RNA pools from each genotype by RT-PCR.

No genetic variants were identified

between susceptible WF and Mcsl b resistant genotype ORFs or 3' UTRs for these
transcripts.

Nucleotide sequences were submitted to NLM-NCBI and the GenBank
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accession numbers are provided in Table 9.
Four of the Mcsl b candidate genes are predicted transcripts based on sequence
containing gene-coding properties, e.g. intron-exon boundaries and polyadenylation
signals,

or

sequence

similarity

to

known

expressed

transcripts:

Actbl2,

ENSRNOG00000013098, C50rj35 and U6 snRNA (labeled with asterisks in Figure 5).

Rat Actbl2 was identified as a pseudo gene and is located outside rat genomic sequence
orthologous to the human 5qll.2 haplotype block that associates with breast cancer risk.
Predicted transcript ENSRNOG00000013098 was listed on the Ensembl genome browser
(Flicek et aI., 2011). I found no evidence by RT-PCR of a transcript from Actbl2 or
ENSRNOG00000013098 in total RNA samples from multiple susceptible and Mcslb

resistant mammary glands or in rat mixed tissue total-RNA samples that included
embryo, brain, testes, ovary, thymus, spleen, and liver. Since cDNA was not attainable
and Actbl2 was predicted to be a single-exon transcript, we sequenced genomic DNA
spanning this predicted pseudo gene and found no sequence differences between WF and
COP alleles.
Rat C50rj35

IS

an ortholog of human C50RF35.

This gene was recently

identified to have a SET domain and renamed SETD9 (SET domain containing 9). SET
family members are histone methyltransferases involved in regulating chromatin
structure by methylation of lysine residues on tails of histones. Dysregulation of SET
proteins plays roles in the progression of many cancer types. For instance, the SET
member EZH2 has been implicated in the development of breast and prostate cancer
(Kleer et aI., 2003; Yu et aI., 2007). Although the human C50RF35 protein has not been
fully characterized it could be a potential candidate based on its sequence similarity to
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SET proteins. However, rat C50rj35 was not present in any total RNA samples tested
from various rat tissues. Additionally, I successfully amplified C50RF35 from human
thymus, spleen, and ovary, but not human breast tissue cDNA (Figure 16A) suggesting
that human C50RF35 is not highly expressed in the breast. However, in an Oncomine
(Rhodes et al., 2004) database search I found that other groups have reported detection of
C50RF35 in human breast carcinoma and non-diseased breast tissue.

Using

bioinformatic analysis I discovered that the annotated 5'- and 3'- UTRs of human
C50RF35 are poorly conserved between humans and rodents (Figure 16B); therefore, we

concluded that C50RF35 is a human, but not a rat transcript.
A predicted small nuclear RNA (snRNA) at rat position Chr2:4376581143765918 named U6 or ENSRNOG00000034909 is estimated to be 108 bp on the
forward strand. I noted that ENSRNOG00000034909 sequence aligned to approximately
100 distinct regions of the rat genome using both NCBIIBLAST and UCSC/BLAT (den
Dekker et al., 2012; van Boxtel et al., 2011) (Table 11). Because of the highly repetitive
nature of the sequence, I was unable to design specific probes to determine if this
predicted single exon gene was transcribed from rat Mcsl b.

Mcslb Potential Candidate Gene Expression Levels Uncover Mier3 as a Potential
Gene Candidate

Rat Mcs 1b did not contain any protein coding genetic variation between Mcs 1b
susceptible and resistant alleles; therefore, rat Mcsl b may contain variation in one or
more non-protein-coding regulatory elements that differentially control gene expression
between mammary cancer-susceptible and resistant genotypes. To test this hypothesis, I
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Figure 16: Predicted human C50RF35 is not conserved in rats. A; Predicted C50RF35
transcript was detected in multiple human tissues by RT-PCR. B; Splice variants of
C50RF35 detected in human tissue and sequence similarity between human C50RF35

exons and other species. A C50RF35 splice variant that did not contain exon 2 was
detected in human thymus and spleen samples.

C50RF35 is not conserved between

primates and rodents based on degeneration of 5' and 3 'UTR sequences in rodents.
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Table 11:

llLAT alig!1ment ofENSRNOUOO000034909 scguencc against l1eSe Cicnome 13rowscr Rat DNA build (llilylor 3.4,m4 assembl!Ll
Tranlleript 10

........
N

w

No rat transcripts annotated in browser
RefSl,)q ID: NM 153738
No rat transcripts annotated in browser
RefSeq ID: NM ~ 001108397.1
RefSeq 10: NM_001191653.1
No rat transcripts annotated in browser
RefSeq ID: N M 17310 1.I
No rat transcript. annotated in browser
No ral transcript, annotated in browser
No ral transcript, annotated in browser
No rat transcripts annotated in bf<)wscr
No rat transcripts annotated in browser
No rat transcript' annotated in browser
No rat transcripts annotated in browser
RefSeq ID: NM 031337
No rat transcripts atmotatcd in browser
No rat transcripts annotatcd in browser
No rat transcripts annotated in browser
RefSeq ID: NM OOWI1915
RcfScq ill: NM 001011915.1
No rat transcripts annotated in browser
No rat transcripts annotated in bmw!;er
No rat transcripts annotatoo in browRer
No rat transcripts annotated in browser
RefSeq ill: NM 001135761.1
No rat transcripts annotated in browser
No rat transcripts annotated in browser
No rat transcripts annotated in browser
No rat transcripts annotated in browser
No rat transcripts annotated in browser
Rat mRNA lrom GenB.1I1k, ID: OCI66504
No rat transcript~ annotated in browser
RefSeq ID: NM 001170548. I
Rat mRNA from OenBank. ID: FQ230829
No ral transcript~ annotated in browser
No rat transcript~ annotated in browser

Transcript OC'lK"ription

Rat Prlpn intronic region
Rat SfTS 14 intronic region
Rat Tanc2 intronic region

Chromosome

108
82

Chr:15

43765918
43789333
136766580
19667415
95198796
98699471
74882468
110618978
63198175
103440263
75525763
69993128
19496085
245228564
105395722
79649236
29978469
25410031
21384682

Chr:2
Chr:9
Chr:2
('h,.: II
Chr:3
Chr: 7
Chr:!8
Chr:8
Chr:5
Chr:2
Cllr:l
Chr:!
Chr:4
Chr:19
Chr:14
Chr:9

173740365
112012955
124284322
70013852
17548151
135345735
27228793
31027110
15608653
240633692
227408075
18291369
148933048
41214051
18935943
47499507

173740453
112013153
124284416
70013937
17548246
135345826
27228894
31027202
15608741
240633780
227408163
18291554
148933143
41214136
18936031
47499595

72
71
71

Chr:~

Rat ~lyo Ie intronic region

Rat Siat9 intronic rcgion

Chr:8
Chr.·4
Chr:1f
Chr:!
Chr:1
Chr:3
Chr:2
Chr:1
Chr:4
Chr:~

Chr:20
Chr:/~

Rat Plilkhcl intronic region
Rat Fcmlt2 intronic r~gion

Rat Faml89a2 intronic region
Rat ·lbumpd3 intronic region
No identified bomolog

Start Position End Position Orientation Seo....

43765811
43789233
136766481
19667327
95198700
98699371
74882368
110618884
63198076
103440155
75525663
69993031
19495997
245228475
105395193
79649136
29978369
25409944
21384589

Chr:2
Chr:r
Chr:6
Chr:!6
Chr:!O

79

78
78
77
75
75
75
75
75
74
74
74
73
73
73
73
73

71

70
70
70
69
69
69
69
69
68
68
68
67

%10

Span (bps)

100.00
88.20
88.70
93.10
89.40
91.10
89.90
92.80
89.70
90.50
89.90
90.70
90.70
91.20
95.20
88.80
88.80
90.60
88.80

108
101
100
89
97
101
101
95
100
109
101
98
89
90
530
101
WI
88
94

89.60
94.00
90.40
90.40
93.90
88.10
86.70
90.20
92.30
92.30
92.30
92.70
85.60
84.40
87.30
91.00

89
199
95
86
96
92
102
93
89
89
89
186
96
86
89
89

Table II c(mtinue<i
Transcript ID

tv

.j::.

RcfSeq 10: NI<.1 001197907.\
R~fSeq ID: NM.001171177.2
No rat transcripts annotatold in browser
RcfSeq ill: NM 031057
No rat transcript~ annotated in browser
No rat transcripts annotated in browser
RefSeq 10: NM.OOI134463.1
No rat transcripts annotated in browser
RefSeq ID: Nt.IOOII08005.1
No rat trlUlSCripts annotated in browser
No rat transcripts annotated in browser
No rat transcripts annotated in browser
No rat transcripts annotated in browser
No rat transcripts annotated in browser
No rat transcripts annotated in browser
RefSeq ID: NM_OO103496I
No rat transcripts annotated in browser
No rat transcripts annotated in browser
No rat transcripts annotated in browser
RefSeq ID: NMOO!OO4020.1
No rat transcripts annotated in browser
No rat transcripts annotated in browser
RIlISeq 10: NM.001191634.1
Rat mRNA from GenBank, 10: FQ232940
No rat transcripts annotated in browser
RcfSeq 10: NM 012774.1
No rat transcript, annotated in browser
No rat transcripts annotated in browser
RcfScq 10: NM 001134628.1
No mt transcripts annotated in browser
RefSeq 10: NM.022217.1
No rat transcripts annotated in browser
No mt transcripts annotated in browser
No rat transcripts annotated in browser
No rat transcripts annotated in browser
RefSeq 10: NM 001106706.1
No mt transcripts annotated in browser
No rat transcripts annotated in browser
No rat transcripts annotated in browser

Transcript Description
Rat Oll.TI intronic region
Rat Tmtc2 intronic r~gion
Rat Aldh6a1 intronic region

Rat Camkml intronic region
Rat Mast2 intronic region

Rat Sohlh2 intronic region

Rat Tmprs.< lIb intronic region

Rat Gbfl intronic region
No identified homolog
Rat 0pe3 intronic region

Rat RGDl564943 (Predicted) intronic region
Rat Amph intronic region

Rat Tte27 intTOnic region

Chromosome
Chr:Chr:'
Chr:Chr:6
Chr:6
Chr:6
Chr:6
Chr:5
Chr-5
Chr:5
Chr:5
Chr:3
Chr:3
Chr:2
Chr:2
Chr.2
Chr:2
Chr:1
Chr.!8
Chr:l.J
Chr:U
Chr:!O
Chr:!
Chr:f
Chr:1
Chr:X
Chr:Chr:6
Chr:5
Chr:4
Chr:1 ~
Chr:r
Chr:f4
Chr:IO
Chr:X
Chr:6
Chr:4
Chr:2
Chr:18

Start Position End Position Orientation Seo ....
77197714
43891984
11235427
108710588
93546629
72766763
8704054
151444756
136630633
60215398
56854404
36733997
35650885
233090377
168539521
144422171
96996138
35329196
13043912
23014788
9590393
60526129
251394207
23671516
18892950
139315241
127637150
72766085
148336835
102436898
53682453
48877826
111622041
89929380
132443461
20562368
26126909
216457973
33879457

77197802
43892076
11235515
108710676
93546717
72766851
8704142
151444844
136630721
60215486
56854492
36734085
35650973
233090465
168539609
144422259
96996226
35329284
13044000
23014876
9590481
60526217
251394295
23671604
18893050
139315329
127637238
72766173
148336923
102436986
53682541
48877914
111622131
89929468
132443547
20562456
26126997
216458061
33879556

67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
67
66
65
65
65
65

%ID

Span (bps)

91.00
84.50
91.00
91.00
91.00
91.00
91.00
91.00
91.00
91.00
91.00
91.00
91.00
91.00
91.00
91.00
91.00
91.00
88.90
91.00
91.00
91.00
91.00
91.00
85.40
91.00
91.00
91.00
91.00
91.00
91.00
91.00
89.90
91.00
91.00
89.70
91.80
89.70
92.40

89
93
89
89
89
89
89
89
89
89
89
89
89
89
89
89
89
89
89
89
89
89
89
89
101
89
89
89
89
89
89
89
91
89
87
89
89
89
100

Table II continued

Transcript 10

.......
N

VI

Reffieq II): N1\I 001007145
No rat transcripts annotated in browser
No rat transcripts annotated in browser
No rat transcript~ annotated in browser
No I1It transcripts annotated in hrowser
No rat transcript~ annotated in browser
;0.;0 rat transcript. 1mnotated in hrowser
No rat transcripts annotated in hrowser
RatmRNA from GenBank. ID: FQ227174
No rat transcripts annotated in browser
Rat mRNA frulll (~nBank. ID: DQI00481
No rat transcripts annotated in hrowser
"io rat transcripts annotated in browser
RefSeq ID: N\I. 001107047.1
RefSeq ID: 1"1\1 001007630.1
No rat transcripts annotated in browser
No rat transcripts annotated in browser
No rat transcripts annotated in hrowser
~o rat trans.:ri pt~ annotated in hrowser
Reffieq ID: NM 001135718.1
No rat trans.:ripts annotated in browser
No rat transcripts annotated in hrowser
No rat transcript~ annotated in browser
RefSe9 ID: NM 001191669.1
(Hit~

with score:> 60)

T ranscri pt Dt'lICription
Rat Catnal intronic region

Chromosome
Chr:i8
Chr:iR
Chr: 14
Chr:il
Chr:'
Chr.:}
Chr:i8
Chr:f

('hr.· iChr:/4
I JNE- 1 retrotransposon nucleic acid hinding protein mRNA Chr: /
Chr:6
Chr:14
Chr:/{j
Rat Hall intronic region
Rat Zfand6 intronic regi<m
Chr:i
Chr:/
Chr:9
Chr:3
Chr:!
Rat Prexl intronic region
Chr:3
Chr:/6

"io identified hOlllolog

Chr:i4

Rat 1llsd7b intronic

re~ion

Chr:i
Chr:i]

Start Position Rnd Position Orientation Score
27639818
265348
40179238
32577174
1 B696949
190279006
16341735
231873185
15279892
77213446
25793445
116937744
32819567
87362236
140906354
56584008
10.3107997
104572110
194118835
157849079
36604669
54341337
232461672
42749088

27639906
265436
40179338
32577262
113697045
190279094
16341823
231873266
15279979
77213534
25793533
116937821
32819654
87362320
140906442
56584096
103108085
104572198
194118923
157849155
36604747
54341425
232461742
42749194

65
65
65
65
65
65
65
65
64
64
64
64
63
63
63
63
63
63
63
62
61
60
60
60

%10

Span (bps)

89.70
89.70
84.30
89.70
92.30
89.70
89.70
86.60
89.50
89.50
84.10
91.10
89.10
90.50
88.40
88.40
88.40
88.40
88.40
89.20
91.40
90.00
91.20
97.00

89
89
101
89
89
89
89
82
88
89
89
78
88
85
89
89
89
89
89
77
79
89
71
107

measured mammary gland transcript levels of genes located at Mcslb in 12-week old
virgin female rats that were exposed to DMBA at 50-55 days and age matched controls
without DMBA. These studies focused on mammary gland transcript levels due to the
mammary gland autonomous nature of Mcslb previously discussed. Twelve-week old
animals were used because this is the age after the acute phase for DMBA-toxicity and
before induced frank mammary carcinomas are detectable in susceptible strains.
Differences in expression between genotypes were analyzed by non-parametric
Mann-Whitney tests and the effects of Mcsl b genotype and DMBA exposure on
candidate gene transcript levels were analyzed by two-way ANOVA (Table 12).
Transcript levels of Ankrd55, 113 1ra, Ddx4, SIc38a9, or Ppap2a were not significantly
different between Mcsl b resistant and susceptible mammary glands exposed to DMBA or
not. However, the effect of Mcsl b genotype was statistically significant (P < 0.05) for
Gpbpl, Mier3, and Map3kl.

Furthennore, there was a significant effect of DMBA

exposure on Map3kl transcript levels (P=0.0003) and the interaction between Mcsl b
genotype and DMBA exposure approached statistical significance for Map3kl
(P=0.0588). Additionally, there was an effect of Mcsl b genotype on Il6st expression by
ANOVA; however, there was no difference in expression between genotypes in
mammary glands not exposed to DMBA (P=0.1137) and expression only approached
significance in glands exposed to DMBA (P=0.0734). When Mcslb genotypes were
compared by DMBA exposure, mammary gland transcript levels were significantly
different for Gpbpl, Mier3, and k/ap3kl between Mcslb resistant and susceptible
mammary glands that were not exposed to DMBA. However, significant expression
differences between Mcs 1b resistant and susceptible genotypes were sustained only for
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Table 12:

Analysis and statistics of M es 1 b potential candidate gene mammary gland transcript levels in.!v!esl b -resistant and susceptible genotypes at 12
weeks of age

Two-wa~

ANOVA F test Pvalues

Log2

Ta~etIRl!l1!2

mean ± SD (II )

Target

Mcslb Genotype

Exposure

GXE

Exposure

Susceptible

Mcs 1b Resistant

Gpbpl

0.0101

0.209

0.6422

MJER3

0.0023

0.7911

0.6682

Alap3kl

0.0002

0.0003

0.0588

Ankrd55

0.4694

0.2025

0.9019

Jl6st

0.0199

0.1744

0.8435

Il3lra

0.2869

0.8674

0.9928

Ddx4

0.0555

0.5442

0.4045

SIc38a9

0.1008

0.3929

0.973

Ppap2a

0.3918

0.8314

0.5788

Control
DMBA
Control
DMBA
Control
DMBA
Control
DMBA
Control
DMBA
Control
DMBA
Control
DMBA
Control
DMBA
Control
DMBA

0.586 ± 0.600 (34)
0.281 ± 1.309 (45)
0.115 ± 0.594 (34)
0.154 ± 1.557 (45)
-0.092 ± 0.818 (34)
0.105 -t 0.564 (47)
-0.691 ± 0.678 (24)
-0.377 ± 1.296 (17)
-0.066 ± 0.755 (36)
0.189 ± 1.006 (44)
-0.331 ± 1.072 (24)
-0.368 ± 0.942 (20)
-0.107 ± 0.983 (36)
-0.055 ± 1.122 (18)
-0.285 ± 0.600 (24)
-0.144 ± 0.970 (20)
-0.385 ± 0.632 (24)
-0.315 ± 1.357 (20)

0.044 ± 0.734 (29)
0.097 :le 1.246 (42)
-0.522 ± 1.278 (34)
0.688 i 1.943 (48)
-0.725 ± 0.767 (32)
-0.104±0.651 (45)
-0.826 ± 1.108 (22)
-0.567 ± 1.006 (22)
0.418 ± 1.054 (33)
-0.227 ± 1.181 (48)
-0.559 -1 0.761 (23)
-0.592 ± 1.159 (23)
0.359 :t 0.911 (33)
-0.690 ± 1.575 (17)
-0.575 ± 0.681 (23)
-0.422 ± 0.954 (23)
-0.447 ± 0.765 (23)
-0.605 ± 1.029 (23)

N

-...)

3Pisher PLSD test P- values from comparing susceptible and Alesl b -resistant genotypes by exposure.

P-value
0.002
0.1716
0.0104
0.024
0.0019
0.1036
0.618
0.609
0.1137
0.0734
0.4072
0.4949
0.2748
0.1769
0.1284
0.3499
0.7629
0.4315

3

Mier3 when females gIVen DMBA were compared between genotypes (P=O.024).

Transcript levels of Gpbpl and Map3kl were not different between genotypes when
DMBA-exposed females were evaluated.
Mammary gland transcript levels were lower in Mcslb resistant genotype females
for all genes with a significant difference between genotypes: Gpbpl, Mier3, and
Map3kl.

Mier3 mean transcript levels were approximately 4.5-fold lower in Mcslb

resistant compared to susceptible genotype mammary glands whether animals were
exposed to DMBA or not (Table 12). Thus, exposure to DMBA had no appreciable
effect on Mier3 differences between susceptible and Mcsl b resistant genotype females.
No significant differences in Mier3 transcript levels were detected between Mcsl b
resistant and susceptible genotypes in spleen, thymus, ovary, or brain tissues (Figure 17).
This suggests that Mier3 transcript level differences between Mcsl b alleles may be
specific to mammary gland tissue.

Mier3 Is Expressed as Three Different Variants in the Rat Mammary Gland

Gene expression studies identified Mier 3 as a potential rat mammary carcinoma
susceptibility-related gene. Interestingly, I also noted that Mier3 migrated as 2 bands on
electrophoretic gels suggesting that different variants of Mier 3 may be being expressed;
therefore, I sequenced these variants. Moreover, I also sought to check if these Mier3
variants were expressed in the mammary gland and whether they were expressed at the
same level between WF and COP tissue.
Mier3 was cloned into a TOPO vector and many clones were sequenced.

Sequencing showed that both Mier3 variants were expressed in the mammary gland
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Figure 17: Mier3 is not differentially expressed between WF susceptible and MesIb

resistant WF.COP congenic females in rat ovary, brain, .spleen, or thymus tissues.
Expression (QPCR) levels are represented as log base 2 mean quantities of rat Mier3
relative to rat Rplp2 expression +/- SO for each tissue listed on the X axis. Comparisons
between WF susceptible (.) and Mcs I b resistant (_) females for each tissue were not
statistically significant in one-way ANOVA with post hoc Fischer's PLSD test (Ovary:
P=0.4755, N=8 WF, N=13 MesIb resistant line N3; Brain: P=O.3788, N=ll WF, N=10
MesIb resistant line N3; Spleen: P=O.8854, N=8 WF, N=13 MesIb resistant line N3;

Thymus: P=O.9277, N=8 WF, N=12 AlesI b resistant line N3).
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(Figure ISA). One sequence identified the full length Mier 3 transcript (Figure ISB). The
other showed intra-exonal splicing of exon 1 from bp 5S7 to bb 950 resulting in a 3611
bp splice variant. This variant disrupts the normal ATG start site for translation and
results in a new start site at position 1013 in the transcript. This new start site is in frame
and would result in a 23 amino acid truncation at the N terminus of the protein (Figure
ISC). It is not clear what the consequences of this truncation are on the function of the
Mier3 protein. Additionally, it is not known whether this splice variant is conserved
between species.
I attempted to design Taqman gene expression assays to test whether there is a
difference in expression of these splice variants between WF and COP mammary gland
tissue samples; however, due to the constraints of the Taqman assay design this was not
possible. Instead, I resorted to cloning Mier3 amplicons and counting clones (Table 13).
Mier3 amplicons were cloned into a pCR2.1-TOPO vector, clones were picked and

amplified and run on agarose gels. 96 clones were counted per sample and analyzed as
the proportion of·fulliength Mier3 clones out of the total number of clones (containing
full length Mier 3 plus spliced Mier 3) counted. Clone assay results demonstrated there
was not a significant difference in Mier 3 splice variant expression versus the full length
variant expression between WF and resistant WF.COP mammary glands (Figure ISD).
Overall, the full length Mier3 transcript expression was much higher than that of the
splice variant (76% and 79% for resistant N3 and susceptible WF samples, respectively).
Further bioinformatic analysis showed that Mier3 sequence in the mouse and
human have an alternatively used exon upstream of exon 1 that results in an alternative
start site.

The alternate exon usage transcribes three short exons and excludes
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• •

Figure 18: Three different Mier3 variants are expressed in the rat mammary gland. A;
Image of electrophoretic gel of full-length Mier3 and Mier3 splice variant. B; Diagram
of gene structure of full-length, spliced, and alternative 5'-transcript start variant of
Mier3.

C; Amino acid sequence comparison of the three different variants at the N-

terminus.

Molecular weights of each protein are predicted based on sequence.

Expression levels of full-length Mier3 compared to total Mier3 expressed.

D;

Levels

depicted as proportion of full-length Mier3 in total. P values based on t-test of Arcsinetransformed proportion values. E; Expression levels of alternative 5' -transcription start
Mier3 variant. Expression is relative to Rplp2 expression. P values based on results of
ANOVA and Fisher PLSD post-hoc test.

Abbreviations: C, 100 base pair DNA ladder

standard; FL, full length rat Mier3; SV, rat Mier3 splice variant.
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Table 13:

Primer and Probe Sequences Used for Analysis of Rat Mier3 Variants

......
VJ
VJ

Assay Name

Primer/Probe Name

!vlier3 Splice Variant Cloning and Sequencing

Mier3-F3
Mier3-R3

Mier 3 Alternate 5' Transcription Start Site Sequencing

Mier3-alt -5' -end-F3
Mier3-alt-5'-end-R3

lv1ier3 Alternate 5' Transcription Start Site Taqman Expression Mier3-alt5'-I-F
Mier3-alt5' -1-R
Mier3-alt5'-1-Probe

Mier3-alt5'-2-F
Mier3-alt5'-2-R
Mier3-alt5' -2-Probe

Primer/Probe Sequence

AGCCCGTGTATTCCAGACAG
TGCAACCGTTGGAATTGTAG
CTGGCGATTGGCTCAGG
TGTCTAGGACTTTTTCATTTCCA
ATGGCGGAGGCTTCCTTT
TCAAAATCATGATCCTCAGAAGACA
AGCCCAGTTGGGTCT
AGCCCAGTTGGGTCTTTGTCT
TCATAGTCATGGACCAGCACTCA
CTGAGGATCATGATTTTG

exon 1 (Figure 18B). I designed primers to the orthologous rat sequence and amplified
and sequenced these in rat mammary glands (Table 13). To further determine whether
there were expression differences in the alternative start form of Mier 3 compared to full
length Mier3, I designed Taqman assays (Table 13). The results indicate a differential
expression of the alternative start end variant between WF and COP untreated mammary
glands (P=O.OOI7) (Figure 18E). Moreover, differential expression of the alternative 5'start variant appears to be specific to the mammary gland as differential expression was
not observed in ovary and spleen tissue (Figure 18E). The alternative start site variant
results in a transcription start site beginning upstream of the normal start site; however,
the alternate transcription start site stays in frame with the downstream coding of Mier3.
Although, the amino acid sequence is slightly altered at the N-terminus of the protein,
there is no evidence suggesting this change should disrupt translation (Figure 18C). It is
not clear what the implication of this alternative sequence has for Mier 3 function, but
expression differences may be implicated in the reduced expression of total Mier 3 seen in
previous gene expression assays.

Mcslb Genotype Exhibits Pleiotropic Effects on Body Weight

GW A studies have identified several breast cancer susceptibility loci; however,
little is known about how the relative risks associated with these regions are affected by
the established reproductive, behavioral, and anthropometric risk factors for breast cancer
(often referred to collectively as environmental factors, although some, such as height,
are in part genetically determined).

Travis et al. detected a significant association

between human breast cancer risk associated SNP rs889312 and stature in women (Travis
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et aI., 2010). To detennine if rat Mcsl b might also exhibit pleiotropy, we analyzed rat
body weight, which is infonnation we routinely collect and relevant because body weight
is genetically correlated to stature in humans (Czerwinski et aI., 2007).

Significant

effects of Mcslb genotype (P<O.OOOI) and DMBA exposure (P=0.0014) on body weight
at 12 weeks of age were detected (Figure 19). The interaction between Mcslb genotype
and DMBA exposure was also significant (P=0.0004). Females with the Mcsl b resistant
genotype had mean ± SD body weights of 200 ± 11 grams with DMBA (N=47) and 201
± 7.7 grams without (N=33), which were not significantly different (P=0.7880).

Comparatively, mammary cancer susceptible females had higher (P<O.OOOI) mean ± SD
body weight at 192 ± 11 grams with DMBA (N=45) than unexposed susceptible females
(N=34) who had a mean ± SD body weight of 180 ± 12 grams.

Rat Mammary Carcinomas Express Higher Mier3 Transcript Levels Compared to
Normal Rat Mammary Gland Tissue
There was a significant difference in expression of Mier3, Gpbpl, and Map3kl
between untreated N3 and WF mammary glands.

However, only Mier3 exhibited a

significant effect after DMBA induction. Therefore, I next sought to detennine whether
there was an effect of Mcsl b genotype on levels of any of these transcripts in mammary
carcinoma tissue. Further, Il6st was also included because it had been reported to be
higher in rat mammary carcinomas compared to nonnal mammary gland tissues although
in our studies it narrowly missed statistical significance (Qiu et aI., 2003b).

Mier3 mRNA expression was measured in DMBA-induced mammary carcinomas
from Mcslb resistant genotype (N=25) and susceptible (N=28) mammary glands by
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Figure 19: Rat Mcsl b-resistant genotype is associated with higher body weight. Lower
body weight at 12 weeks of age was observed in mammary carcinoma susceptible (.)
compared withMcslb-resistant females (_) with DMBA and without (P< 0.0001
and P=0.0007, respectively). Body weight was significantly higher in susceptible females
that received DMBA compared to females not receiving DMBA (P < 0.0001).
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QPCR and compared to adjacent "non-diseased" mammary glands. We collected total
RNA from DMBA-induced mammary carcinomas (N=l or 2 per rat) and adjacent nondiseased mammary gland tissue from 21-23 week old females (N=6 per genotype). There
were no statistically significant differences in mammary carcinoma transcript levels
between Mcslb genotypes for any of the four genes tested (Figure 20A).

However,

Mier3 transcript levels were significantly higher (1.8-fold) in mammary carcinomas

compared to non-diseased mammary tissue. We also observed that Il6st was potentially
different between mammary carcinomas and non-diseased mammary glands but did not
meet statistical significance (Figure 20A).
To determine whether Mier3 expression differences had been recognized in
human samples, I queried The Cancer Genome Atlas (cancergenome.nih.gov) gene
expression database by using the Oncomine (Rhodes et al., 2004) data-mining platform.
Results show that levels of human MIER3 were, respectively, 1.33 and 1.20 fold higher in
invasive ductal (N=392) and invasive lobular (N=36) breast carcinoma samples
compared to pathologically normal breast tissues (N=61)(P=2.8x10- 13 , ductal; P=6.3xlO4,

lobular; t-tests, Figure 19B). Thus, both human/rat MIER3/Mier3 levels are higher in

breast/mammary carcinoma compared to non-diseased breast/mammary tissues.

Discussion
Within the interval delineated by SNP markers A12v and A1200 lie thirteen
transcripts on rat chromosome 2 (Figure 5). To determine the mechanism by which the

Mcslb locus confers resistance to developing mammary carcinomas when induced with
DMBA I sought to, first, determine if any SNPs in the coding regions of these transcripts
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Figure 20:

Rat Mier3 transcript levels were significantly higher in DMBA-induced

mammary carcinomas
human MIER3 was

compared

significantly

to

non-diseased mammary

higher

pathologically normal breast tissues.

in

breast

gland tissue and

carCInomas

compared

with

A; Mean ± SD are graphed for each variable.

Expression of Mier3 mammary carcinoma (A) is significantly different than in adjacent
non-diseased mammary gland tissue (e; *, P=0.0120;
(www.oncomine.org)
(cancergenome.nih.gov)

was

used

to

query

The

gene expression database.

t, P=0.0569).
Cancer

B, Oncomine
Genome

Atlas

Box plots of 10g2 median

centered MIER3 transcript levels are shown for invasive ductal breast carcinomas
(IDBC, N=392) and invasive lobular breast carcinomas (ILBC, N=36) compared with
pathologically normal breast tissues (Breast, N=61).

MIER3 transcript levels are

significantly elevated in both tumor types compared to normal tissue (*, P < 0.05).
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existed between susceptible and resistant lines. Of the thirteen, 9 were amplified and
sequenced in rat spleen and thymus tissue: Gpbp1, Map3k1, Mier3, Ankrd55, 116st,
1l31ra, Ddx4, SIc38a9, and Ppap2a. The other four were predicted transcripts and had

not been validated. These were identified to be pseudo genes upon further investigation
using bioinformatic tools.

Sequencing results showed that there was no variation

between susceptible WF and resistant WF.COP cDNAs. This suggests that the basis for
Mcs1b COP-conferred resistance is regulatory in nature; therefore, further studies would

be needed to identify potential gene candidates.
There are many mechanisms that could be responsible for the Mcs1 b-conferred
mammary carcinoma resistance phenotype, e.g., a variant in a promoter or enhancer
disturbing transcription or a variant in a splice site disrupting mRNA processing. To
investigate this mechanism the most suitable starting point was to examine expression
levels of the transcripts. Gene expression of the nine validated transcripts was measured
in mammary glands from animals treated with DMBA or not. Three transcripts were
differentially expressed "between susceptible and resistant untreated mammary gland
tissue samples: Gpbp1, Mier3, and }.1ap3k1.

However, only Mier3 was statistically

different between susceptible and resistant mammary glands after DMBA was
administered. Moreover, 1l6st was previously reported to be upregulated in mammary
carcinomas versus non-diseased mammary gland tissue (Qiu et aI., 2003a) but missed
statistical significance in my studies.

The interaction between Mcs 1b genotype and

DMBA exposure approached statistical significance for Map3k1; however, Map3k1
expression was not differentially expressed in DMBA-treated mammary glands. The loss
in statistical significance between DMBA-exposed susceptible and Mcs1 b resistant
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females for Map3kl was due to an increase in mean level of Map3kl (P=0.0003) in the
Mcs 1b resistant genotype females with DMBA compared to age-matched controls of the

same genotype without DMBA (Table 13). Map3kllevels were not different (P=0.2038)
between susceptible WF mammary glands with or without DMBA. Regardless, Map3kl
expression was not different between genotypes in DMBA-exposed mammary glands
suggesting it was not a likely candidate. Hence, Mier3 stood out as the most likely
candidate.

Indeed, further study of Mier3 in rat tumor samples showed that Mier3

expreSSIOn was also increased in mammary carcinomas compared to adjacent nondiseased mammary gland tissue.

This was reinforced by Oncomine microarray data

confirming significantly elevated MIER3 expression in human breast cancer samples
compared to normal breast tissue.
Mier3 (Mesoderm induction garly response 1, family member 1) has not been

characterized.

However, based on sequence similarity, human MIER3 has been

identified as having two key domains: ELM2 and SANT (2012). The MIER3 ELM2
domain is from amino acid position 174 to 272.

The ELM2 (Egl-27 and MTA1

homology 2) domain was initially identified in the protein MTA1 a component of the
NuRD chromatin regulatory complex and is involved in recruiting HDAC leading to
changes in chromatin structure and resulting in transcriptional repression (Ding et aI.,
2003; Solari et aI., 1999). The SANT domain is located from amino acid position 277 to
329. SANT domains are present in nuclear receptor co-repressor proteins and in the
subunits of many chromatin-remodeling complexes (Aasland et aI., 1996). Moreover,
SANT domains are characterized by tandem repeats of three alpha-helices arranged in a
helix-turn-helix motif, each alpha helix containing a bulky aromatic residue making them
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similar to the DNA-binding domain of Myb proteins involved in DNA binding and
transcriptional repression (Grune et aI., 2003; Vargova et aI., 2011). Taken together, the
presence of these domains suggests that Mier3 may bind DNA or regulate chromatin
structure.
Another Mier family member, Mier 1, has also been implicated in breast cancer
progression (McCarthy et aI., 2008a).

Human and rat MIER3/Mier3 (GenBank

re~

NP _689835.3 and NP _001161472.1) gene products share 93% amino acid sequence
identity, and human MIER3 and MIERI (GenBank

re~NP_00I071172.1)

identical amino acids based on BLAST (van Boxtel et aI., 2011).

have 54%

Mierl

IS

a

transcriptional regulator that was discovered during a screen for fibroblast growth factor
response genes (Paterno et aI., 1997; Paterno et aI., 1998; Thome et aI., 2005). Notably,
MIERI physically interacts with ERa, Spl, and Creb-binding protein (Blackmore et aI.,
2008; Ding et aI., 2004b; McCarthy et aI., 2008b). The impact of hormone receptors and
co-regulators on breast cancer development has been noted.

Of particular interest,

MIERI contains a C-terminal LxxLL motif referred to as LXD (McCarthy et aI., 2008a).
The LXD is a highly conserved sequence shown to interact with variety of hormone
receptors (Heery et aI., 1997). Moreover, studies have shown that different arrangements
of the LXD confer varying specificities for different hormone receptors. For example,
whereas a single LXD is sufficient for activation by ERa, different combinations of two,
appropriately spaced, LXDs are required for actions of the thyroid hormone, retinoic
acid, peroxisome proliferator-activated, or progesterone receptors (McInerney et aI.,
1998b). Strikingly, MIERI contains a single C-terminal LXD while MIER3 contains 2
LXDs. Concordant with this, studies demonstrate that loss of MIERI may contribute to
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breast cancer progression while our data indicate that reduction in Mier3 expression is
protective against mammary carcinoma development.

Taken together, a potential

functional difference between MIERI and MIER3 may be that a difference in the number
of LXD motifs between them results in physical interactions with different nuclear
hormone receptors.
Amplification of Mier3 m rat thymus cDNA for sequencmg resulted in two
distinct bands on agarose gel. I further examined these bands by, first, confirming their
expression in mammary tissue and sequencing.

Sequencing revealed a full-length

transcript and a splice variant in which a 363 bp segment was internally spliced out of
exon 1. Additionally, the human and mouse MIER3Imier3 annotated sequences indicate
that additional exons may exist upstream of exon 1. To test this, I successfully amplified
and sequenced the rat orthologous region. Sequencing identified alternative usage of
three short exons upstream of the original exon 1 being transcribed and skipping exon 1.
Further, I measured gene expression of both variants. No differences were identified
between the full-length and splice variant forms; however, the alternative start site variant
was specifically down-regulated in resistant compared to susceptible mammary gland
tissue.

This was similar to the gene expression for all Mier3 isoforms performed

previously, suggesting that the differences in total Mier3 expression may be defined by
expression of the Mier3 alternative transcription start site variant.
Both Mier3 variants have different translation start sites compared to the original
full length Mier3 transcript. This would change the N-terminus of the Mier3 protein for
each of these variants; however, neither rat Mier3 nor its human ortholog has been
characterized and it is not clear what the consequence of these variants may be on protein
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function. Examining the N-terminus with The Eukaryotic Linear Motif resource (Dinkel
et aI., 2012) (http://elm.eu.org) shows that full length Mier3 contains a USP7-binding
motif that is lost in the intra-exonal splice variant.

Additionally, the alternative

transcription start variant retains this USP7 -binding domain and adds a Casein kinase I
(CKI) phosphorylation site (Dinkel et aI., 2012). USP7 is a deubiquitinating enzyme
most commonly involved in regulation p53 regulation by deubiquitinating it and
protecting it from MDM2-mediated degradation (Li et aI., 2002).

CKI is a

serine/threonine kinase involved in a variety of cell signaling pathways with a myriad of
targets; however, it has been recognized to be involved in the activation of the Wnt
signaling pathway (Davidson et aI., 2005). Therefore, the alternative start site form of
Mier3 may be more mitogenic compared to the other isotypes.

Taking everything

together, Mier3 emerges as a positive regulator of cell proliferation affecting
carcinogenesis in the mammary gland.
Travis et al. reported pleiotropic effects on stature in women associated with the
breast cancer-associated SNP rs889312 (Travis et aI., 2010). During the course of our
experiments we routinely gather data on body mass of the rats. I used this to test whether
a correlation existed between body mass and Mcsl b genotype since body mass can be
used as a proxy for stature in humans. Lower body weight was observed in susceptible
female rats compared to resistant congenic rats at 12 weeks of age. These animals differ
essentially only at the Mcs 1b locus and resistant female rats express less Mier3 than
female rats harboring a susceptible Mcs I b allele. Therefore, this seems counter-intuitive
as it is believed that Mier3 is mitogenic and increased expression would result in
increased weight gain. However, as previously mentioned, PR is known to attenuate
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effects of ERa (Hsueh et aI., 1976; Tseng and Gurpide, 1975). What is more, loss of
estrogen activity has been identified to associate with a reduction in catabolism and an
increase in weight, femur length, and bone density in male mice (Ford et aI., 2011). As
discussed earlier in this chapter, human MIER3 contains 2 LXDs which may confer
affinity for PR (McInerney et aI., 1998b). Therefore, a likely scenario would be that in
resistant congenic females expressing lower amounts of Mier3, there is less PR bound to
Mier3 and more that is available to inhibit ERa activity. ERa inhibition in these animals

results in higher body mass compared to susceptible animals expressing higher amounts
of Mier3. However, this is based on an assumption that Mier3 is binding to PR supported
only by sequence similarity to Mier 1 and the presence of 2 LxxLL motifs. Therefore,
this is entirely speculative and more empirical work is necessary to determine the
mechanism by which Mier3 is working.
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CHAPTER V
CONCLUDING REMARKS

Rat mammary carcinoma susceptibility, like human breast cancer risk, is complex
as both are controlled by multiple susceptibility alleles and environmental factors. We
have mapped rat Mesl b to a 1.1 Mb region of rat chromosome 2 using multiple congenic
lines. We found that rat Mesl b is highly relevant to human breast cancer susceptibility as
it contains genomic sequence orthologous to a low-penetrance breast cancer risk allele at
human chromosome 5qll.2.

This human susceptibility allele was first reported by

Easton et al.(2007) in the first population-based breast cancer risk GWAS.

Human

5qll.2 has been confirmed to strongly associate with breast cancer risk in multiple
independent studies of European- and Asian-descent populations (Antoniou et aI., 2008;
Broeks et aI., 2011; Campa et aI., 2011; Garcia-Closas et aI., 2008a; Han et aI., 2011;
Zheng et aI., 2010). This is the first report of a rodent complex disease susceptibility
QTL with a GWAS-identified concordant human ortholog that had a probability of
association below a stringent significance level ofPS 10 -7, which is widely deemed to be
required for genome-wide studies.
An experimental organism with a segregating concordant susceptibility allele
implies that functional genetic studies may translate directly to human biology and
disease.

For example, Gould and colleagues reported that rat Mes5a, a WKY strain

resistance QTL that is concordant to human MeS5A, acted in a non-mammary cell-

146

autonomous manner that involves immune cells (Smits et aI., 2011a). Here, we used rat
genetic lines to show that Mcsl b controls mammary cancer susceptibility by an
undetermined mammary gland cell autonomous mechanism.

While our result is in

agreement with previous work that concluded a majority, but not all, of the COP rat strain
resistance to mammary cancer is mammary gland autonomous (Zhang et aI., 1990); it
further highlights that the WKY and COP strains may achieve mammary carcinoma
resistance through different genetically determined cellular and molecular mechanisms
that are likely genetically determined in humans as well.
Further, Gould and colleagues developed a clonogenic transplant assay using rat
MEC preparations to reconstitute mammary glands in the intrascapular fat pads of
recipient rats (Gould and Clifton, 1985). To date no one has demonstrated an ability to
induce carcinomas in these ectopic glands.

The window for DMBA to induce

carcinogenesis in endogenous rat mammary glands and whole mammary gland
transplants was established to be at 50-55 days of age. Herein, I show that glands formed
from the injection of MECs have a longer latency'compared to whole mammary gland
grafts since DMBA-induced carcinogenesis is delayed to 70-75 days of age. This is a
significant result for future use of this protocol.
Most common genetic variation associated with human complex disease
susceptibility appears to be located in non-protein-coding DNA.

Since we found no

genetic variation between susceptible and resistant allele Mcs 1b ORFs, we conclude that
Mcsl b is likely a noncoding gene regulatory element(s), such as a transcription factor

binding site or noncoding RNA. This would be similar to the hypothesized identity of the
human 5qll.2 breast cancer risk associated element. Human polymorphisms that are
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contained in public databases and highly correlated with human 5q11.2 breast cancer risk
associated SNP rs889312 are in non-protein-coding DNA.

There are no known

noncoding RNAs in either the human or rat ortholog; therefore, another type of gene
regulatory element is likely responsible for or associated to susceptibility differences.
Our studies suggest that MIER3 is a strong candidate breast cancer susceptibility
gene at human 5qll.2. We identified Mier3 as a strong Mcs1 b candidate gene in this
study based on different Mier 3 mammary gland transcript levels between susceptible and
Mcs1b resistant genotypes. Lower levels of Mier3 in Mcs1b resistant genotype females

were genetically determined and not dependent on the induction of mammary
carcinogenesis by DMBA.

We also found Mier3 levels significantly lower in non-

diseased rat mammary tissue compared to mammary carcinoma. Further, we queried The
Cancer Genome Atlas gene expression database and noted that human MIER3 levels were
higher in both ductal and lobular breast carcinomas compared to breast tissue.
MIER3 or mesoderm induction early response 1, family member 3 (GenBank
re~NM~152622)

nucleus.

is an uncharacterized gene. We determined that MIER3 localized to the

Human

and

rat

MIER3/Mier3

(GenBank

re~

NP _689835.3

and

NP_001161472.1) gene products share 93% amino acid sequence identity, and human
MIER3 and MIER1 (GenBank

re~NP _001071172.1)

have 54% identical amino acids

based on BLAST (van Boxte1 et aI., 2011). MIER1 physically interacts with ERa, Sp1,
and Creb-binding protein (Blackmore et aI., 2008; Ding et aI., 2004b; McCarthy et aI.,
2008b). MIER1 contains one, while MIER3 has two conserved LxxLL sequences, which
is a motif that facilitates nuclear hormone receptor interactions (Heery et aI., 1997). A
potential functional difference between MIER1 and MIER3 may be that a difference in
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the number of LxxLL motifs between them results in physical interactions with different
nuclear hormone receptors (McInerney et aI., 1998a). In addition, MIERI and MIER3
harbor ELM2 and SANT domains. The ELM2 domain is involved in recruitment of
HDAC activity, which leads to changes in chromatin structure and results in
transcriptional repression (Ding et aI., 2003).

Likewise, the MIERI SANT domain

functions in gene repression by interacting with Sp 1 and interfering with its ability to
bind to its cognate site on responsive promoters (Ding et aI., 2004a). The presence of
two LxxLL motifs along with the ELM2 and SANT domains suggests that MIER3 is a
potential transcriptional repressor whose activity is mediated by interaction with nuclear
hormone receptors. To test this idea, more functional studies are necessary to determine
the mechanism by which Mier3 is controlling mammary carcinogenesis in the rat.
In addition to MIER3, MAP3Kl and C50RF35 reside within the human 5qll.2
haplotype block that associates with breast cancer risk.

Even though there are no

published studies in support, MAP3Kl is often considered the candidate breast cancer
susceptibility gene at 5qll.2 due to its location within the breast cancer risk associated
haplotype block and known function as a serine/threonine kinase. In our rat studies,
Map3kl was differentially expressed between susceptible and Mcs 1b resistant congenic

rats that had not been induced to undergo mammary carcinogenesis; however, mammary
glands that had been exposed to mammary carcinogen did not show a difference in
Map3kl levels between Mel b alleles. An interesting result in our study with respect to
Map3kl, which may have important implications for human studies of potential

genotype-environment interactions, is exposure to mammary carcinogen resulted in
increased mammary gland Map3kl levels for the Mcsl b resistant, but not the susceptible
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genotype. We found no evidence of a rat orthologous transcript to human C50RF35 in
multiple rat tissues. Further, exonic elements of C50RF35 have not been conserved in
the rat. Therefore, we conclude that MAP3Kl and C50RF35 are not as likely as MIER3
to be breast cancer susceptibility genes.
I also identified multiple variants of Mier 3 expressed in the rat mammary gland.
One of these variants exhibits alternate exon usage compared to the annotated Mier3
transcript (GenBank

re~NM _152622).

Similar to what was observed in the original

Mier3 gene expression studies, expression of the alternate exon variant is reduced in

resistant Mcs 1b mammary gland tissue compared to susceptible controls. The sequence
of the variant differs only at the 5' end of the transcript, but is predicted to introduce a
casein kinase phosphorylation site at the N-tenninus. However, the implications are not
clear and more study is necessary to detennine whether differential expression of this
variant affects mammary carcinoma susceptibility. Regardless, differential expression of
this variant adds to our evidence that Mier3 is the most likely breast cancer gene.
We noted that both rat Mcslb and human 5qll.2 exhibit pleiotropy. Travis et at.
reported that carriers of the increased risk allele at human 5qll.2 were significantly
shorter in height than non-carriers (Travis et aI., 2010). In our study, high risk female
rats had lower body weight than Mcs 1b resistant females. There is a predicted rat body
weight QTL named Bwl that overlaps Mcslb and is associated with mesenteric body fat
amount (Ogino et aI., 2000). Both human and rat study results are counter intuitive as
one might expect taller women and heavier rats to be at greater cancer risk. Thus, it is
important to note that, as expected with low-penetrance alleles, the quantitative
difference between the means for each human genotype were subtle with overlapping
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distributions. Mean height difference was 7 mm between non-carriers and carriers of the
increased risk allele. In our study, we analyzed only body weight, and not specific
components of body weight, such as bone density or fat. Thus, better descriptive traits
would likely be more informative. It is notable that the pleitropic effects of these alleles
opens the possibility that other experimental organisms, approaches, and study designs
without focus on breast or mammary cancer may be useful to functionally characterize
breast cancer risk associated genetic variation at 5qll.2.
In conclusion, rat Mcsl b contains a mammary gland-autonomous allele and a
non-protein-coding genetic element that is orthologous to the GWAS-identified human
5qll.2 breast cancer susceptibility locus. We propose that MIER3 is a strong candidate

breast cancer susceptibility gene.
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Introduction
During the course of my dissertation work some supporting experiments were not
completed or were omitted into dissertation chapters as to not distract from the focus of the
project. Despite this, some of the experiments and resulting data not included in the main
body of this dissertation contributed to the conclusions of the work presented here and
therefore are shown in the appendix. Below, these data will be explained in the context of
the previous work described.

Endogenous Control for Taqman Gene Expression Studies
Introduction
Early attempts to measure gene expressIOn of rat Mcsl b transcripts were
performed using Gapdh as an endogenous control. However, the variability in Gapdh
expression was high between samples and this was believed to be due to poor RNA
quality. RNA quality was within acceptable limits (-1.8) for absorbance ratios at 260 nm
and 280 nm when analyzed on a Nanodrop 2000 (Thermo Fisher Scientific); regardless,
attempts were made to improve RNA isolation times and conditions but resulted in no
change in the high variability in Gapdh expression between samples. I further analyzed
RNA quality using RNA Pico Chips and an Agilent Bioanalyzer (Agilent, Santa Clara,
CA). Based on RNA Integrity Numbers (RIN) determined by Bioanalyzer data, RNA
was determined to not be compromised and that variability was due to variations in
Gapdh expression itself and was not a good endogenous control candidate.

Thus, I

sought to identify a better endogenous control by measuring a panel of endogenous
control gene candidates in WF and resistant WF.COP mammary glands.
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Materials and Methods
RNA clean-up using sodium acetate
As stated above, Gapdh expression was highly variable between samples in initial
gene expression assays. I initially believed this was due to degraded or contaminated
RNA. To improve RNA quality I made some changes to the RNA isolation protocol.
First, fewer samples were isolated in individual sessions to reduce the amount of time the
RNA isolates were on ice.

Total RNA was extracted with TRI-Reagent (Molecular

Research Center) followed by standard chloroform/ethanol precipitation.

To reduce

possible solvent and DNA contamination RNA samples were further processed by a 1110
v/v 3M sodium acetate and 2.5x v/v 100% ethanol wash on ice for 10 minutes followed
by 80% ethanol wash followed by Turbo DNase (Life Technologies) treatment. Total
RNA quantity and quality were measured with a Nanodrop 1000 (Fisher Scientific) and a
Bioanalyzer with RNA 6000 NanoChips (Agilent).

Endogenous Control Array
To determine a good endogenous control candidate for the Mcs 1b gene expression
studies, I used an endogenous control array micro-fluidic card (Life Technologies). The
card contains 16 different endogenous control probe/primer sets (Table S 1) preloaded
into the card. cDNA was prepared from four mammary carcinoma resistant WF.COP and
four susceptible WF mammary gland samples and normalized to 2 Ilg.

They were

loaded in triplicate into the endogenous control array card according to manufacturer
specifications, centrifuged and run on an ABI Prism 7900 HT using standard conditions.
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Statistical Analysis
Endogenous control data were analyzed using SDS software (Life Technologies)
and StatView (SAS Institute). Geometric means were calculated for each sample and
Mann-Whitney tests were used to analyze expression between genotypes.

Results
3M sodium acetate results in higher quality RNA
Total RNA had higher RIN and 28S and I8S bands were stronger when analyzed
with the Bioanalyzer.

However, differences in Gapdh expression between WF and

resistant mammary gland samples did not change following reducing time on ice or by
sodium acetate cleanup.

Rplp2 is a good endogenous control gene for gene expression assays in rat mammary
gland samples
- Expression levels were highly variable between the genes in the panel (Figure
S 1). Ct values for most of the Mcsl b target transcripts were in a range of ~20 - 25 cycles
(data not shown). Therefore, genes with mean Ct values outside the range of 20 - 25
cycles were omitted from further analysis.

Candidate control genes were further

analyzed for variance between replicates and between samples. Samples with SD higher
than 0.5 Ct were excluded.
Seven genes in the panel fell inside the allowable Ct range: Actbl2, Arbp, B2m,

Ppia, Ppib, Rplp2, and Ubc (Table S2). Of these, only Rplp2 and Ubc had SDs below
0.5 cycles for both genotype groups. Ubc was differentially expressed between WF and
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Table SI:
Endogenous control genes contained on ABI Endogenous Control Array MicroFluidic Card

......
-..I
-..I

Name (Alternate Name)
18S
Beta-actin
Attachment region binding protein
Beta-2 microglobulin
Glyeeraldehyde-3-phosphate dehydrogenase
Beta-glucuronidase
Hydroxymethylbilane synthase
Hypoxanthine phosphorihosyltransferase 1
Phosphoglycerate kina<;e 1
Peptidylprolyl isomerase A (Cyclophilin A)
Peptidylprolyl isomerase B (Cyclophilin B)
Ribosomal protein, large, P2
TATA box binding protein
TransfelTin receptor (p90, CD71)
I Tbiquitin C
Tyrosine 3-monom.ygenase i tryptophan 5-monooxygenase activation protein, ze!l:I.polypeptide

Gene Symbol
18S
Actb
Arbp
B2m
Gapdh
Gusb
Hmbs
Hprt
Pgkl
Ppia
Ppib
Rplp2
Tbp
Tfrc
Ubc
Ywhaz

ABI product reference number
Hs99999901
RnOO667869
RnOO821065
RnOO560865
Rn99999916
RnOO566655
RnOO565886
Rn01527840
RnOO821429
RnOO690933
RnOO574762
Rn014799271
Rn01455648
Rn01474695
Rn017898121
RnOO755072
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Figure SI: Mean Ct Values for Genes tested in ABI Endogenous Control Array. The

geometric mean of the Ct value for each genotype is plotted. Error bars represent SD.
The dashed line delineates the Ct value range desired for an optimal endogenous
control.
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Table S2:
Results of ABI Endogenous Control Array Micro-Fluidic Assay

Mean Ct value ± S.D.
Gene Symbol

WF

WF.COP

P valuea

18S
Actb
Arbp
B2m
Gapdh
Gusb
Hmbs
Hprt
Pgkl
Ppia
Ppib
Rplp2
Tbp
Tfrc
Ubc
Ywhaz

21.5 ± 2.3
22.2 ± 1.3
24.8 ± 1.2
21.6 ± 0.6
26.0 ± 1.1
29.0 ± 1.2
28.0 ± 0.9
26.1 ± 0.7
26.9 ± 1.0
22.2 ± 0.7
23.6 ± 0.7
20.7 ± 0.5
28.9 ± 0.7
33.3 ± 1.6
22.4 ± 0.5
26.2 ± 1.3

17.9 ± 1.8
21.0± 1.3
24.6 ± 0.8
21.3 ± 0.8
24.4 ± 1.2
28.8 ± 1.2
28.1 ± 1.5
26.4 ± 0.9
26.7± 1.1
22.5 ± 0.8
24.0 ± 0.7
20.8 ± 0.4
28.4 ± 1.3
31.5 ± 1.8
23.0 ± 0.2
25.7 ± 1.0

0.0433
0.2482
0.3865
0.7728
0.1489
>.9999
0.7728
0.7728
0.7728
0.7728
0.3865
0.7728
>.9999
0.1489
0.0433
0.7728

a Non-parametric

Mann-Whitney test
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resistant WF.COP samples (P=0.0433); however, Rplp2 was not different between
genotypes (P=0.7728). Therefore, Rplp2 was used in all subsequent gene expression
experiments.
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LIST OF ABBREVIATIONS AND SYMBOLS

17~-HSD

17~-hydroxysteroid

18S

18S

ACF

Adherent cell fraction

ACI

ACI rat strain

Actb

Beta-actin

AI

Aromatase inhibitor

Ankrd55

Ankyrin repeat domain 55

Arbp

Attachment region binding protein

B[a]P

Benzo( a)pyrene

B2m

Beta-2 microglobulin

BAC

Bacterial artificial chromosome

BC

Backcross generation

BN

Brown Norway rat strain

bp

Base pairs

BPA

Bisphenol A

C50rj35

Chromosome 5 open reading frame 35 (SET domaincontaining protein 9)

cDNA

Complementary DNA

gDNA

Genomic DNA

Chr

Chromosome

CI

Confidence Interval

dehydrogenase
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CKI

Casein kinase 1

cM

CentiMorgan

CNV

Copy number variant

COP/Hsd

Copenhagen (Harlan Sprague Dawley) rat strain

CYP

Cytochrome P450

DCIS

Ductal carcinoma in situ

Ddx4

DEAD (Asp-Glu-Ala-Asp) box polypeptide 4

DES

Diethylstilbestrol

DMBA

7,12 Dimethylbenz(a)anthracene

DMEM

Dulbecco's Modified Eagle Medium

DNase

Deoxyribonuclease I

dATP

Deoxyadenosine triphosphate

dCTP

Deoxycytidine triphosphate

dGTP

Deoxyguanosine triphosphate

dTTP

Deoxythymidine triphosphate

dNTP

Deoxynucelotide triphosphate

El

Estrone

E2

Estradiol

E3

Estriol

ECM

Extracellular matrix

EDTA

Ethylenediaminetetraacetic acid

ELM2

Egl-27 and MTAI homology 2 domain
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ERE

Estrogen Response Element

ERa

Estrogen receptor alpha

ER~

Estrogen receptor beta

Gapdh

Glyceraldehyde-3-phosphate dehydrogenase

Gpbpl

GC-rich promoter binding protein 1

Gusb

Beta-glucuronidase

GWAS

Genome-wide association study

HCA

Heterocyclic amine

HDAC

Histone deacetylase

Hmbs

Hydroxymethylbilane synthase

Hprt

Hypoxanthine phosphoribosyltransferase 1

HR

Hazard Ratio

HRT

Hormone replacement therapy

IACUC

Institutional Animal Care and Use Committee

IDBC

Invasive ductal breast carcinoma

Il31ra

Interleukin 31 receptor A

Il6st

Interleukin 6 signal transducer

ILBC

Invasive lobular breast carcinoma

indel

Nucleotide Insertion/Deletion variant

LD

Linkage disequilibrium

LTR

Long terminal repeat

LxxLL

Leu-Xaa-Xaa-Leu-Leu domain
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MAF

Minor allele frequency

Map3kl

Mitogen-activated protein kinase kinase kinase 1

Mcs

Mammary carcinoma susceptibility locus

MEC

Mammary epithelial cell

MHC

Major histocompatibility complex

Mier3

Mesoderm induction early response 1, family member 3

miRNA

MicroRNA

MMTV

Murine mammary tumor virus

MTAI

Metastatic tumor antigen 1

MWS

Million Women Study

NCI

National Cancer Institute

nitro-PAH

Nitrated polycyclic aromatic hydrocarbon metabolite

NMU

N- N itroso-N-methylurea

NSABP

National Surgical Adjuvant Breast and Bowel Project

NuRD

Nucleosome remodeling and histone deacetylase complex

OR

Odds ratio

ORF

Open reading frame

PAH

Polycyclic aromatic hydrocarbon

PCB

Polychlorinated biphenyl

PCR

Polymerase chain Reaction

Pgkl

Phosphoglycerate kinase 1

PhIP

2-amino-l-methyl-6-phenylimidazo(4,5-b )pyridine
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PI3K

Phosphatidylinositol 3' kinase

Ppap2a

Phosphatidic acid phosphatase type 2A

Ppia

Peptidylprolyl isomerase A (Cyclophilin A)

Ppib

Peptidylprolyl isomerase B (Cyclophilin B)

PR-A

Progesterone receptor A

PR-B

Progesterone receptor B

PyVmT

Polyoma virus middle T antigen

QPCR

Quantitative polymerase chain reaction

QTL

Quantitative trait locus

R

Resistant mammary carcinoma phenotype

RF

Radiofrequency/microwave radiowave emissions

RIN

RNA integrity number

Rplp2

Ribosomal protein, large, P2

RR

Relative Risk

S

Susceptible mammary carcinoma phenotype

SANT

Swi3, Ada2, N-Cor, and TFIIIB domain

SD

Standard deviation

SERM

Selective Estrogen Receptor Modulator

SETD9

SET domain containing 9

SIc38a9

Solute carrier family 38 , member 9

SNP

Single Nucleotide Polymorphism

snRNA

Small nuclear RNA
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SS

Dahl/Salt-Sensitive rat strain

STAR

Specific Targeted Research Project

Tbp

TAT A box binding protein

TEB

Terminal end bud

tet

Tetracycline

Tire

Transferrin receptor (p90, CD71 )

U

Undetermined mammary carcinoma phenotype

U6

Spliceosomal small non-coding nuclear RNA component

Ube

Ubiquitin C

UTR

Untranslated region

WF/Hsd

Wistar Furth (Harlan Sprague Dawley) rat strain

(WF X COP) FI

First generation from a Wistar Furth/Copenhagen mating

WHI

Women's Health Initiative

WKy

Wi star Kyoto rat strain

WMG

Whole mammary gland transplant

Ywhaz

Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta polypeptide
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